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ABSTRACT 
Chastity L. Walker: Attitudes, Practices, and Beliefs About  
Human Papillomavirus Vaccine Among Young Adult African-American Women: 
 Implications for Effective Implementation 
(Under the direction of Suzanne Havala Hobbs, DrPH) 
 
Cervical cancer is both a preventable and treatable disease. Racial and ethnic 
minorities and those of low-socioeconomic status tend to experience the greatest 
morbidity and mortality due to cervical cancer. Vaccination against the human 
papillomavirus (HPV) has been shown to prevent cervical cancer and genital warts, 
and subsequently reduce the number of women requiring follow-up and treatment of  
abnormal Pap Tests. There is relatively little published evidence to assess acceptance 
and utilization of the HPV vaccine among minority and low socioeconomic groups. 
The purpose of this study was to generate knowledge and inform policy 
considerations to reduce cervical cancer incidence and mortality by use of the HPV 
vaccine among African-American women, aged 18-26. A qualitative descriptive 
study design sought to characterize the barriers to, and potential facilitators of HPV 
vaccine introduction to young adult African-American women, aged 18-26, while 
recommending strategies for implementation. The study comprised a mix of both 
primary and secondary data collection and analysis methods. Interviews were 
conducted with stakeholders demonstrating expertise in cervical cancer prevention 
and an assessment of the literature on vaccines, diffusion of innovation, and policy 
adoption was conducted to inform policy alternatives to promote receipt of the
 
 
iv
 vaccine among the target group. Several overarching themes emerged to suggest 
factors that might deter or promote use of the vaccine including: mistrust of 
government, access to vaccination, attitudes about health, varying opinions regarding 
HPV vaccine guidelines, social determinants contributing to cervical cancer 
disparities, and a comprehensive strategy for introducing vaccination among others. 
 Strategic recommendations to support implementation of HPV vaccination 
catch-up programs, specifically designed for African-American women, aged 18-26, 
include addressing gaps in knowledge thru expansion of a cervical cancer prevention 
social marketing educational campaign to Historically Black Colleges and 
Universities (HBCU’s) and enhancing access by evaluating how best to integrate 
HPV immunization and cervical cancer screening delivery. These findings confirm 
that introduction of HPV vaccination to African-American women will require an 
incremental and targeted approach, and can be used by public health officials and 
policy-makers as they strive to improve the overall quality and delivery of cervical 
cancer prevention services. 
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CHAPTER I: INTRODUCTION 
 
 
A. Statement of the Issue 
 
Cervical cancer incidence rates in developed countries such as the United States (US) 
are much lower than those in developing countries. Eighty percent of global cervical cancer 
cases and deaths occur in less developed nations, 1-3 and most of these deaths occur in Sub-
Saharan Africa, South Asia and Latin America 4, 5. In the United States, approximately 
11,000 women are diagnosed with invasive cervical cancer, and 4,120 die from it annually.6, 7   
At one time, cervical cancer was the leading cause of cancer death among US women. 
However, regular use of the Papanicoalaou Test (Pap Test), beginning in the 1970s, moved 
cervical cancer to the seventh most common cancer in the United States. Nonetheless, not all 
populations and geographic regions of the US have experienced equal declines in morbidity 
and mortality.  In the US, groups with the highest mortality include African-American 
women in the South, Hispanics along the Texas-Mexico border, Whites in Appalachia, 
American Indians of the Northern Plains, Vietnamese-American, and Alaskan natives. 8 
The statistics related to African-American women are alarming considering cervical 
cancer can be detected through Pap screenings and treated when caught early.  Recent data 
from the 2005 United States Cancer Statistics Report show significantly higher age-adjusted 
incidence rates of cervical cancer among African-American women- at 10.3 per 100,000 ( 7.7 
per 100,000 for Whites).7 African-American women are twice as likely to be diagnosed at 
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later stages as compared to white women, particularly in the Southern region of the United 
States. 9, 10 Similarly, the mortality rate for African-American women was 4.4 per 100,000, 
twice that of non-Hispanic White (2.2 per 100,000) women. 9, 11 
While some studies show that African-American women have similar rates of 
cervical cancer screening as their white counterparts, more recent data suggest disparities in 
cervical cancer screening, morbidity and mortality remain. 11, 12  African-American women 
over the age of forty have higher incidence rates of invasive cancer  than white women  but 
lower or equivalent rates to those <40 yrs of age.9 Studies confirm the highest rates of HPV 
infection occur among African-American women 20-29 years of age. 13, 14 Ley et al. 
concluded, the determinants of genital HPV infection are consistent with those associated 
with an increased risk of cervical cancer, particularly among African-American women .14  
Hence, considerable racial and ethnic differences exist with regard to the burden of HPV 
infection and cervical cancer.  
 
B. Background 
The human papillomaviruses (HPVs) are a group of more than 100 viruses that may 
cause warts or benign tumors. Of these, over thirty types can be passed from person to person 
through sexual contact. HPV is the most common sexually transmitted infection (STI) 
worldwide. 8, 15-17 The incidence rates of HPV among men and women in the US are 
approximately 5.5 million per year, while the prevalence is even greater at 20 million. 
Prevalence rates for young adult women (18 to 30 years) typically range from 28 to 46 
percent. 18  The Alliance for Cervical Cancer Prevention (ACCP) estimates that fifty to 
eighty percent of sexually active women will be infected with the virus at least once in their 
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lifetime. 16 The majority of women are infected during their teens, 20s, or early 30s.  Most 
HPV infections occur without any symptoms and go away without any required treatment.19  
Persistent infection with high-risk HPV types increases a woman’s risk of developing 
invasive cervical cancer. 19, 20 Two types of HPV, 16 and 18, account for approximately 60 to 
70% of cervical cancer cases.21 The rates of most STIs are higher among adolescents, young 
adults, minority populations, and populations with low socioeconomic status. 22  The data 
appear to signal that race, ethnicity, and socioeconomic status are in some way associated 
with the burden and treatment of STIs, including HPV. 
Studies confirm that in the United States there is a 50 percent higher incidence of 
cervical cancer among African-Americans compared to Whites.10  Data from the most 
recently published United States Cancer Statistics (USCS) report showed that in 2005, 
approximately 12,000 women in the U.S. were diagnosed with cervical cancer and nearly 
3,900 women died in that year. Of those diagnosed in 2005, 1,794 were African-American 
women; 783 African-American women died as a result of cervical cancer in 2005. Thus, the 
rates of cervical cancer morbidity and mortality exceeded the proportion of this population in 
the larger U.S. population.7   
In 2009, the U.S. Food and Drug Administration (FDA) approved Gardasil®, a new 
vaccine developed to prevent cervical cancer, precancerous genital lesions, and genital warts 
due to HPV. Gardasil®, manufactured by Merck, prevents infection of four HPV types, HPV 
types 16 and 18, which cause a  large proportion of cervical cancer cases, and types 6 and 11 
which cause 90 percent of genital warts cases.21, 23, 24 Steps are underway to approve Glaxo 
Smith Kline’s Cervarix®, a bivalent vaccine against HPV types 16 and 18. Most of the 
research to date regarding the HPV vaccine has focused on adolescent girls, and the vaccine 
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has been extensively tested in females aged 9 to 26 years old.  The vaccine has been shown 
to be highly effective in preventing the four types of HPV24 in young women not previously 
exposed to the virus or prior to the onset of sexual activity. The current research suggests the 
vaccine is effective for five years. 8, 24     
There has been much controversy associated with the vaccination of women in the 
upper age range, 19-26 years, in terms of effectiveness of the HPV vaccine and previous 
exposure to HPV. The prevalence rates of infection with HPV-6,-11.-16, or -18 shortly after 
sexual debut are well documented.25, 26 The current HPV vaccines are most certain to yield 
the greatest advantage to those girls and women who have not engaged in sexual activity, 
limiting their exposure to HPV. Though the benefit of vaccination among women who are 
sexually active may be less, catch-up vaccination of 13 to 26 year olds is recommended. 
According to Dr. Lauri Markowitz, “women infected with one HPV vaccine type could 
essentially benefit from protection against the other type(s) in the vaccine and may benefit 
from boosting the antibody response from future re-infection with the same HPV type.27” 
Likewise, conclusions presented in a report from the  Gardasil® FUTURE II Study Group 
support universal catch-up vaccination among young adult women, including those showing 
evidence of previous or current infection with 1 or more HPV vaccine types. 25 The 
prophylactic HPV vaccine has no therapeutic effect nor does it have a role in treatment.  
Further data from ongoing vaccine trials is needed to support recommendation in women 
older than 26 years.24   
The federal Advisory Committee on Immunization Practices (ACIP), who issues 
recommendations for use of vaccines in the US,  in 2006 recommended the routine 
vaccination of girls 11 to 12 years of age for HPV.28 Furthermore, the recommendation 
 5
allows for girls as young as nine years old, as well as girls and women ages 13-26 years, to 
be vaccinated.28 29 Gardasil® is to be dispensed in three doses over a six month period. 8  
Similarly, the American Cancer Society (ACS) published its own recommendations in early 
2007 for HPV vaccine use. These guidelines are generally consistent with those of the ACIP, 
with the exception of routine screening for women aged 19-26. According to ACS, the 
efficacy and potential benefit of universal prophylactic vaccination of women aged 19 to 26 
years diminishes, as the likelihood of sexual intercourse and exposure to HPV has occurred 
among this group. The ACS states there is currently insufficient evidence to recommend for 
or against universal vaccination of women aged 19-26 years in the general population. Catch-
up vaccination is recommended for females aged 13-18 years.30  
 As a result of the ACIP recommendation, the HPV vaccine will be administered 
through the Vaccine for Children (VFC) program, which provides free vaccines for children 
and adolescents through age 18 who are uninsured or receive Medicaid. Many young adult 
women who do not qualify will likely face significant challenges in accessing the HPV 
vaccine due to cost.  There remains a lack of coverage for low-income women between 19 
and 26 years of age, as there is no public purchase program for non-elderly adult 
recommended vaccines. Efforts to reduce the cost of HPV vaccination and facilitate the 
delivery of the vaccine through governmental, private and charitable support must continue 
to ensure equitable access.  
 
C. Significance of Issue 
Researchers and health professionals alike are encouraged by a vaccine against 
HPV24 for millions of women, not only in the United States, but globally. Widespread 
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vaccination has the potential to reduce cervical cancer deaths around the world by as much as 
two-thirds. 31 In addition, the potential to reduce both the economic and emotional burdens 
faced by women with an abnormal Pap test result who require additional testing and 
treatment will be a welcome benefit. The healthcare costs associated with follow-up of 
abnormal results are estimated to be as much as $6 billion USD annually.21, 32-34 35  Although 
research on the uptake of the HPV vaccine among young women is limited, evidence 
suggests that this group would greatly benefit from immunization. Thus further study is 
warranted to determine the attitudes, beliefs, and practices regarding the uptake of HPV 
vaccines for young adult women, especially for high-risk populations such as racial and 
ethnic minorities.  
Cancer disproportionately affects racial and ethnic minorities. The HPV vaccine has 
the potential to significantly reduce morbidity and mortality associated with cervical cancer. 
11, 36, 37  As a result, increasing uptake of the vaccine among certain populations may impact 
the disparities. Access to, and acceptance of HPV vaccinations may be influenced by factors 
ranging from insurance coverage, availability of vaccine, healthcare provider attitude, ability 
to navigate healthcare system, and potentially, the ability to pay out of pocket. 36-38  In 
addition, other factors may influence one’s ability to receive appropriate and timely health 
care. 16, 37, 39, 40 
 
D. Purpose & Specific Aims 
The purpose of this study is to more fully understand the issue of HPV vaccination among 
African-American women by addressing the following research questions:  
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1. What are the attitudes, practices, and beliefs about human papillomavirus vaccine 
among young adult African-American women? 
 
2. What factors would be likely to hinder or enhance the effectiveness of policies aimed 
at increasing use of the HPV vaccine for cervical cancer risk reduction among young 
adult African-American women, aged 18-26?  
 
 
 
The research aims were: 
 
1. Describe attitudes, practices, and beliefs about HPV vaccine among young adult 
African-American women; 
 
2. Explore factors associated with nonparticipation in HPV vaccine use among African-
American women;  
 
3. Identify related attitudes and health practices associated with use or nonuse of HPV 
vaccine among young adult African-American women; and 
 
4. Use the data collected to recommend policy considerations for enhancing acceptance 
of the HPV vaccine among young adult African-American women. 
 
 
 
  
CHAPTER II: REVIEW OF THE LITERATURE 
 
While access is important, there is a known relationship between knowledge, 
attitudes, and beliefs about preventive health; HPV vaccination; and intention to receive the 
vaccine. 36, 41  Studies show that, in general, women have a vague or poor knowledge of HPV 
and how the infection is transmitted and treated. The literature also suggests there is a 
significant gap in knowledge of the association between genital HPV and cervical cancer. 42-
44 Furthermore, there are concerns around the efficacy and safety of the new HPV vaccine. 
Awareness and knowledge about the HPV vaccine could affect acceptance and a woman’s 
ability to make an informed decision about vaccination. 45 According to Mays et al, 46 “the 
preponderance of existing research in this area has targeted women’s knowledge of Pap 
smear testing or cervical cancer or both.” This statement lends support to the need for 
additional research related to HPV vaccine knowledge and attitudes, especially among the 
African-American population.  
There are unique challenges associated with a vaccine that targets an STI. 47 Social 
stigma and fear are often related to sexually transmitted diseases. Social processes are 
considered to have a key role in making healthcare decisions for certain population groups. 
The opinions of family members, friends, and significant others- those who form one’s social 
network- are highly valued. Several elements of social support have been identified as having 
a strong influence on the health and well-being of individuals: emotional support, 
informational support, and instrumental support 48, 49.   
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Therefore, this literature will review factors that influence or deter young adult women from 
receiving the HPV vaccine. Definitions of key terms for the purposes of this literature review 
are as follows: (1) Knowledge is defined as one’s awareness and understanding of HPV, the 
HPV vaccine, cervical cancer, and the relationship between the two (i.e, knowing how HPV 
is transmitted, diagnosed, and treated and that HPV is a precursor to cervical cancer, etc). (2) 
Attitude relates to one’s acceptability of a vaccination to prevent HPV and willingness to be 
immunized (i.e. physician recommendation and/or consultation and issues around safety and 
efficacy, etc ). (3) Young Adult Women refers to females between the ages of 18 and 26, all 
races.  
This chapter reviews the literature (See Table 2.1) in two areas of inquiry related to this 
issue: 
• Part 1: Knowledge of HPV and cervical cancer, and 
• Part 2: Attitudes regarding HPV and the HPV vaccine 
In addition, a portion of the literature will address the development of policy to inform 
decision-making: 
• Part 3: Policy Analysis and Interpretation 
 
A. Part One: Knowledge of HPV and cervical cancer 
Knowledge of Human Papillomavirus 
Despite the prevalence of human papillomavirus and its potentially harmful 
consequences, many people are not aware of HPV. Numerous studies 18, 43, 44, 50-52 
demonstrate that the US population generally has little awareness or knowledge of HPV a 
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lack of understanding that HPV is a sexually transmitted disease and that it is linked 
to cervical cancer. For example, the Moreira et al 53 study showed that women demonstrated 
a vague understanding of how HPV is diagnosed and treated. While women participating in 
this study have a higher rate of awareness of HPV in comparison to the general public, the 
majority remain unaware that persistent infection with high-risk HPV types is associated with 
almost all cervical cancers. 53, 54  
Dempsey and Davis (2006) 50 reported that among a sample of college students less 
than one third had ever heard of HPV; approximately 17 percent correctly indicated HPV as 
a sexually transmitted disease; and only 2 percent identified HPV infection as a risk factor 
for cervical cancer. This general lack of awareness about HPV correlated to low perception 
of risk of acquiring HPV infection and/or developing HPV-related disease.   
In an effort to inform HPV education efforts, Friedman and Shepeard conducted 
thirty-five focus groups with members of the general public in six geographically dispersed 
U.S. sites. The study explored knowledge, attitudes, and communication preferences 
regarding HPV and its associated conditions. The results confirmed a lack of knowledge 
about HPV which was shown to serve as a barrier to acceptance of a vaccine. 54 
Giles and Garland 55 conducted a survey of ninety women, aged 18-30 years, from 
three different groups: those attending a dysplasia clinic, a local university health service, 
and participants of  Phase 3 HPV vaccine trial, about their knowledge of HPV infection, 
cervical cancer, Pap tests and HPV vaccine. Their results suggest that the majority of 
respondents have a good understanding of the Pap test; however, they did not understand the 
risk factors for HPV infection and the long-term consequences of persistent HPV infection 
such as cervical cancer. Likewise, most of the women surveyed had not heard of the HPV 
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vaccine.  Similar results were noted in the Hoover, Carfioli, Moench 42 study in which a 
convenience sample of sixty women were asked to complete a short survey that evaluated 
their HPV knowledge and priorities. Once again, the need for more education on HPV was 
identified. Although knowledge of HPV was low, the concern about cervical cancer was high 
among this group of women.   
More recent work, as exemplified by Tiro et al  52 documented an inverse correlation 
between factors associated with HPV awareness and factors associated with HPV-cervical 
cancer knowledge. Familiarity with HPV does not necessarily guarantee accurate knowledge 
about its link to cervical cancer.56 The findings also suggest a woman’s knowledge is likely 
to increase once she has had an adverse consequence from an HPV infection.  
B. Part Two: Attitudes Toward/ Perception of Human Papillomavirus 
Attitudes Toward Human Papillomavirus 
Human papillomavirus is the most common sexually transmitted infection in the 
United States.18, 42, 50, 51, 54, 55, 57 The diagnosis of an STI like HPV can be embarrassing. 
Numerous studies show an association between the term sexually transmitted 
disease/infection or STD/STI with ‘promiscuity’, ‘infidelity,’ ‘shame,’ and ‘guilt’.53, 54, 56, 58  
Results from a study conducted by Waller et al suggest awareness that HPV is sexually 
transmitted was associated with significantly higher levels of stigma and shame. 59  HPV-
based technologies may be associated with stigma that could adversely affect women’s use of 
them and acceptance of HPV vaccination programs.52   
  Mayeaux 60 proposes that patients are less anxious and more comfortable about their 
diagnosis if they are educated about their condition and available treatment options. Waller et 
al confirms, higher knowledge regarding the prevalence and cause of HPV is associated with 
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lower anxiety, suggesting that information may have a “normalizing” effect.59  Conversely, 
Tiro et al 52 state that the majority of women do not receive treatment for HPV and therefore 
miss the opportunity to learn about the infection and its effects from a health care provider. 
The Friedman study found a relationship between fear of being labeled as promiscuous if one 
received a vaccine against an STD as rationale for not seeking more information about HPV 
and not being immunized.54 Waller et al 58 report increasing awareness of the link between 
HPV and cervical abnormalities might cause women with abnormal Pap smears to resent or 
distrust their partner and to feel unable to disclose their test results for fear of stigma. 
Acceptance of Human Papillomavirus Vaccine 
Gardasil®, a quadrivalent vaccine, targets HPV types that are responsible for 
approximately 70% of cervical cancer cases and 90% of genital warts. Cervarix®, a bivalent 
vaccine is expected to be introduced and considered for approval in the U.S. some time in 
late 2009. An important component to ensuring successful implementation of the vaccine is 
public acceptance. According to Mayeaux,60 creating the foundation for acceptance begins 
with determining what people need to know about HPV through education and candid 
discussions about HPV-related diseases and the potential benefits of HPV vaccines. 
 Increasing general awareness and understanding of HPV infection and its effects, as 
well as assuring vaccine safety and efficacy, are key elements to vaccine acceptance.51 
Hymel 51 surmises that public and patient educational efforts must be consistent and promote 
messages that are clear and appropriate for the intended audiences. In addition, 
recommendation of the vaccine by a healthcare provider is essential to vaccine 
acceptability.51, 53, 61, 62 A study involving both adolescents and adults suggested that 
physician recommendation was one of the most important factors leading to the decision to 
 13 
be vaccinated.51 In general, healthcare providers are more likely to recommend use of an 
HPV vaccine based on the following factors: 1) endorsement by a professional organization, 
2) efficacy of the vaccine, 3) preference to administer vaccine to older versus younger 
patients, and 4) vaccination against both cervical cancer and genital warts rather than cervical 
cancer alone.61, 63, 64 
Likewise, individual acceptance is dependent on a number of factors including 
personal beliefs about the vaccine, as well as perceptions of the beliefs of others such as 
partners and parents. Health beliefs and prior behavior are important in motivating future 
health protective actions such as STI vaccination.65 Khan et al 18 explored the attitudes about 
and intention to receive an HPV vaccine among young women using a theory based model. 
The results of this study associated knowledge with intent to receive the vaccine and suggest 
that perceived beliefs of people within ones social network would significantly impact one’s 
decision to be vaccinated.18  Similarly, studies suggest that education and information 
actively designed to inform men about cervical cancer have an impact on their female 
partners’ willingness or ability to access services.66 
 Perception of risk was identified as a strong predictor of vaccine acceptance in a 
study conducted by Moreira et al.53 A sample of 204 women attending a public outpatient 
gynecological clinic was administered a questionnaire to assess their knowledge and attitudes 
toward HPV vaccination and clinical trials.They found that sexually active women and those 
with a history of three or more sexual partners were more likely to enroll in the HPV 
immunization trial.This suggests that one’s perceived risk of the disease and benefits of the 
vaccine were factors associated with vaccine acceptability.53, 54, 56  
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 HPV vaccination has numerous public health benefits and holds remarkable promise 
for alleviating the clinical burden of illnesses related to HPV infection, as demonstrated in 
several studies.18, 42, 50, 51, 62  Zimet et al 45, 62 found in their study examining the attitudes of a 
hypothetical HPV vaccine among women in a clinical setting that acceptability of the vaccine 
was dependent on how efficacious it was. Safety of the vaccine, side effects, cost, and degree 
of protection have been identified as contributing factors to a woman’s acceptance of the 
vaccine. These conclusions are consistent with those of  other studies of STD vaccine 
acceptability.54, 62 
C. Part Three: Policy Analysis and Interpretation 
In addition to reviewing the literature on human papillomavirus, an assessment of  
policy analysis and development was conducted. Policy refers to plans, positions, and 
guidelines of an organization (government or private sector), groups, and individuals which 
influence decisions to achieve a desired outcome. Policy analysis can be described as the 
breaking up of a policy problem into its component parts, understanding them, and 
developing ideas about what to do.67 As a result of these processes, alternative policies or 
programs are identified and evaluated that can be used to lessen or resolve social, economic, 
or physical problems.  
In thinking about policy, Stone presumes that policy is shaped in political 
communities in a somewhat orderly sequence of stages.68 Policy analysis and development is 
therefore a systematic evaluation of the technical and economic feasibility and political 
viability of alternative policies (plans or programs), strategies for implementation, and the 
consequences of policy adoption. Both quantitative and qualitative information, as well as 
various perspectives to approaching the problem, can be integrated into the analysis and 
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development of policy. Patton and Sawicki 67 offer six-steps of a basic policy analysis 
process: 1) Defining the problem and objectives to be pursued, 2) Determining the evaluation 
criteria, 3) Generating a range of alternative policies, 4) Evaluating the policy options, 5) 
Comparing alternatives, and 6) Evaluating and assessing the policy outcomes. 
 
 
Figure 2.1: A Basic Policy Analysis Process 
 
Adopted from Basic Methods of Policy Analysis and Planning  2nd Edition Patton and Sawicki 
   
At the most fundamental level, Stone describes policy issues within a three part 
framework: goals, problems, and solutions.67, 68 Formation of policy involves political actors 
or a group of actors who are concerned about the selection of goals and the means of 
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achieving them within a specified situation, where those decisions should be, within the 
power of those actors to achieve.67, 68 Community values such as equity, efficiency, security 
and liberty, express goals and serve as standards for evaluating existing situations and policy 
proposals. Problems occur when there is a divergence between social goals and the current 
state of affairs; they are defined in terms of causes-what generated the issue; interests- who is 
lined up on each side; and decisions- what kind of choice they pose.  Solutions then are an 
attempt to resolve this conflict by employing policies, which in some way, involve changing 
behavior. In Policy Paradox, the author addresses mechanisms for bringing about such 
change which include: creating incentives and penalties (inducements), mandating rules, 
informing and persuading, stipulating rights and duties, and reorganizing authority.68  
There are various direct and indirect actions that can be undertaken to address public 
policy issues when the private market or government does not allocate goods efficiently or 
there are equity or distributional problems. Policy analysis is political argument which 
involves choices to include some things, while excluding others.68 Utilizing a framework for 
policy analysis and planning has shown to reduce problems to a manageable size, allow 
others to evaluate the analysis and lessen subjectivity.67 A systematic approach to policy 
analysis combines diverse ideas, which leads to better evaluation of alternatives. 
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Table 2.1. Results of Literature Review 
AUTHOR (S) AND  YEAR TITLE METHOD(S)/ STUDY TYPE PURPOSE KEY THEMES 
Dempsey, A., & Davis, 
M. 
2006 
Overcoming Barriers to Adherence to 
HPV Vaccination Recommendations Descriptive Analysis 
Describe barriers to effective 
implementation of HPV 
vaccines 
 Attitudes Toward/ Perception of 
HPV 
 Knowledge of HPV 
Friedman, A. & 
Shepeard, H. 
2007 
Exploring the Knowledge, Attitudes, 
Beliefs and Communication 
Preferences of the General Public 
Regarding HPV: Findings from CDC 
Group Research and Implications for 
Practice 
Focus Groups 
Explore knowledge, attitudes 
and beliefs about HPV and 
HPV vaccine 
 Knowledge of HPV 
 Attitudes Toward/ Perception of 
HPV 
Giles, M. & Garland, S. 
2006 
A study of women’s knowledge 
regarding human papillomavirus 
infection, cervical cancer and human 
papillomavirus vaccines 
Survey 
Assess knowledge regarding 
HPV infection, cervical cancer, 
Pap tests and HPV vaccines 
 Knowledge of HPV 
Hoover, D., Carfioli, B 
& Moench, E. 
2000 
Attitudes of Adolescent / Young Adult 
Women Toward Human 
Papillomavirus Vaccination and 
Clinical Trials 
Survey 
Evaluate HPV knowledge and 
priorities, vaccine 
acceptability, and willingness 
to participate in HPV vaccine 
clinical trial 
 Knowledge of HPV 
 
Hymel, P. 
2006 
Decreasing Risk: Impact of HPV 
Vaccination on Outcomes Descriptive Analysis 
Discuss issues related to US 
vaccine implementation  Acceptance of HPV vaccine 
 
 
  
18
 
AUTHOR (S) AND  YEAR TITLE METHOD(S)/ STUDY TYPE PURPOSE KEY THEMES 
Kahn, J., Rosenthal, 
S., Hamann, T., & 
Bernstein, D. 
2003 
Attitudes about human papillomavirus 
vaccine in young women Survey 
Assess  knowledge, attitudes 
about HPV vaccination and 
risk behaviors & Identify 
association between attitudes 
and intention to receive 
vaccine 
 Acceptance of HPV vaccine 
Lambert, E. 
2001 
College Student’s Knowledge of 
Human Papillomavirus and 
Effectiveness of a Brief Educational 
Intervention 
Survey 
Longitudinal Study Cohort 
Pre and post-test 
(3months after 
intervention) 
Educational intervention 
Assess college student’s 
knowledge of HPV 
 Knowledge of HPV 
 
Mays, R., Zimet, G., 
Winston, Y., Kee, R., 
Dickes, J., & Su, L. 
2000 
Human Papillomavirus, Genital 
Warts, Pap Smears, and Cervical 
Cancer: Knowledge and Beliefs of 
Adolescent and Adult Women 
Descriptive Study/ Semi-
structured Interviews 
Examine knowledge and 
beliefs about genital warts, 
HPV, cervical cancer and Pap 
tests 
 Knowledge of HPV 
 
Mayeaux, E. 
2005 
Overcoming Barriers to HPV Vaccine 
Acceptance Descriptive Analysis/ 
Assess knowledge about  HPV 
among women & psychosocial 
issues of HPV infection 
 Knowledge of HPV 
 Attitudes Toward/ Perception of 
HPV 
 Acceptance of HPV vaccine 
 
Moreira, E., Oliveira, 
B., Neves, R., Costa, 
S., Karic, G., &  
Filho, J. 
2006 
Assessment of Knowledge and 
Attitudes of Young Uninsured Women 
toward Human Papillomavirus 
Vaccination and Clinical Trials 
Cross-sectional study 
Interview 
Assess knowledge and 
attitudes toward HPV 
vaccination  
 Knowledge of HPV 
 Acceptance of HPV vaccine 
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AUTHOR (S) AND  YEAR TITLE METHOD(S)/ STUDY TYPE PURPOSE KEY THEMES 
Phillip, Z., Johnson, S., 
Avis, M. & Whynes, D. 
2003 
Human Papillomavirus and the 
value of screening: young women’s 
knowledge of cervical cancer 
Descriptive Study/ Survey 
Assess knowledge of cervical 
cancer and screening and its 
relationship to HPV 
  Knowledge of HPV 
Pitts, M. & Clarke, T. 
2002 
Human Papillomavirus infections 
and risks of cervical cancer: what 
do women know? 
Descriptive Analysis/ 
Questionnaire 
Assess knowledge of cervical 
cancer screening , risk factors 
for cervical cancer and its link 
to HPV  
 Knowledge of HPV 
Tiro, J., Meissner, H., 
Kobrin, S. & Chollette, 
V. 
2007 
What Do Women in the U.S. Know 
about Human Papillomavirus and 
Cervical Cancer? 
Survey 
Descriptive Analysis/ Cross-
sectional study 
Assess factors associated with 
women’s awareness of HPV 
and link to cervical cancer 
 Knowledge of HPV 
 Attitudes Toward/ Perception of 
HPV 
Waller, J., McCaffery, 
K., Forrest, S., 
Szarewski, A., 
Cadman, L. & Wardle, 
J. 
2003 
Awareness of human 
papillomavirus among women 
attending a well woman clinic 
Survey 
Descriptive Analysis Assess knowledge of HPV  Knowledge of HPV 
Waller, J., McCaffery, 
K., Forrest, S.& 
Wardle, J. 
2004 
Human Papillomavirus and 
Cervical Cancer: Issues for 
Biobehavioral and Psychosocial 
Research 
Literature Review 
Assess psychosocial impact of 
HPV testing and cervical 
cancer screening 
Risk factors associated with 
persistent HPV infection 
Prevention of HPV infections 
 
 Knowledge of HPV 
 Attitudes Toward/ Perception of 
HPV  
Zimet, G., Mays, R., 
Winston, Y., Kee, R., 
Dickes, J. & Su, L 
2000 
Acceptability of Human 
Papillomavirus Immunization Individual Interviews 
Examine attitudes about HPV 
vaccine  Acceptance of HPV vaccine 
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A total of 64 articles and abstracts were identified by searching a variety of databases using a 
variety of search terms in various combinations (See Appendix A). After applying the 
inclusion and exclusion criteria (See Appendix A), a total of 18 papers were reviewed and 16 
were considered appropriate for inclusion in this review.  Study results offered mixed 
conclusions regarding the knowledge and attitudes of young adult women as it relates to an 
HPV vaccine. The majority of the studies indicated a generally low level of knowledge 
regarding HPV. Attitudes toward HPV and vaccination against the sexually transmitted 
disease were varied. In addition, two texts, Basic Methods of Policy Analysis and Planning 
(Patton and Sawicki)  and Policy Paradox-The Art of Political Decision Making (Stone), 
were used to review the literature on policy analysis and development. 
D. Discussion 
While awareness about HPV has increased over the past decade, understanding about 
HPV, how it is diagnosed and treated, and its link to cervical cancer remains low.52, 53, 56  
Common barriers to HPV vaccination, in general, fall into 3 broad categories: 1) lack of 
knowledge about the vaccine or target disease, 2) problems of access to medical care, and 3) 
fears about vaccine safety. Vaccine efficacy, physician endorsement, and cost have shown to 
be important predictors of vaccine acceptability. Results emphasize the importance of 
informing and training healthcare providers about the vaccines and about the contribution of 
provider recommendations to decision making about health.55 Moreover while most family 
physicians are aware of new information about human papillomavirus, including new DNA 
tests and a prophylactic vaccine, many remain unaware of information that may influence 
counseling messages and clinical management  of HPV-related conditions.69 
Three principal findings emerged from this review of knowledge and attitudes of 
young adult women about human papillomavirus. The first and most definitive finding across 
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the literature confirmed the dearth of knowledge about HPV among the general population, 
specifically among young adult women.  The development of appropriate and effective HPV 
communications must be based on an in-depth understanding of the target audience’s current 
knowledge, attitudes, perceptions, and beliefs about HPV as well as their information needs 
and communication preferences.54 
Significant and sustained public education efforts designed to raise awareness about 
HPV and the benefits of HPV immunization will become necessary to ensure the wide use 
and successful implementation of the HPV vaccine.  To be effective, HPV immunization 
initiatives aimed at young adults should provide accurate information about HPV infection 
and its link to cervical cancer and genital warts; should emphasize efficacy, safety and 
benefits of vaccination; and should assess normative beliefs about vaccination.  
 Furthermore, an air of skepticism and distrust of the government exists among 
certain populations that have historically been discriminated against in health research. 
Receptivity to public health information and vaccination messages is likely to be negatively 
affected as a result. Special efforts may be needed to reach certain populations such as 
African-Americans and American Indians with HPV messages that are perceived to be 
trustworthy. 
  The second major finding dealt with attitudes toward HPV. The public health and 
medical community must disconnect HPV from notions of promiscuity and stigma. While 
significant media attention has focused on the sexual nature of HPV transmission, much of 
the information is incomplete and fails to emphasize the importance of the link between high-
risk HPV types and cervical cancer.54  Whereas the preponderance of studies support 
increasing knowledge about HPV, it should be noted that raising public awareness has been 
associated with increased anxiety and fear among some groups. In addition, previous 
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research findings suggest that raising awareness of the HPV-STD-cervical cancer link could 
potentially result in further stigmatization of HPV, cervical cancer, cervical cancer screening, 
and HPV vaccination.54, 58 
  Given the lack of a cure for HPV or agreement on effective prevention strategies for 
sexually active adults, and no approved test to detect HPV in men or no vaccine approved for 
boys, the public health community must be careful not to cause undue public alarm while 
promoting HPV awareness. Framing HPV as a cause of cervical cancer and universal public 
health issue as opposed to an STI will improve education efforts and the public’s attitude 
toward HPV.  The sexually transmitted nature of HPV could have further implications for 
vaccine adoption and the establishment of supportive state vaccination policies in the U.S.   
The third finding addresses acceptance of the HPV vaccine. Misperceptions about 
vaccine safety pose additional barriers to use and add to the fear of vaccination. There appear 
to be reservations related to the newness and efficacy of the vaccine and its potential side 
effects.70 Support from national medical organizations and professional associations will play 
an important role in facilitating vaccine implementation. 
Reidesel et al 61 reported that provider practice characteristics, knowledge about 
HPV, and attitudes were independently associated with intention to recommend HPV 
vaccination. Physicians whose focus is on women’s health issues and those that work with 
patients at high risk for HPV-related disease may have a better understanding of HPV 
infection recognizing the potential health benefits of  an HPV vaccine and thus more likely to 
recommend immunization.61 In contrast, there are some providers who may not recommend 
the vaccine to women who are sexually active or may have been exposed to HPV.  
Nevertheless, healthcare providers are an important source of information regarding the 
vaccine and recommendation from a doctor is known to be associated with acceptance of  
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HPV vaccination.71, 72 Results of a survey of physicians conducted by Raley et al 64 suggest 
that gynecologists are widely accepting of the HPV vaccine as a result of recommendation by 
the American College of Obstetricians and Gynecologists.73  
As the number of suggested vaccines rise along with escalating costs, financing for 
newly recommended vaccines is a potential barrier, particularly among young adults without 
private health insurance who may be left with the decision to pay out of pocket.  Young 
women will be responsible for the full list price of the vaccine series ($375.00) and additional 
expenses related to the administration of the vaccine and personal costs will be incurred. 
While the HPV vaccine has been added to the Vaccine for Children’s (VFC) program, 
individual states will have to decide whether to make it available in public health 
departments or covered as a benefit through state Medicaid programs. It is likely that 
financial barriers may impede achievement of high vaccination coverage among those for 
whom the vaccine is recommended and most likely to benefit. 
Although attitudes about HPV vaccination are broadly positive, parents have 
concerns about vaccinating young girls against STIs. Similarly, conservative Christian 
groups and pro-abstinence lobbies have spoken out against the vaccine.70 The HPV vaccine 
should be seen and marketed as a cervical cancer prevention approach rather than one that 
promotes sexual promiscuity. Based on the literature, acceptability of the vaccine and its use 
should increase as the vaccine becomes more familiar and efficacy is proven over time.  
There is also a concern that accomplishing effective implementation of an HPV  
vaccination program will lead to a reduction in adherence to Pap test screening. It is possible 
that as a result of this “success,” the number of cervical cancer cases could potentially 
increase.  Implications for public health policy should be directed at timely vaccination in 
conjunction with prescheduled screening times to detect and treat cervical lesions.51 
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E. Limitations of Literature Review 
On the whole, there is a paucity of empirical research on HPV knowledge and even 
less regarding the attitudes and beliefs about HPV of young women. The papers included in 
this review represent the majority of research currently available. As pointed out by Waller et 
al,58 studies investigating knowledge and awareness of HPV have tended to concentrate on 
the visible effects of the STI, such as genital warts, rather than the cancer-causing HPV 
types. Further emphasis should be placed on HPV and its link to cervical cancer.  
Much of the available research is purely descriptive in nature. Few of the studies 
identified a particular theoretical framework, limiting the ability to examine whether a 
theoretical model explains how HPV knowledge influences attitudes and acceptance of a 
vaccine. The majority of the articles describe studies using survey methodology. Sample 
sizes were varied, ranging from small samples for focus groups or in-depth interviews to 
moderate and large sample sizes for studies conducted on a national level. Moreover, there is 
considerable variability in the format and a lack of standardized measures among the 
questionnaires used. Therefore, comparisons between and across studies were difficult to 
make.  
Generally, the demographic characteristics of the samples examined were biased 
toward White women with a higher level of knowledge. Samples that are heterogeneous with 
respect to SES, age, and ethnicity are needed. Research to assess knowledge and acceptance 
of the HPV vaccine among minority and low socioeconomic status (SES) subgroups were not 
well represented and inadequate to a certain extent. As such, this suggests that the results of 
this body of research may not be generalizable to the broader population.  
The methods used in this search are not exhaustive nor representative of all the 
literature available on the subject. Limiting the search primarily to the scholarly literature 
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could have resulted in the exclusion of relevant literature from other data sources. The search 
was conducted over a short period of time by a single author, and as such, limitations were 
placed on the number of articles reviewed. Future work in this area should include additional 
reference identification from the “grey literature” (e.g. papers, reports, technical documents) 
and material or publications from organizational websites. 
For the purposes of this review, the literature is deficient and significant gaps in 
knowledge exist. With that said, the current body of knowledge offers a springboard for 
further analysis. In the coming months and years, the amount of literature related to HPV and 
immunization against the virus is expected to increase significantly.  Additional research 
should focus on specific groups, for example high-risk populations, boys, and older women 
above thirty-five years of age who might make use of the vaccine, if the vaccine were 
approved.  
Use of the HPV vaccine is an urgent public health policy issue. Further study from a 
socio-ecological approach will be required at all levels of influence including  1) policies and 
legislation at the institutional level, 2) cultural and social norms at the community level, 3) 
social support and social networks at the interpersonal level, and 4) personal knowledge, 
attitudes and behaviors at the individual level. This will help gain a better understanding of 
the issue and to prevent growth in the current socio-demographic inequalities that exist 
relating to cervical cancer incidence and mortality.  
  
CHAPTER III: METHODOLOGY 
 
 
 
 Qualitative research methods permit an in-depth exploration of individual’s 
intentions, actions, and interpretations and allow for a close examination of the context in 
which actions occur.74 Additionally, qualitative research methods are useful for generating 
detailed descriptions of how context and action interrelate in specific cases.74  A qualitative 
inquiry design was used in this study to learn more about the barriers and potential 
facilitators to increasing acceptance and use of the HPV vaccine among young adult African-
American women. As will be described in this section, this research study included three 
separate but interrelated stages along with the two guiding research questions.  This chapter 
describes the approach used to address the research questions posed in this study. 
Specifically, the guiding research questions and aims in this study were:   
Research Questions 
1. What are the attitudes, practices, and beliefs about human papillomavirus vaccine 
among young adult African-American women? 
2. What factors would be likely to hinder or enhance the effectiveness of policies 
aimed at increasing use of the HPV vaccine for cervical cancer risk reduction 
among young adult African-American women, aged 18-26?  
Study Aims 
Aim 1: To describe attitudes, practices and beliefs about HPV vaccine among young 
adult African-American women; 
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Aim 2: To explore factors associated with nonparticipation in HPV vaccine use 
among African-American women;  
Aim 3: To identify related attitudes and health practices associated with use or 
nonuse of HPV vaccine among young adult African-American women; 
Aim 4: To apply data collected to an analysis of and recommendations for policy 
considerations for enhancing acceptance of the HPV vaccine among young adult 
African-American women 
A. Conceptual Framework  
Many ecological factors have the potential to improve or harm health, and the 
“ecological perspective” offers a framework for understanding the complex interplay of 
individual, relationship, social, political, cultural, and environmental factors to addressing 
health problems.75 The Social Ecological Model, also called Social Ecological Perspective, is 
a framework that examines multiple effects and the interrelatedness of social elements in an 
environment.76 Elder et al 77 concluded that socio-ecological frameworks are essential in 
programs or studies that employ multi-level interventions and measurement strategies.  The 
model recognizes that many external forces (intrapersonal, interpersonal, organizational/ 
community, and societal) influence individual determinants (Table 3.1). To facilitate 
behavior change, it is important to address these external forces.  
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Table 3.1: Social Ecological Model 
LEVEL OF INFLUENCE INTERVENTION TARGET VARIABLE OF INTEREST 
Intrapersonal Individual 
Psychological (attitudes, knowledge, beliefs, perceived 
risk, perceived benefits, self-efficacy) 
Biological (health status, risk factors, ethnicity) 
Interpersonal Relationship Partner influence; Peer/Family influence; Social support; Social Networks; Healthcare Provider 
Community/Organization 
Community, Schools, 
Worship Centers, 
Neighborhoods, Religious 
community, work setting 
Social Norms; Cultural Norms & Beliefs; Rules; Access 
to resources and services; Social Capital 
Society 
Local, State, Federal Laws 
Public Health Community 
(governmental agencies & 
advocacy organizations) 
Media 
Legislative and/or Regulatory approaches at multiple 
levels, Educational Campaigns 
Health Promotion Messages 
Adapted from National Cancer Institute -Theory at a Glance: Summary of Theories (2005) 
 
A conceptual model (Figure 2) was designed and used to guide the research. The 
model included factors supported by the existing literature and informed by the socio-
ecologic framework. This model allowed for the integration 76 of multiple levels and contexts 
to establish the “big picture” associated with health behavior change, specifically uptake of 
the HPV vaccine for the purposes of this study. Research that focuses on any one level has 
been reported to underestimate the effects of other contexts.78-80 Hence, constructs of the 
Health Belief Model (HBM) are embedded within the ecological framework at the 
intrapersonal or individual levels. The Health Belief Model assumes that people’s beliefs 
about whether or not they are susceptible to disease, and their perceptions of the benefits of 
trying to avoid it may influence their readiness to act.75, 81, 82  This framework was used to 
identify facilitators and barriers to HPV vaccine acceptance and develop appropriate 
strategies to address the issue (Appendix A).   
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B. Study Design 
Multiple data sources were triangulated including an extensive review of the 
literature, data from semi-structured interviews, and a review of documents related to HPV 
vaccine,  to reduce the validity threat of mono-methods bias.83 Due to the exploratory nature 
of this study and novelty of the subject- HPV vaccine – a qualitative descriptive approach for 
this dissertation was most appropriate for creating knowledge and contributing to the body of 
research.84  The formative research for this paper was conducted over several phases: Phase 
1- Review of the Literature; Phase 2- Semi-structured Key Informant Interviews and; Phase 
3- Policy Analysis and Interpretation. Systematic data collection methods such as interviews 
and document analysis were used. This process involved systematically gathering detailed 
and in-depth information about a person, social settings, phenomenon or group to allow 
researchers to understand how it operates or functions. For the purposes of this research 
study, and because it is an investigation into emerging health policy, the qualitative research 
design employed a multiple data gathering strategy to gain a detailed understanding of 
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facilitators and barriers to HPV vaccine acceptance and use while assessing policy 
considerations to promote immunization and cervical cancer prevention measures among 
young adult African-American women. 
C. Phase One: Review of Literature February 2007 to July 2008  
In the first phase of the research, an extensive review of both published and the 
“grey” literature was conducted describing factors that influence and/or deter young adult 
women from receiving the HPV vaccine. There were very few published manuscripts that 
dealt with the specific issues of HPV, cervical cancer, and HPV vaccine knowledge and/or 
attitudes among young adult African-American women, during the time in which the 
systematic review was conducted. Study results offered mixed conclusions regarding the 
knowledge and attitudes of young adult women as it related to HPV vaccination. In addition, 
the literature on policy analysis and development was reviewed.  
D. Phase Two: Key Informant Interviews December 2008 to January 2009  
During phase two of the research, a series of key informant interviews were 
conducted to supplement the publicly available literature and to explore the perceptions of 
individuals who are likely to have the greatest potential to inform policy considerations for 
improving vaccine use. Building upon data regarding HPV vaccine acceptance and use, 
individual health practices and cervical cancer prevention themes identified through review 
of the literature, a series of semi-structured interviews were conducted with key informants. 
The interviews were conducted to learn more about the determinants of HPV vaccine use 
among African-American women aged 18-26 years and to identify factors that may hinder or 
facilitate acceptance of the HPV vaccine. This phase of the study gathered information 
regarding preventive health of African-American women and knowledge of HPV and 
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cervical cancer. Additionally, the data collected included overarching HPV vaccination 
issues such as education, fiscal matters, implementation strategies, and barriers and 
facilitators to vaccination. Key informants offered insight into the issues around acceptance 
and use of the HPV vaccine and were able to offer recommendations to address them.     
Selection of Key Informants 
Political scientists categorize stakeholder groups across varied constituency groups. 
For this study, key informants from three principal stakeholder groups: healthcare 
professionals, government officials, and public interest groups were included. The 
participants represented a variety of sectors such as consumers, cervical cancer survivors, 
healthcare professionals (physicians of various specialties and non physicians), government 
and interest groups. Included in the sample were several national experts who offered 
extensive insight around the issues.  Purposeful sampling of key informants with extensive 
knowledge of cervical cancer prevention, allowed for in-depth study and understanding of 
the proposed research questions.  
Data Collection 
To identify potential informants, a list of individuals with expertise in cancer 
prevention and control across stakeholder groups was generated, in collaboration with 
dissertation committee members.  The initial list included 30 people representing the 
following: healthcare professionals (7); government officials (7); and public interest groups 
(16). The study design used a maximum variation purposive sampling approach to ensure 
that  perspectives were representative of the major stakeholder groups.85 Under the paradigm 
of maximum variation, data were collected to ensure inclusion of  representative 
perspectives, while identifying new and emerging issues and important common patterns.74 
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An invitation to participate in the interviews was extended to twenty-eight 
individuals. Due to time constraints and reasons of feasibility, two individuals who 
responded in the affirmative after the cut-off date of January 31, 2009 were not invited to 
participate. Overall, a total of nineteen interviews (N=19) were conducted in Phase 2 (See 
Table 3.2 below).  
Table 3.2: Phase Two-Informant Interviews 
Stakeholder Category # Participants 
Healthcare Professionals 5 
Government Officials 5 
Public Interest Group Stakeholders 9 
Total Interviews 19 
 
Initially, a goal was set to interview 24 individuals, however once theoretical saturation had 
been reached by the 15th interview, an additional 4 informants were interviewed to ensure 
strong consensus in addressing the research questions and to confirm that saturation had been 
reached. In this study theoretical saturation was defined as having been achieved when no 
new information or relevant themes were obtained from the interviews.  The study thus 
included 5 practicing healthcare professionals (4 female, 1 male), including a nurse 
practitioner, pediatrician and obstetrician/gynecologists; 5 government officials (4 female, 1 
male) representing various areas of expertise in public health; and 9 public interest group 
stakeholders ( 8 female, 1 male) reflecting the views of African-American women, the 
pharmaceutical industry, cervical cancer groups, and professional health and policy 
organizations. The interviews took place between December 2008 and January 2009.   
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Potential subjects were contacted by telephone or email to request their participation, 
at which time a brief description of the study was shared using a standardized script in 
English (See Appendix C-Recruitment script).  For those agreeing to participate, a follow-up 
email was sent further explaining the nature of the study and the participant’s role along with 
an informed consent form (See Appendix D- Informed Consent). Participants were asked to 
review, sign, and return informed consent forms at the time of or prior to the interview 
session. Appointments for interviews were also scheduled and confirmed by telephone and/or 
email.   
Semi-structured interviews were conducted in person or over the telephone in an 
office setting. All interviews were conducted in English. A standardized instrument was 
developed and submitted to the UNC Institutional Review Board (IRB Study# 08-1601) for 
approval. The interview guide(s) contained both semi-structured and open-ended questions 
and related to each individual’s role and experience in one of the three principal stakeholder 
groups (i.e. healthcare professionals, government officials, public interest groups). The full 
set of interview questions are available in Appendices E thru G.  Stakeholders’ perspectives 
were explored broadly, allowing the researcher to uncover hidden and emerging themes 
while maintaining the study focus. At the time of the interview session, subjects were asked 
to verbally confirm their permission to be audio recorded. All interviews were digitally 
recorded and detailed field notes were taken during and immediately afterward. The length of 
the interviews varied from 45 minutes to 75 minutes with the average interview taking 
approximately 55 minutes. Participants were extremely engaged and the general tone for all 
of the interviews was conversational. Each subject was sent a thank you note along with a 
$25 gift card. Several participants declined the gift card.  
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Data Analysis 
Immediately after each interview, the digitally recorded files were uploaded and 
saved onto a password-protected computer in the researcher’s home office. The interview 
files were sent electronically in two separate sets to an individual external to the research 
team for transcription. Interviews were transcribed verbatim and verified against the audio 
recording to ensure that all thoughts and opinions were included in the analysis. Once 
verification of the transcripts was complete, the investigator conducted a content analysis, 
which involved identifying themes and categories prior to coding the data. In addition to the 
principal investigator, three individuals not involved in the research independently reviewed 
15% or (3 of 19) of the transcripts to ascertain themes and categories. As a result, a set of 
codes and code definitions were developed. Each subject was given an alphanumeric 
identifier so their specific comments could not be linked to the data.  
Upon completion of the content analysis, the interviews were imported into 
NVivo8™, a qualitative analysis software program for systematic analysis. The primary 
investigator performed all of the coding. Interviews were coded for important themes related 
to the phenomena under investigation. A variety of themes and patterns emerged through this 
multi-phase coding process.  The themes included in the coding were based on the collective 
knowledge, perceptions, and experiences of the researcher, members of the research team, 
and informant interview participants, allowing for a robust analysis of each issue or topic that 
was being researched.  
The codes that were used in Phase 2 were designed to reflect the research questions 
being asked, but also to allow for sufficient opportunity for informants to expand upon the 
issues. The primary categories of “Attitudes, Practices, Beliefs”, “Barriers”, “Facilitators” 
and “Implementation Strategies” were subdivided or branched into more specific groupings, 
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and an “Other category” was added to include information that was important, but did not 
necessarily address the research questions being explored. Please refer to Appendix H for the 
primary codes, sub-codes, and definitions, used in Phase 2. Following the coding of all 
interviews, coding reports were generated for each of the codes in order to systematically 
analyze the information from the informants. The results of Phase 2 are presented in Chapter 
4: Results of this dissertation.  
E. Phase Three: Policy Analysis & Interpretation 
During this phase of the research study a review and interpretation of relevant 
literature was performed associated with vaccine policy, diffusion of medical innovations, 
and the adoption of policies. A review of the vaccine literature was conducted to assess the 
current state of immunization policy in the U.S. and identify evidence-based approaches that 
may influence the determinants to increasing acceptance of the HPV vaccine. Two 
frameworks, the Socio-Ecological Model and Kindgon’s Three Stream Model, were 
employed in the evaluation of policy options addressing both the individual and public health 
perspective associated with increasing acceptance and use of a vaccine to prevent cervical 
cancer. The Diffusion of Innovations theory served as a framework for adopting new 
innovations, which has direct application to this study in relation to HPV vaccine adoption; 
concepts of this theory also aided in evaluation of policy diffusion. Furthermore, 
interpretation of the policy analysis will be used to guide development of the policy 
intervention and advocacy plan.  
F. Ethics & Confidentiality 
      A request for ethics approval was submitted to the Office of Human Research Ethics- 
Institutional Review Board (IRB) at the University of North Carolina in September 2008, and 
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approval from the Public Health-Nursing IRB was obtained in early November 2008 (See 
Appendix D).  As per the guidelines of ethical research, each individual who participated in 
this study was first contacted either by telephone or email. If the individual willingly chose to 
participate in this research by agreeing to an interview, they were emailed a cover letter 
describing the study, a follow-up email to schedule a time for the interview, and the consent 
form. As described elsewhere, the participants were then asked to review and return the 
signed consent form by fax to the primary investigator. All informants in this study provided 
voluntary, written and informed consent, gave verbal permission to tape record the interview, 
and understood fully that their answers were provided with anonymity. Once the data had 
been analyzed and the study completed, all recordings were destroyed to ensure that no 
responses would be linked to an individual or institution. The results are presented in 
aggregate and the names of the individuals held as confidential. Descriptors of key 
informants are attached to respondent’s comments as depicted in Chapter 4: Results; in order 
to maintain confidentiality of the respondent, the participants name and organization are not 
included.
  
CHAPTER IV: RESULTS 
 
 This chapter reports the analysis and results of interviews conducted with key 
informants to learn more about the determinants of HPV vaccine use among African-
American women aged 18-26, and to identify factors that may hinder or facilitate acceptance 
of the vaccine. The findings are presented and answer the studies research Aims 1, 2, and 3.  
 
Research Question 1: What are the attitudes, practices, and beliefs about human 
papillomavirus vaccine among young adult African-American women? 
Aim 1: Describe attitudes, practices, and beliefs about HPV vaccine among 
young adult African-American women; 
Aim 2: Explore factors associated with nonparticipation in HPV vaccine use 
among young adult African-American women; and 
Research Question 2: What factors would be likely to hinder or enhance the 
effectiveness of policies aimed at increasing use of the HPV vaccine for cervical 
cancer risk reduction among young adult African-American women, aged 18-26?  
Aim 3.Identify related attitudes and health practices associated with use or 
nonuse of HPV vaccine among young adult African-American women. 
  
The questions posed to key informants were developed specifically for each of the three 
stakeholder groups 1) healthcare professionals, 2) government officials, and 3) public interest 
groups represented in the study, based on their area of expertise. It should be noted that 
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subjects’ responses cannot be generalized to all African-American women but offer insight 
into the issues some may face.  
A. Descriptive Analysis 
 The individuals included in this portion of the study embody a wealth of knowledge 
and expertise with regard to cervical cancer prevention and African-American women’s 
health.  Table 4.1 describes the interview participants- representatives of  a variety of sectors 
including consumers, cervical cancer survivors, practicing healthcare professionals 
(physicians of various specialties and non physicians), government officials- representing a 
range of expertise in public health- cervical cancer, immunization, women’s health and 
sexually transmitted diseases and representatives of public interest groups reflecting the 
views of African-American women. The participants included a group of national experts 
who offered extensive insight into the issues, underscoring their levels of experience and 
commitment, domestically and internationally. 
Table 4.1: Key Informant Interview Participants by Stakeholder Group 
STAKEHOLDER CATEGORIES NUMBER OF PARTICIPANTS SECTOR 
Healthcare Professionals 5 
Nurse Practitioner 
Pediatrician 
Obstetrician/Gynecologist 
Government Officials 5 
Public Health professionals: 
° STD/HIV 
° Immunization 
° Cancer 
° Women’s Health 
Public Interest Groups  9 
Women Legislators 
Cervical Cancer Survivor  
Cancer Professional Org 
University Health 
Pharmaceuticals 
Educational Development 
African-American Health 
African-American Sororities 
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Nineteen individuals, out of a possible twenty-eight, participated in the key informant 
interviews for a total response rate of 68%. The following distribution of key informants 
across stakeholder groups: five healthcare professionals (27%), five government officials 
(27%) and nine members of public interest groups (48%), constituted the sample.  A total of 
19 semi-structured interviews were conducted, reflecting a diversity of knowledge, 
experience, and perspectives across the stakeholder groups. Work environments/settings of 
the sample were varied and included: private practices, public health department, non-profit 
healthcare organization, academia, federal and state government, academia (university), 
pharmaceutical industry, professional health and policy organizations, and civil society 
groups. Interview questions may be found in Appendices E-G. 
B. Emergent Themes 
 Upon further review and analysis, codes that were associated or similar with each 
other were merged and organized into overarching themes. Through the analysis of the 
interviews, several themes emerged to suggest factors that may hinder or facilitate 
acceptance and use of the HPV vaccine among young adult African-American women. The 
themes are described below in Table 4.2. 
       
Table 4.2: Emergent Themes 
THEMES 
1. AA perceptions of prejudice and a healthcare system rooted in racism and 
discriminatory practice’s exacerbates disparities in HPV-related disease and 
is likely to impede vaccination. 
2. The high cost of the HPV vaccine is a significant barrier to both patients and 
providers. 
3. Health beliefs are influenced in numerous ways, having implications on 
health behavior decision-making. 
4. Social support and trust are essential in fostering HPV vaccination to AA 
women and building community buy-in. 
  40
5. Concerns about the HPV vaccine, such as safety and side effects must be 
thoroughly addressed within communities of color prior to introduction. 
6. Overcoming barriers to HPV vaccination requires a multifaceted approach 
based upon community engagement. 
7. Preventive health and cervical cancer reduction should be considered within 
the context of overall health for AA women. 
8. Provider role and experience with HPV vaccination is a key component to 
vaccine delivery and patient decision-making. 
9. Benefits of HPV Vaccination to AA women 18-26 extend beyond protection 
against genital warts and cervical cancer. 
10. HPV knowledge and awareness is deficient across audiences- general 
public, patients and providers 
11. HPV education and communications would benefit from the use of 
technology and celebrity spokespersons. 
12. Effectively integrating HPV vaccination policies & strategies is critical to 
advancing reductions in cervical cancer incidence and mortality. 
13. Issues surrounding acceptance and uptake of vaccination against HPV 
extend beyond the women themselves and would benefit from further 
exploration (e.g. male vaccination and community confidence in vaccination). 
 
 After evaluation of the data based on these themes, the data were assessed in relation 
to the research aims. The various statements within the themes are organized to address 
research question one (Aim 1& 2) and research question two (Aim 3). The results are reported 
in this dissertation from this perspective. Following is an overview of the themes along with 
illustrative comments by the interview subjects.  
 
C. Key Findings 
 
Key Finding 1: An inherent mistrust of government, the healthcare system, and 
industry is pervasive throughout the African-American community. Perceived or real 
discrimination and mistrust create skepticism, influencing the choices one does or does 
not make about his/her health.  The significance of mistrust in the AA community is 
demonstrated on several levels.   
 
 Mistrust emerged as an issue of high importance, a barrier to a multitude of problems 
that plague the African-American community, including health. The overwhelming majority 
of informants agreed that uncertainty in terms of vaccines and suspicion of the healthcare 
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system in general hamper efforts to increase use of the HPV vaccine in this population. These 
findings are consistent with results of a study examining acceptability of HPV vaccination 
conducted by Scarinci et al, which confirmed a historical lack of trust in the medical system 
as a concern among African-American women.36 Several respondents were familiar with the 
Tuskegee Study 86, 87 and acknowledged its role and the nation’s history of racism and 
discrimination, in shaping the negative views about government, the medical community and 
pharmaceutical industry, for generations of people of color.    
I think overall, you know, African-American people have kind of a distrust with new things 
and new medicines and feel like things are experimental and that there’s potential harm. 
(Government Official)  
 
People still feel that the African-American population is still at risk of being tested on. 
(Healthcare Professional) 
 
You know there are the traditional barriers, everything from history to genocide, to 
suspicions of the “man”. (Public Interest Group- Pharmaceutical Industry) 
 
Ramming it down people’s throats is not a good idea and is potentially going to do more 
harm than good. I mean some people in some communities see it as “look at what the man is 
trying to make us do”. (Public Interest Group- University Health nonprofit) 
 
A participant who is a cervical cancer survivor speaks passionately about the consequences 
for African-American women who focus on medical abuse from the past: 
I think the worse thing we do to ourselves as African-American women, we take care of 
everybody else and we don’t take care of ourselves.  We always say how we’re left out, we’re 
underserved. But I think we miss out on good quality healthcare when we have this 
preconceived notion of our past, of what’s happened in our past. Are we going to keep living 
in the past, or demand and have access to good quality health care? (Public Interest Group- 
Cervical Cancer nonprofit)  
  
 Another informant representing a public interest group spoke about African-
American people feeling as though they are being targeted for vaccination, which has 
considerable repercussions for acceptance of the vaccine.  She states, “When Gardasil® first 
came out, and the commercial had a number of black and brown girls in it, we [MERCK] 
were accused of trying to target them.” She went on to explain that bearing a 
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disproportionate share of disease makes black and brown women targets, and if women of 
color understood this, perhaps they would be more aggressive in seeking out the vaccine. 
 Aware of the disparities in HPV infection and cervical cancer mortality rates, the vast 
majority of respondents pointed to the need to share data about the burden of disease among 
this population. On the contrary, a few respondents raised concerns that there is an 
underlying sentiment of ‘bad news fatigue’ among communities of color and especially 
within the African-American community; that disclosing these differences would have 
harmful implications.  
Because we were talking about disparities and messages and things like that, you know, there 
should be no program and no messaging about black people getting more STD’s than white 
people.  I think that is something that is not going to encourage anybody to go get an HPV 
vaccine or get a pap smear. (Public Interest Group- Health Education nonprofit)  
 
The respondent went on to suggest that framing the statistics differently so as not to blame 
the victim would perhaps engender a feeling of receptivity.  
I mean, this whole notion of saying black people are at higher risk, you have to then say why 
they’re at higher risk I guess.  I mean, you know, why not just say, black people are at higher 
risk and one of the reasons is because, we so often historically had less access to getting 
early care and we deserve to get that early care and you know, there are ways to get that. 
Maybe that is more palatable than saying black folks are out there having unprotected sex 
more than white folks, which just can get people really pissed off and defensive and, you 
know, it’s very blame oriented. (Public Interest Group- AA Health nonprofit) 
 
The above finding reveals a sentiment which suggests that emphasizing negative health 
outcomes may detract African-Americans from taking action to improve their health status. 
Rather than motivating people, the unintended consequences of framing health disparities 
and messages negatively may actually steer minorities away from participation in services 
and further reinforce mistrust. Consensus on the effectiveness of positively versus negatively 
framed messages has not been reached in health communications. 
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 Skepticism about the validity of the data and how it is reported was expressed on 
several occasions.  At a minimum these highlight respondents concerns about information 
bias, and mistrust of the medical establishment. One respondent suggested that all of the data 
about rates of infection and disease weren’t being reported consistently across racial groups; 
that it was dependent on where one received healthcare (i.e. public health clinic versus 
private provider or not at all) 
I know when I see that data I’m like I cannot believe that data, I’m skeptical.  How do they, 
how do they prove that more black people get STD’s than white people?  You know, more 
black people use the public health system so they definitely have to track it that way but, these 
private docs, are they? I’m not clear on how that data gets collected.  I’m absolutely not 
clear at all. (Public Interest Group- Health Education nonprofit)  
 
As illustrated above, fundamental to these particular findings is the recognized need for 
information to be perceived as unbiased by both young adult women and the African-
American community as a whole.  
I think the education has to come from the community themselves, and for people who look 
like them because they think that’s the only way that they feel that there’s not a bias in how 
it’s being brought to the community.(Government Official). 
 
Several informants suggested that the government take a less prominent role, given historical 
and current events resulting in racist and discriminatory practices against blacks committed 
by government entities. 
 These particular findings suggest that high levels of medical mistrust hinder 
participation in preventive health practices, for instance vaccination and screening; as a 
result, individuals are more likely to present at more acute stages of illness when conditions 
have worsened. Medical behaviors such as this place an additional burden on the individual 
and systems of healthcare. Consequently, segments of society suffer from conditions that are 
preventable because of lack of confidence in the systems responsible for delivering high 
quality care to all.  
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Key Finding 2: Access to HPV vaccination by young adult African-American women is 
hampered, due to lack of affordability and availability, substantially limiting entrée by 
this population. 
 
A number of questions were posed to informants about perceived barriers to HPV 
vaccination among African-American women.  While there was no one response to this 
question, subjects repeatedly emphasized affordability of the HPV vaccine as a barrier. The 
high cost of the vaccine, at $120 per dose with a requirement of three doses, was deemed a 
formidable obstacle for young adult women seeking vaccination, as this group is generally 
low-income and uninsured. One informant, an expert in immunization, noted that this was the 
most expensive vaccine of all of those recommended by the ACIP.  For those over the age of 
18, without private insurance that covers it, there is no system of financing in place to 
support full or subsidized payment for adult immunizations. Informants commented: 
 
The issue of cost is something that I think in and of itself is a barrier to young adult females- 
if you have to pay $300 then it’s going to be a huge barrier, so all the communication 
messaging and attempts to influence its use are inconsequential without some kind of system 
that helps them cover it. I mean, if they can’t afford it, they won’t get it. (Government 
Official) 
 
 
Expense of the HPV vaccine to providers was also viewed as a barrier because it affects their 
ability to adequately stock and administer the vaccine. 
Reimbursement is not adequate, you don’t always get paid for the vaccine from the insurance 
company…... In my opinion, Merck has priced the vaccine too high. The cost of the vaccine is 
about the same as what insurance companies reimburse. Which means there’s no ability to 
have any overhead coverage, no profit in the vaccine. (Healthcare Professional) 
 
These findings illustrate how cost can serve as tremendous obstacle in the receipt and 
administration of the HPV vaccine to both patients and providers. Currently, the high price is 
an impediment to the availability of the vaccine thereby reducing access, and subsequently, 
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introduction and uptake are likely to be delayed, particularly among certain populations. 
Furthermore, consideration must be given to the resources required to administer an 
immunization program beyond the purchase of vaccine, such as monitoring and surveillance 
functions, which contribute to the costs born by governments, insurers, and individuals. 
Ensuring access, especially to vulnerable populations, is a precursor for successful 
implementation.      
 
 
Key Finding 3: The interplay of external forces in one’s environment, at multiple levels 
(individual,  relationship, community, society) are influential in determining attitudes 
about health and health behaviors, particularly as it relates to AA woman’s acceptance 
of the HPV vaccine. These forces can either pose barriers or facilitate behavior change.     
 
Barriers 
 
Echoing the findings of numerous studies, respondents recognized that sociocultural 
issues of African-Americans and other minorities are germane to furthering efforts that 
support HPV vaccination to at-risk populations. Beyond identifying these factors, a thorough 
examination of how they impact attitudes toward immunization against HPV and 
consideration of the ways in which these attributes can be exploited to benefit these groups is 
critical to the development and employ of strategies for vaccine introduction.  Table 4.3 
summarizes the barriers that may hinder acceptance and uptake of HPV vaccination by 
young African-American women.  
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Table 4.3 : Barriers that Hinder Acceptance/Use of HPV Vaccine 
BARRIERS INFORMANT RESPONSES 
Lack of Knowledge about Issues 
 Lack of knowledge/ information about HPV/ cervical cancer/ HPV 
vaccination 
 Unaware of risks & benefits 
 Lots of misinformation 
 Awareness has not translated into knowledge  
Access  Cost- unaffordable  Availability 
Lack of Perceived Risk/Need 
 Unaware of personal risk factors 
 Preventive health is generally not a priority among this age group-
feelings of invulnerability 
 Sexual behavior- monogamous relationship 
 Age group not part of routine vaccination schedule 
Stigma associated with HPV and STI  Taboo subject  Implies promiscuity 
Personal and Cultural Beliefs 
 Religious beliefs 
 Opposition to vaccines 
 Not motivated 
 Fear 
Safety/Efficacy Concerns 
 Side effects 
 New vaccine-hasn’t been out long enough 
 Duration of Protection 
Patient Compliance  3 dose compliance 
Providers  Recommendation (lack of)  Interpretation of guideline not favorable to older cohort 
Mistrust of Healthcare System, 
Government and Pharmaceutical 
Industry 
 Skepticism  
 Racism/discrimination 
 Past negative experience with medical community 
 African-Americans  perceived as being targeted 
 Biased information (disparities among AA) 
 
Lack of perceived risk and need for vaccination, for example whether a young woman 
thought her own behaviors put her at risk, was highlighted as a barrier. Several informants 
suggested that the importance of taking preventive measures and being proactive about one’s 
health is generally not a priority among this demographic.  Two respondents stated that 
regular vaccination was generally outside the norm for 18-26 year olds; they also discussed 
getting a vaccine to prevent cancer was not considered an important issue because at this age 
there is a sense of invulnerability.  
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I mean often, you know, a lack of perceived need is kind of a barrier.  Lack of perceived risk 
for HPV or cervical cancer, misunderstanding sometimes, you know, that cervical cancer is 
hereditary, and that the vaccine just won’t work. (Government Official) 
 
Yet another common theme that surfaced was the view that educational efforts need 
to be communicated in a way that was not perceived to be stigmatizing; that HPV not be 
considered a taboo subject. Several respondents suggested that the stigma associated with 
getting the HPV vaccine impeded acceptance and use, because for some it implies 
promiscuity. They argued that a concerted effort should be made by the medical community 
to market immunization against HPV as a cervical cancer prevention issue; removing 
language from the vaccine guideline which recommends its routine use prior to the onset of 
sexual activity.  
MERCK has done a really good job at kind of promoting it without that kind of stigma and 
keeping as far away from the issue, you know, of STDs. (Healthcare Professional) 
 
On the contrary, one informant felt as if the vaccine was being mismarketed because of its 
focus on cervical cancer; arguing that the main emphasis should be getting people to protect 
themselves from acquiring HPV, secondary to protection from the common complications of 
HPV. The respondent noted that while the virus is sexually transmitted; vaccination and 
prevention are NOT about sexual activity or promiscuity. 
 Additional barriers expressed by informants identified personal and cultural beliefs, 
views on vaccination, and an individual’s motivation as having the potential to hinder use of 
the vaccine. Several individuals suggested there are those who are ideologically opposed to 
vaccines, feeling as though they do more harm than good.  
Another recognized that even when individuals are educated and well informed, they may not 
have the motivation to take further action. In some ways, this correlates to the value of health 
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and wellness in the African-American community, another key finding brought forth during 
the interviews.  
 Concerns around safety, side effects and fear of a new vaccine were expressed as 
barriers to use and acceptance. Several informants suggested that some believe there is a risk 
associated with the use of new vaccines; that the HPV vaccine hasn’t been out long enough, 
and both females and parents want to see more evidence of its safety before making a 
decision. On more than one occasion, informants expressed that, in general, people don’t like 
taking new medications and once they hear of one bad outcome or potential side effects, 
regrettably, they become afraid. Likewise, several informants raised issues concerning the 
mass of misinformation being exchanged about the HPV vaccine 
 The barriers are lack of, what I would call, real information…… understanding who it’s for 
and understanding what side effects it’s going to cause. (Healthcare Professional)   
   
Just basically people say, oh, you know, there have been deaths and I think the media and the 
internet have done a bad job about that, putting that stuff out that’s unfounded per se. I think 
that’s the number one barrier. (Government Official)  
 
As was mentioned previously, several informants also stated that requiring three doses of the 
vaccine posed significant challenges. For a variety of reasons there will likely be a fall off in 
the proportion of women who get the second and third shots.  
 As these findings suggest, the variety and complexity of issues that may hinder 
acceptance and uptake of the HPV vaccine among young African-American women are 
wide-ranging. Successfully addressing these obstacles is expected to contribute to 
willingness to recognize the importance of primary prevention and consent to vaccination. 
The extent to which they can be overcome will require the collective efforts of many, 
centered around: community engagement, education, transparency and the investment of 
resources.     
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Facilitators  
 
Along with identifying barriers associated with HPV and HPV vaccination, subjects 
were asked to consider what actions should be taken to support women in overcoming them. 
Similarly, they were asked to offer insight into approaches that could potentially facilitate 
acceptance of the vaccine. As was expected, there was no one consistent answer for 
addressing the obstacles that discourage the practice of healthy behaviors and use of 
preventive health services among young adult African-American women. The majority of 
responses fell within the following categories: 1) Education, 2) Access, 3) Social Support, 
and 4) Trust. Participants identified factors that encourage acceptance and use of HPV 
vaccination presented below in Table 4.4. 
 
Table 4.4: Facilitators that support Acceptance and Use of HPV Vaccine 
FACILITATORS INFORMANT RESPONSES 
Education  
 Peer education (particularly for this age group) 
 Appropriate information needed to make informed decisions 
 Accessible information  
 Simple, accurate, consistent messages 
 Culturally competent 
 Dispel myths 
 Increase acceptance 
 Knowledge is Power- empowerment over bodies 
 Physicians to educate/recommendation 
Access 
 Reduce cost of vaccine 
 Expand public funding for adult vaccination 
 Availability in multiple venues 
Social Support 
 Encouraged by partner, family, peers, community 
 Peer education (particularly for this age group) 
 Credible source communicating information (AA, someone from 
community/identify with) 
 Cervical cancer survivors 
 Physicians of color community outreach 
Trust  Needs to be built from within community 
 
The value and importance respondents attached to education and information for 
making health decisions cannot be overstated. Across stakeholders, education about HPV, 
cervical cancer, and primary and secondary prevention methods was suggested to enhance 
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knowledge, but it was also seen as a way of dispelling myths while increasing acceptance. 
Motivating individuals to apply that knowledge, assess the risks and benefits, and understand 
what the information means was seen as one way of empowering people to want better health 
for themselves. 
  Educating women in this way was also perceived as a form of empowering African-
American women to take control of their bodies; and consider issues of health and 
prevention. One respondent suggested that becoming informed about HPV encouraged young 
women to better understand how their bodies work and what actions can be taken to protect 
their sexual health. Another stated enthusiastically, “knowledge is power” and that this 
preventive measure was an opportunity deserved by African-American women, who have 
historically had less and/or delayed access to care. Informants also cited the importance of 
accurate, consistent, and transparent information. Such messages framed without stigma 
would be well received by African-American women.  
Respondents raised several issues associated with the expense of the HPV vaccine: 1) 
need for cost reduction, 2) need for options to help underwrite the cost for people who can’t 
afford it, and 3) expansion of insurance coverage and increasing reimbursement rates. One 
government official suggested that the cost of the vaccine would decrease over time, 
improving availability. The respondent went on to say, this will likely have a substantial 
impact on the provider’s willingness to administer the vaccine and increase access to young 
adult women.  
 Routine funding for adult immunization is limited at best and in some cases non-
existent. Four informants expressed familiarity with a couple of programs designed to 
increase financial support of adult vaccination- CDCs Section 317 Program and MERCKs 
Vaccine Patient Assistance Program. They suggested expansion and greater use of these 
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programs to enhance access to the HPV vaccine among African-American women, 19-26 
years of age. Additionally, subsidizing the cost of the vaccine through use of a sliding fee 
scale or at no cost; as well as a combination of public and private financial support, were 
recommended by a number of subjects. Another respondent noted that cost was not the only 
barrier to accessing the vaccine; enhancing availability of the vaccine through multiple 
venues in the community was also perceived as a strategy to promote use. Examples included 
having a mobile vaccine clinic, providing transportation, and enhancing hours of operation. 
 Encouraging vaccination against HPV by family, a spouse/partner, community and 
knowing someone who had been vaccinated were mentioned as facilitators to use and 
acceptance by several informants. As mentioned previously the use of peer educators to 
facilitate discussions was seen as a way to increase knowledge and acceptance. One 
informant stated: 
I think that if you had peer groups… educators, having information where people within the 
age group, actually bring it up and discuss it. At this point, speaking about HPV in a social 
situation is really not common. So it’s one of those of making it more common, making it 
known, making it not a hard thing to say and not a hard thing to discuss. (Public Interest 
Group- AA Health nonprofit) 
   
The key is engaging young women…… Their willingness to participate will probably 
persuade those around them, their peers to get involved. (Public Interest Group- Health 
Education nonprofit) 
   
The significance of having a trusted and credible source to communicate information 
was highlighted often. One respondent noted the value in having someone from within the 
community, whom African-Americans can identify with to discuss the vaccine’s efficacy, 
safety and concerns about side affects, with an emphasis on health and wellness. Another 
respondent spoke of her success with cervical cancer survivors from the African-American 
community telling their stories and the impact on young women opting to be vaccinated. A 
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celebrity that resonates with young women, who is a proponent or perhaps recipient of the 
HPV vaccine, opinion leaders, athletes, musical figures, entertainers were examples given.  
Patients look to physicians for guidance on decisions regarding their health. The 
benefit of having a provider of the same racial background disseminating information, 
conducting community outreach and recommending use of the vaccine was recognized as a 
means to fostering acceptance.  
 
Key Finding 4:  There is no consensus on how important the prevention of cervical 
cancer is in African-American women, but it should be considered in the context of 
overall women’s health rather than a stand alone issue.   
 
 According to respondent’s taking a proactive stance toward a healthy lifestyle and 
ensuring one’s health and well being has taken a backseat to more pressing issues and 
competing priorities. Thus, when asked the question ‘How much of a priority is cervical 
cancer reduction for preventive health among African-American women?’ one informant 
suggested that discussions about health for African-American women should focus on her 
overall health- a woman’s reproductive, sexual, and mental health because they are so 
interconnected. This was not meant to imply that cervical cancer was not a priority; however, 
given the significance of other health issues currently faced by African-American women and 
communities of color, a more holisitic approach to prevention was offered. Additionally, 
taking action against competing chronic disease conditions such as diabetes, obesity, 
hypertension, and cancer in general was given preference over cervical cancer prevention. It 
was also suggested that the medical community places more emphasis on these other chronic 
disease conditions. As one respondent, a healthcare provider, noted, “I have to say that I look 
at all of the other diseases, you look at, the U.S. Preventive Services Task Force, you look at 
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the CDC Healthy People Guidelines, and you realize that if we could prevent diabetes or if 
we could prevent hypertension, or if we could increase exercise and prevent obesity, we 
would have a much bigger impact, a much bigger number of people than with cervical 
cancer.”    
Amongst African-American women and those of other population groups, disparities 
in cervical cancer morbidity and mortality persist. In addition, the rates of sexually 
transmitted infection, including HPV are higher among this population. Several subjects cited 
the differences in cervical cancer diagnosis, treatment, and survival among women of color 
as a motivating factor in preventing the disease. The responses of informants were mixed 
regarding cervical cancer risk reduction as a priority for preventive health among African-
American women. The continuum of responses ranged from cervical cancer prevention being 
a high priority, of moderate importance, to no concern at all.  
 
Since black and brown women are disproportionately affected by cervical cancer and are 
more likely to get the disease and more likely to die from this disease, this should be a major 
public health concern in our community. (Public Interest Group- Pharmaceutical Industry)  
 
Not as important. Diabetes and hypertension and mainly weight and obesity. And I think that 
comes from providers and what they emphasize as well as what a lot of African-American 
women are concerned about. (Healthcare Professional) 
 
 Across respondents, a general lack of understanding about cervical cancer was 
expressed frequently as one of the primary reasons prevention of the disease was less of a 
priority among African-American women. This included the link between HPV and cervical 
cancer and use of the Pap test as a tool for cervical cancer screening.  As one public interest 
group respondent put it, “Well, I don’t know how many African-American women honestly 
make the connection between cervical cancer and HPV….” It was suggested on numerous 
occasions that individuals are not sufficiently informed about their risk of acquiring HPV and 
thus their perceived risk of cervical cancer is minimal at best. Knowing someone personally 
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with the disease was commonly associated with a woman perceiving herself to be at 
increased risk and taking action toward prevention.  
I think it’s still not a priority the way that it should be because I think people still think that it 
won’t happen to them and even with all the commercials that are out now,  I still get plenty of 
calls like what is HPV?...... How is it linked to cervical cancer? (Public Interest Group- 
Cervical Cancer nonprofit)  
 
 Among young adults, pregnancy and acquiring other STDs such as HIV and 
Chlamydia were mentioned as priorities for prevention. This is due in part to the fact that 
these conditions disproportionately affect African-Americans (AA women) in greater 
numbers when compared to cervical cancer alone. When looking specifically at young adult 
women, aged 18-26, respondents were consistently of the same opinion; that the benefits and 
importance of preventive health was not something that was highly valued among this 
population. As a group, young adults 19-26 are generally healthy and utilize the healthcare 
system less frequently. They are also more likely to be low-income and uninsured. 
 
 
Key Finding 5:   Deficiencies in understanding of HPV, the HPV vaccine, cervical 
disease and prevention remain among the general public and healthcare providers, as 
an obstacle to vaccine acceptance and decisions regarding vaccination. Addressing the 
educational needs of these multiple audiences will require that messages successfully 
attend to the views and concerns of each group.   
  
The overwhelming consensus among those interviewed is that health literacy in 
general is poor in this country and improvements in this area alone would be a big step 
toward reducing some of the health disparities that currently exist. Inadequate channels for 
communicating health information to individuals, communities, and the public further limits 
the ability for  enhancing knowledge about HPV and cervical cancer prevention. It was also 
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mentioned that women of color often times have less access to health information which 
influences their understanding and decision-making. A universal theme across stakeholder 
groups was the need for more education about cervical cancer issues encompassing 
understanding HPV, primary and secondary prevention measures and education at 
appropriate levels which incorporate messages that are culturally tailored to specific 
populations. 
Overall, the topic of HPV was described as confusing to both the general public and a 
large majority of the healthcare community.  Several reasons for this were given such as: the 
complexities associated with HPV’s prevalence - at some point everyone will likely be 
exposed to one or more of the virus types and its ability to clear on its own; the sexually 
transmitted nature of HPV and; being unaware of its relation to cervical cancer. On several 
occasions, informants make a distinction between the patient’s lack of understanding of HPV 
and the provider’s limited knowledge, and the need for targeting educational messages for 
specific audiences.  
Patients were perceived as not having a basic understanding of HPV or their risk of 
acquiring the virus to make an informed decision about vaccination. An informant noted that 
women needed to understand the risk of the disease prior to receiving information on how to 
prevent it.  In general, informants indicated that African-American women should become 
more aware of their personal risk of exposure to HPV and development of cervical cancer, 
based on a variety of individual factors. The disparities in cervical cancer morbidity and 
mortality and higher rates of sexually transmitted infections among this population certainly 
place this group at higher risk. Two respondents specifically took issue with use of the term 
cervical cancer risk behavior because it evoked a negative connotation of something 
abnormal; they noted that the primary behavior associated with infection of HPV is sexual 
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activity, a natural human behavior. Herein lies some of the controversy associated with HPV 
and vaccination against the virus: the nature of transmission. 
What is the main behavior that causes HPV infection? Sex, ok?  Now are we going to say that 
having sex is a risk behavior?  I mean, sex is a normative human behavior so that’s why it’s 
kind of like, ah, you know, it’s a little uncomfortable to say that, you know, how do we 
address that risk behavior?(Public Interest Group- Pharmaceutical Industry) 
 
Sex is part of a healthy life for adults and HPV is the water in the swimming pool of sex and if 
you have sex, you’re going to be exposed to HPV, so let’s protect ourselves against the 
complications of it (Public Interest Group- University Health nonprofit) 
 
Nevertheless, the general consensus was there are ways one can limit exposure to 
different types of HPV and likewise the number of exposures, to reduce the risk of 
developing cervical cancer. Some strategies for risk reduction included things like reducing 
the number of sexual partners, smoking cessation, proper nutrition/diet, and condom use 
especially if a young woman had multiple sex partners.    
 Similar to being educated about ones personal risk of acquiring HPV, it was 
important for African-American women to understand the risks and benefits of vaccination in 
order to make informed decisions. Incorporation of a decision tool similar to those used to 
help men decide whether to be screened for prostate cancer was recommended as one method 
for ensuring that women have enough information.  
I think that there could very easily be a really wonderful decision aid to put together that 
would list the pros and list the cons, including safety issues that have arisen, and include the 
magnitude of those issues, ... something about the woman and her own values are being 
protected against HPV and that decision aid could then very clearly guide them into helping 
them make a decision about whether they wanted it or not.(Healthcare Professional)  
  
 The vast majority of respondents indicated the need for physicians to be well 
informed and deliver information in such a way that it becomes a routine part of healthcare. 
One respondent, an OB/GYN, commented on the importance of provider knowledge in 
relation to improving health literacy about HPV and cervical cancer prevention among 
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patients. This finding suggests a connection between providers that are educated on the issues 
and their ability to supply information to patients.  
Understanding the disease process and available modalities to prevent HPV related 
disease, was identified as one of the key components necessary to effectively educate and 
inform patients. In some instances, healthcare providers were criticized for conveying 
messages that were characterized as ‘stigmatizing’ and not helpful to the patient. All 
respondents suggested that providers needed to be equipped with the appropriate information 
and tools to communicate in ways that are meaningful to the patient. Several informants 
agreed that providers who were most knowledgeable about HPV exhibited greater buy-in 
regarding the importance of vaccination and had higher levels of comfort discussing HPV 
information.  
 
 
Key Finding 6:  In the face of complex and ever-changing information demands 
regarding HPV and cervical cancer prevention, a comprehensive communication 
strategy that is relevant, culturally appropriate, and tailored to meet the needs of 
African-American women is desirable for fostering acceptance and uptake of the HPV 
vaccination.  
  
Considering the importance of education for increasing acceptance and uptake of the 
HPV vaccine, the types of messages, how they are disseminated, and to whom is a piece of 
the puzzle with which many in practice struggle. When attempting to reach minority 
communities regarding health matters, a multi-faceted approach should be used. The findings 
below illustrate the need to clarify the role of education and information in understanding 
HPV, the etiology of cervical cancer, and the HPV vaccination decision-making process for 
multiple audiences.  
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Conveying information and communicating messages about HPV occurs analogously 
at the patient and provider level. Both patients and providers need to have a general 
understanding of HPV prior to any conversations or decisions about vaccination. 
Respondents emphasized the need for information that is presented in simple terms, using 
common language, and that learning about this particular issue should begin early. One 
respondent, a government official stated, “If we [African-American women] don’t 
understand it, we’re not going to do it.”  
 Messages were classified into two categories: 1) a general HPV message and 2) one 
specific to African-American women, underscoring the importance of customizing health 
communications to the audience.  According to respondents, HPV messages should include: 
a basic understanding of the virus and related disease process, ones individual risk of 
acquiring HPV, prevention methods- what can be done to prevent the disease, the pros and 
cons of vaccination, and the need for continued Pap testing. The message was clear that 
cervical screening needs to continue after vaccination and that providers should stress this 
point to women. This message should coincide with any education about HPV vaccination. 
As a healthcare professional, I personally think continued cervical screening has to be the 
first message. And then the second message is HPV vaccination will help your cervical 
cancer screenings be more likely to remain normal. There is a tremendous amount of 
misunderstanding about what the vaccine can and cannot do, which is why I would put the 
cancer screening message first. (Healthcare Professional) 
 
For young women in particular it was also important to emphasize the vaccines safety and 
100% effectiveness against those HPV types, even after becoming sexually active. 
Acknowledging safety concerns- that side effects may occur and duration of protection were 
also issues that have to be attended to.  
 With regard to young adult African-American women, informants consistently 
affirmed that the women themselves should be involved in crafting messages and developing 
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programs intended to reach them. African-American media and those who are familiar with 
AA audiences should also be involved in designing messages and educational tools along 
with members of the community that are recognized as credible, those with communication, 
language and marketing expertise, sociologists/ anthropologists, religious leaders, and 
parents. 
 
 Cervical cancer prevention messages aimed at African-American women were similar 
to the general messages discussed above. According to several informants, educational 
campaigns and materials designed for African-American communities should be culturally 
and instructionally appropriate. Not only was this deemed as a way to increase 
understanding, it was also believed to be a way to reject some of the myths and dispel many 
of the fears that exist to move toward action. Evaluating how the messages are understood 
and how individuals relate that to the benefits that might occur is especially critical, given the 
complexities of HPV.  
So language has to be tailored in a way that when someone says I get it or I understand you 
know that there’s at least a, you know, a 90% chance that they really do get it. (Government 
Official-Cancer) 
 
 Without exception, across informants/stakeholder groups, no one individual or 
organization was identified as the best or most appropriate to deliver HPV/cervical cancer 
prevention messages. Several informants felt that medical specialty groups with expertise in 
cancer prevention and vaccination – family planning, OB/GYNs, pediatricians, teen clinics at 
health departments, student health clinics on college campuses- needed to come together with 
a more cohesive message and understanding of who should benefit from HPV vaccination.  
I don’t think there is any one organization because people listen to different organizations 
according to what their exposures are and what their lifestyles like. (Public Interest Group- 
Health Education nonprofit)  
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 Celebrity spokespersons of color were mentioned; someone recognized by the 
intended audience, such as Jennifer Hudson or Alicia Keys, perhaps a female of prominence 
within this demographic that has been vaccinated themselves. Other potential messengers 
included cervical cancer survivors and young women who have suffered the negative 
consequences of abnormal Pap tests. African-American young men also surfaced as 
individuals who should be part of the solution when it comes to increasing knowledge and 
awareness about HPV and reducing transmission of the virus.  
Given that communications between the two are highly important, it is critical that 
patients see clinicians as a credible and trusted source. The responses were mixed when it 
came to utilizing providers as the primary authority to educate and communicate information 
to young adult African-American women, on what is considered to be a sensitive issue by 
many. Some argued that healthcare providers should be at the forefront; while others were 
steadfast in their belief that physicians of color are most appropriate for delivering HPV 
education. For example: 
I certainly think healthcare providers have responsibility in, in disseminating the message 
one on one. (Government Official) 
 
African –American healthcare providers, including doctors, nurse practitioners, PA’s, 
whoever the appropriate person is, but I think appropriately seeing the face of an African-
American health professional.(Healthcare Professional)  
 
I’m not sure that a doctor is absolutely the best…particularly with an African-American 
audience.  I think there is some distrust of the medical community. (Public Interest Group- 
Cancer Professional Organization) 
 
 
 Among young adult African-American women, information channels about health 
related matters were varied. A personalized one-on-one approach to educating women of 
color/African-American about HPV and cervical cancer prevention was a commonly 
expressed view.  Proponents of this approach stressed the importance of providers being 
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visible out in the communities that they serve, providing information, and education. Most 
assumed that women with access to healthcare received cervical cancer prevention messages 
from a health professional; however given that this age group uses the healthcare system less 
often, that is likely not the norm. 
Television and the internet were seen as primary sources by which African-American 
women generally got information about HPV. Respondents recognized that African-
American women in this age group are heavy users of the internet, especially if they are 
enrolled in college.  According to several informants, the internet was recognized as an 
essential medium for increasing awareness and knowledge, but that also brought forth a fair 
amount of concern regarding the amount of inaccurate information accessed on the internet.  
This finding illustrates the need for accurate information on the world-wide- web from 
credible sources that is easy to navigate due to the influence and broad reach the internet has 
on this age group. Below, Table 4.5 describes the various communication channels of young 
adult African-American women identified by key informants. 
Table 4.5: Communication Channels of young adult AA women 
COMMUNICATION TYPE COMMUNICATION CHANNEL 
Electronic Media Internet, Text Messaging 
Public Media Television, Radio (Urban), Billboards, PSAs, Entertainment Channels/Music/Videos 
Healthcare Providers Physicians, Nurses 
Entertainment & Sports Venues Celebrity spokespersons 
Social Networks Peers, Family, Community Groups, Beauty Salons 
Survivor networks Cervical Cancer Survivors 
Greek Lettered Fraternal Organizations Historically African American Sororities 
 
 
Word-of-mouth (Oral Networks), peers, family, and social networks were cited as 
equally important ways of sharing information, particularly among African-American women 
and those who don’t routinely see a healthcare provider. Because of the significant influence 
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these networks have, it was evident by many that the communities themselves need to 
become better informed and educated; grandmothers, mothers, daughters, opinion leaders, 
and in fact the male partners of these women.   
That for us, you know, we may see something on TV, but you know, our networks are our 
biggest part of where our information comes from because we will see something on TV and 
then, you know, go talk to Aunt Bessie, and Aunt Bessie, um hum, I heard, you know, and 
then, and then it goes on, and…………before you know it, you are not necessarily getting 
information that is valid or accurate.(Public Interest Groups-Pharmaceutical Industry)  
 
 These findings speak to the perceived role and power of social influences on 
knowledge and understanding of HPV related issues. Interestingly enough, MERCK’s “One 
Less” campaign promoting the vaccine Gardasil® was acknowledged to be very successful in 
increasing awareness about HPV because of the multiple-media (print, television, radio and 
internet) channels used to promote their message. However, this heightened awareness has 
not necessarily translated into increased acceptance and understanding among certain 
racial/ethnic groups.  
 
Collective responsibility for disseminating information to as many people, using a 
variety of approaches to ensure that the messages connected and resonated with people, 
appear to be the general consensus. Opportunities to get information out about HPV, risk 
reduction, and preventive measures in as many different venues that young African-
American women gather and are responsive to, was encouraged by the majority of 
informants. Multiple avenues for dissemination were offered including: provider offices and 
student health clinics, community programs, beauty salons, television, billboards, public 
service announcements on urban radio, internet, African-American sororities, entertainment 
and sports venues, and faith-based activities. Use of technology and electronic media were 
endorsed for the college-aged, 18-23 year olds. The internet, pop-up messages, text 
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messaging, music videos and entertainment channels on television were examples referenced 
as ideal venues for discussing health issues.   
 In particular, these findings speak to the importance of identifying the information 
needs of individuals, how best to educate them, and who should be involved in the 
educational process. Assessing these unique variables, in advance of implementing 
immunization efforts, is critical element of making informed decisions to be vaccinated.  
 
Strategies/ Ways to Improve Knowledge 
Methods suggested to improve knowledge about HPV and cervical cancer prevention were 
wide ranging. Woven throughout was the importance of prevention and health promotion in 
general and engaging members of the community to support these efforts. 
 
You have to do the right kind of research upfront like focus groups, for parents, different race 
and ethnic groups, socioeconomic, etc., and figure out what works. (Government Official) 
 
Training existing community leaders to deliver messages and gain buy-in was repeated quite 
often. Organized groups that deliver preventive health messages to their stakeholders should 
incorporate information about HPV and cervical cancer prevention. For this age group in 
particular, 18-26 year olds, the use of a peer educator model emerged as a well-known 
method for educating on a variety of issues, with measurable success. Informants suggested 
this as an effective strategy implemented across college campuses for increasing knowledge 
and acceptance; a few noted the use of peer educators for health education purposes on 
historically black college campuses. 
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Key Finding 7: The benefits of reducing the transmission of HPV among a group 
considered to be at higher-risk, those aged 18-26, are numerous and extend beyond the 
vaccines efficacy and protection benefit to the individual.  The fiscal, personal and 
societal cost savings associated with vaccinating this population are equally significant.  
 Measures to protect against cancer and sexually transmitted diseases, both threats to 
the health of communities of color, are necessary and should be widely supported. 
Vaccination against four HPV types 6-11-16-18 that cause the majority of genital warts and 
70% of cervical cancers has shown to be 100% effective. The ACIP recommendation allows 
for vaccination of girls beginning at nine years old, as well as vaccination of girls and women 
13-26 years old, with the routine vaccination of 11-12 year olds. The vaccine is given in a 
series of three injections over a six-month period, and ideally it should occur prior to the 
onset of sexual activity before exposure to the virus, HPV. Several respondents felt inclusion 
of the statement regarding sexual activity actually dissuades many young adult women and 
healthcare providers from considering the advantages of vaccination for this group. A 
physician shares her thoughts on this particular issue: 
 
It’s really a shame because there are many, many women in that age range who would very 
much benefit from the vaccine who, either their physicians are unwilling to give it or don’t 
feel that it is a priority to give them the vaccine, or the women themselves just don’t hear the 
message because what they hear is, I should have gotten it when I was 12 and it’s too late for 
me.(Healthcare Professional) 
 
 
Although a woman may be sexually active, significant protection benefit from vaccination 
can still be derived. According to an industry official, approximately 97% of women 
participating in the Gardasil® clinical trials were sexually active 18-26 year olds; the efficacy 
data is in fact based upon those in the “catch-up” group. 
I think that certainly the way in which the literature is written to explain that the vaccine 
efficacy is 100%, certainly for everybody through the age of 26, and when you actually broke 
it down by age group, which is never published, you saw that the efficacy was actually higher 
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in our 24 to 26-year-old women than it was in our 15 to 16-year-old women. (Public Interest 
Group- Pharmaceutical Industry)  
 
  Several respondents believed there was a bias against recommending and offering the 
vaccine to women who were ‘assumed’ to be sexually active, based solely upon their age. 
Healthcare providers acknowledged that among this age group, there are those who have had 
minimal exposure to HPV. Some interview participants were of the opinion that, in many 
ways, the ACIP recommendation makes it sound as if the upper age limit is a second class 
group; however, it is just as important for them to be vaccinated as it is for the 11-12 year old 
target group, given the evidence supporting effectiveness of the vaccine. Despite the fact that 
it is highly unlikely that young adult females have been infected with all HPV types, this 
finding illustrates the value judgments shared by many about a woman’s worthiness to 
receive the HPV vaccine after she has become sexually active.  
 The prevention of cervical cancer and genital warts was by far the most 
acknowledged public health benefit of vaccinating young African-American women, aged 
18-26 against HPV. Quite a few informants emphatically stated that prevention of any type is 
always going to be a benefit to the public’s health. A variety of explanations were given, 
including: a reduction in the number of Pap tests and diagnostic procedures; decreases in 
morbidity and deaths; lessening the burden of disease in a population at higher-risk; and 
reducing the strain on an already fragile healthcare system. The advantage of population-
based HPV vaccination over that of a high-risk strategy is evidenced by higher rates of 
immunization coverage of women, which has direct benefits to men in terms of decreased 
transmission of the virus, according to public health experts.   
 Particularly among young adult African-American women, higher rates of HPV 
infection, late stage diagnosis, and cervical cancer deaths were confirmed as a factor in 
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directing immunization efforts towards this group. A compelling argument raised by one 
subject implied that an inadequate healthcare system contributed to disparities in diagnosis 
and treatment of cervical cancer, and perhaps vaccination against HPV was one means of 
rectifying this. 
African-American women, have high rates of Pap testing, however they are still diagnosed at 
more advanced stages of the disease and have worse prognosis which kind of indicates 
something to do with the healthcare system and the quality of care they are getting. So, I 
think if we recognize that, then the vaccine is actually one way to sort of get around some of 
the issues that might come with screening and treatment, because the treatment isn’t really 
adequate or not up to par maybe. (Government Official) 
 
 Quite a few respondents mention lack of access to routine healthcare among young 
adults as a key consideration for encouraging vaccination; as it is assumed that at some point 
among a vaccinated population, cervical cancer screening intervals would likely be 
increased. Another informant suggested that this was an equity issue providing quality 
healthcare to those in greatest need rather than just to those who can afford it.  
 Colleges and universities were referenced by several informants, as high risk 
environments for women to start becoming sexually active; this cohort of females was 
mentioned as ideal candidates for HPV vaccination upon entry onto campus. Two informants 
commented that education and appropriate counseling about HPV related disease would 
increase as a result of vaccination, and considered this advantageous.    
 Many respondents noted the suffering and considerable costs- personal, emotional, 
social, and financial- attributable to HPV related disease that could be lessened to a great 
extent. An unexpected finding suggested a correlation between HPV vaccination and a 
woman’s reproductive health; as vaccination against HPV increases, pre-cancerous cervical 
lesions and rates of hysterectomy among African-American women will decrease. While the 
evidence confirms other conditions more commonly associated with hysterectomy among 
African-American women, the notion that rates of hysterectomy might be diminished as a 
  67
result of vaccination may encourage its use. Additionally, three informants specifically 
mentioned a possible connection between childbearing (e.g. cesarean births and adverse 
pregnancy outcomes) as a result of weakened/ incompetent cervixes.  
 The healthcare dollars tied into treating patients that have genital warts, pre-cancers 
and cervical cancer is sizeable. Several informants felt that the reduction in diagnostic 
procedures due to abnormal cervical screenings could save upwards of $3-4 billion in direct 
costs per year. An OB/GYN and leading expert in cervical cancer prevention went on further 
to quantify the cost savings:  
When you consider the anxiety, and the pain, and all of the secondary costs that are 
associated with this, I think that’s really considerable, …it may triple or quadruple in value.  
So you know we may be saving $16-$20 billion which could be spent on primary 
preventatives, like vaccines. (Government Official) 
 
 
 On a societal level, the cumulative benefits that accrue to the individual would be 
applied broadly. Two informants commented on the reduction of societal costs; for example 
deaths, loss productivity in the older age group, and transmission of the virus associated with 
vaccination of HPV.  From a public health perspective, the population-based approach was 
believed to be less resource intensive on physicians and the healthcare system in general.  
 Evidence is needed to aide policy makers in evaluating the benefits and costs of 
healthcare innovations for decision-making. These findings suggest there are numerous 
criteria that may be considered for the adoption of HPV vaccination among young adult 
women. Furthermore, they reveal the importance of societal values, fiscal, political, and 
ethical issues in the equation.   
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Key Finding  8:  There are varying opinions about who the priority population(s) for 
HPV vaccination should be. Differences in recommendation of the HPV vaccine and 
who it is given to are influenced by the providers interpretation of the vaccination 
guidelines.  
  
 The effectiveness of prophylactic HPV vaccination is maximized when exposure to 
the virus is minimal, generally during childhood or adolescence before initiation of  sexual 
activity. Therefore the routine recommendation is for young girls, 11-12 years of age, when 
exposure to the virus is minimal. Distinguishing the priority populations for HPV vaccination 
was a source of contention among several respondents as the findings below illustrate a 
divergence from the vaccination guidelines.  
 More than half of the informants were asked about their level of understanding 
concerning human papillomavirus and the vaccine to prevent infection of HPV. Overall, 
respondents were moderately to very familiar with HPV and associated the virus as having a 
causal link to cervical cancer. This was not unexpected, given that informants were identified 
because of their involvement in cervical cancer prevention and control.   
 Responses pertaining to specific aspects of the HPV vaccine- priority for vaccination, 
protection, and vaccination guidelines- were mixed. While all were aware that the vaccine 
protected against the HPV types that cause cervical cancer, not everyone was familiar with 
its protection against genital warts. When asked about the priority populations for 
vaccination, most offered the recommendation of females, aged 9 to 26. Those very familiar 
with the vaccination guidelines were specific in stating that priority be given to 11 and 12 
year old girls or adolescents prior to sexual debut. One healthcare provider expressed a 
criticism of the ACIP’s recommendation- coupling the HPV vaccine with the adolescent 
health visit, “HPV vaccine development happened to coincide with this push to get young 
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adolescents in for a pediatric visit.  So, in many ways, the HPV vaccine has become co-opted 
into an 11 and 12-year-old vaccine because the intended purpose is to increase the number 
of pediatric visits so that those very important preventative healthcare discussions can 
occur.”   
 Several respondents conveyed their preference of providing the HPV vaccine to 
females in the ‘catch-up’ population, particularly those who are most likely to get HPV. 
Females entering into early adulthood- college students and 18 to 22 year-olds who are 
becoming independent and starting to live on their own were identified by several 
respondents as a priority population. This was thought to be a time in a young woman’s life 
in which she should be responsible for making decisions about her health and sexual 
partners; vaccination against HPV was perceived to be a key consideration in that decision-
making. A public interest group stakeholder expressed dissent, emphasizing that those who 
could afford the vaccine were the ‘real’ priority population; that the vaccine was out of reach 
to those who would likely benefit most, minorities, low-income, uninsured, and underinsured 
girls and young women.  
Furthermore, there was variation in familiarity with the various vaccination 
guidelines across respondents and perceived differences in understanding in general.  
Respondents suggest that a misunderstanding of eligibility for vaccination and a narrow 
interpretation of the HPV vaccination guidelines appear to have resulted in variation in the 
usage of the vaccine by healthcare providers. Physicians considered the least knowledgeable 
about HPV disease and vaccination, are more stringent in only recommending and 
administering the vaccine to those fitting the criteria for routine vaccination; girls prior to the 
onset of sexual debut.  
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So I think there’s a tremendous amount of misunderstanding about the use of the vaccine on 
the providers’ interpretation of what the ACIP and the CDC have written for guidelines. 
Some of my colleagues feel the guidelines have been written so strongly that it should be 
given only to 11 and 12-year-olds…….they are very influenced by the statement that says the 
vaccine must be given prior to the onset of sexual activity. (Healthcare Provider) 
 
To illustrate, one informant described instances where providers refused to administer the 
second and third doses of vaccine if a young woman admitted to becoming sexually active 
after receipt of the first dose. Such a strict interpretation of the guidelines raises concerns 
because it imposes a systematic barrier to accessing the vaccine intended for women up to 
age 26, including those who are sexually active. Another healthcare professional raised 
concerns that the ACIP HPV vaccine recommendation as currently written is not 
comprehensive enough, that it is too brief.  
 The above mentioned findings demonstrate that policies and knowledge about HPV 
vaccine dissemination may not be universally known or widely accepted, suggesting the need 
to further address some of these misunderstood issues. Due to the high prevalence of HPV 
infection among sexually experienced individuals, priority for vaccination to pre-adolescent 
and adolescent girls is expected to achieve the greatest reduction in cervical cancer incidence 
over time. Until vaccination coverage levels of this cohort become high, “catch-up” 
vaccination of young adult females may be advantageous. Because several studies have 
confirmed that African-Americans are more accepting of HPV vaccination for teens and 
young adult women, perhaps directing initial HPV vaccine program efforts toward these 
groups may foster acceptance of immunization for the 11-12 year old target population. 
 
Key Finding 9:  Provider knowledge, personal beliefs, and experiences with HPV are 
decisive factors associated with their acceptance and recommendation of the HPV 
vaccine. Numerous obstacles faced by healthcare providers related to administration of 
the vaccine pose challenges to increased uptake of the vaccine. 
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 Interviews with a number of respondents reinforced the notion that provider 
recommendation of preventive health services, such as screenings and immunizations is a 
critical determining factor in the use of such services. A strong recommendation from the 
provider increases the likelihood that women will accept vaccination. Several informants 
noted that patients are generally uninformed about HPV and strategies to prevent acquiring 
the virus; consequently they rely on the healthcare provider’s knowledge and experience to 
help them determine their individual risk of acquiring HPV infection and the pros and cons 
of vaccination.  Furthermore, several subjects stated acceptance of HPV vaccination by 
African-American women has shown to increase with education and recommendation from a 
provider of the same racial background. 
I found that who the messenger is, is really important, and I feel that, if they have, physicians 
of color who believe in the vaccine and talk about it and go over the safety and explain things 
like, and answer questions, then you can get some buy-in. (Healthcare Professional)  
 
 One informant observed that many African-American physicians remain very 
questioning of the HPV vaccine and have not necessarily been strong advocates. As with 
patients, a healthcare providers own personal and cultural beliefs are both powerful dynamics 
when it comes to the delivery of healthcare. Given the burden of disease in this population, 
hesitancy on the part of providers to recommend the vaccine is certainly an obstacle that 
must be overcome.  
If black doctors don’t take up the charge and are kind of lukewarm about the vaccine, we are 
going to widen the gap between the majority population cervical cancer rate and the black 
and brown women cervical cancer rate. And we are going to do it to ourselves. (Public 
Interest Group- Pharmaceutical Industry)  
 
Several factors were noted as influencing the provider’s belief in HPV vaccination: 1) time-
provider buy-in would likely come about over time, 2) a reduction in cost of the vaccine, and 
3) confidence in its safety.    
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 Among the healthcare professionals interviewed, there were a variety of provider 
office settings represented including the health department, family planning and hospital 
indigent care clinics, private practices, and a nonprofit healthcare organization whose 
services are aimed at reaching African-American women. A vast majority of patients seen in 
these settings included women from the population of focus- African-Americans, aged 18-26. 
A high percentage of women were described as low-income and/or uninsured, some of which 
were identified as college students.   
 All provider respondents were knowledgeable of the HPV vaccine and routinely 
recommended it in accordance with the ACIP guidelines. Additionally, several informants 
indicated following the immunization practices established by their respective professional 
societies, for example American Academy of Pediatrics (AAP) and the American College of 
Obstetricians and Gynecologists (ACOG). This suggests that provider buy-in of HPV 
vaccination is strengthened when there is support amongst one’s colleagues. One informant 
suggested that the HPV vaccine is broadly accepted in the medical community; at the same 
time, interpretation of the guidelines for immunization usage and to whom it should be given 
differs significantly among providers depending upon their level of knowledge and 
understanding.  
It’s good that just about every single healthcare segment of our society is behind the 
vaccines, but I think what’s not good is that there is a blind acceptance of that.  There is an 
unwillingness to discuss taking the vaccine outside of the 12-year-old age range, that we need 
to encourage them to say the vaccine is as good in the 18 to 26-year-old range, that this is 
important, that we need to encourage them to admit that. (Healthcare Professional)  
 
 
 Overall, informants characterized their experience with HPV vaccination as positive. 
Interviews with a number of respondents uncovered feelings of skepticism associated with 
the vaccine, most common among African-American patients in comparison to others. 
Among this group, some are less educated about HPV and/or misinformed about the pros and 
  73
cons of vaccination, citing concerns about safety and its effectiveness. Several informants 
noted that a variety of women: sexually active young adults, those with previous HPV 
infection, and women beyond the recommended age for immunization are requesting the 
vaccine. This appears to be occurring across age groups, among multiple ethnicities and 
educational backgrounds.    
 Other issues revealed by respondents were some of the challenges faced by healthcare 
providers in administering the HPV vaccine. They registered concerns related to the high cost 
of the vaccine, the support systems and infrastructure needed to stock vaccines, and the low 
reimbursement rates by insurers. In addition, one provider responded that there was not 
enough time to educate women about the vaccine and that there were more pressing priorities 
to be addressed such as teen pregnancy.   
 Many stated that because the HPV vaccine is priced so high, there’s no ability to have 
any overhead coverage, nor profit in administering the vaccine. This particular finding may 
have implications for access to the vaccine by low-income individuals and among 
communities of color wherein providers have chosen not to make the vaccine available. 
According to several informants, vaccine administration can be intimidating and 
cumbersome, especially to some specialty groups that are not accustomed to providing that 
service. In addition to pediatricians, family physicians, and nurse practitioners were most 
likely to be familiar with administering vaccines, while OB/GYN providers and general 
internists were described as least likely. In support of reaching 18-26 year old adults for 
vaccination, respondents recommended targeting pediatricians, family physicians, and 
OB/GYNs. 
  Respondents noted that on average healthcare providers were ill-equipped with the 
knowledge and tools necessary to communicate HPV and immunization information 
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effectively. In spite of the need, several providers stated that the time required to properly 
educate and counsel patients about HPV and their options for vaccination is very limited. 
Two physicians suggested that patient education is a very important element in the patient 
encounter and delivery of healthcare and regarded it as a reimbursable service, which it is 
currently not. Finally, the vast majority of respondents also referred to the requirement of 
three doses of vaccine as a significant challenge to successfully administering the HPV 
vaccine. Compliance with the three doses of the vaccine was also considered a challenge to 
providers; however, several respondents agreed that women who are highly motivated are 
more likely than those less motivated to be compliant with the 3-dose requirement.   
 
 
Key Finding #10: Social determinants contribute to the disparities in cervical cancer 
among African-Americans. Similar disparities will persist in HPV immunization rates 
due to racism and inequities created by unjust social conditions and policies, increasing 
the burden of negative health outcomes.   
 
 Respondents offered a range of explanations for disparities in HPV infection and 
cervical cancer diagnosis and death rates, some of which included: less access to care, 
inequities in education and income, and racism, among others. For example, young adult AA 
women are likely to be low-income and uninsured restricting access to both primary and 
secondary cervical cancer prevention methods. These factors, commonly known as social 
determinants of health, are beyond the realm of the healthcare system and speak to broader 
issues of equity and social justice.    
One question posed to respondents asked, “What steps can be taken to ensure that the 
inequities that currently exist in cervical screening will not worsen with the introduction of 
the HPV vaccine?” While a myriad of answers were given, still the overall consensus was 
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that those same women who don’t participate in routine Pap testing are likely the same ones 
who will not have access to the HPV vaccine. Several informants expressed great 
dissatisfaction at the challenges faced by women who are unable to obtain vaccination 
because of cost; presently only those who can afford to pay or have some form of insurance 
coverage will get the vaccine. As one respondent explains, even with insurance coverage of 
some vaccines, there are differences in availability as providers are known to accept one type 
of insurance over another; for example, private pay over Medicaid, due to variations in 
reimbursement rates. This in and of itself creates inequities in access particularly to 
populations that are already vulnerable.    
 Racism, discrimination, and the destructive history between African-Americans and 
the healthcare system were identified as contributing factors to health disparities. The 
relationship between racism and inequalities in health status is demonstrated by persistently 
higher mortality rates of cervical cancer and other diseases among blacks and other people of 
color. Several informants raised as an issue, the importance of understanding the relationship 
between the African-American community and medical establishment; the way it impacts 
how they think about, feel about and utilize healthcare resources.   
I see a lot of women who are turned off from the medical system in general because they are 
not well treated. They are not well respected. (Public Interest Group- AA Sorority)   
 
Political power and institutional policies based on the premise of the inferiority of blacks 
have created the conditions that affect health and the receipt of healthcare services.  
 One informant suggested a comprehensive approach to addressing inequities in HPV 
vaccination needs to focus on reaching specific at-risk populations. Efforts should be led by 
the communities themselves and supported by government; with an emphasis on changing 
policies that impose systematic barriers. Coupled with these, addressing the root causes of 
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these disparities will require investments in social spending such as public health, education, 
and job creation among less advantaged groups.  
 These findings illustrate the manner in which socioeconomic conditions and social 
position are implicated in producing health outcomes; those with socioeconomic 
disadvantage are more likely to be susceptible to preventable disease, early death, and 
inequities in health status. Understanding the complex array of socio-demographic, 
behavioral, and attitudinal dynamics associated with health practices among African-
American women will be important to assessing interest in vaccination and ensuring the 
benefits of immunization are shared by all. 
 
Key Finding# 11: A comprehensive strategy for successful introduction of HPV 
vaccination to communities, especially communities of color, must be coordinated at 
multiple levels focusing on effective implementation strategies and vaccine policies to 
ensure program performance 
 
Policies 
 The literature points to the utility of public policy in promoting primary prevention 
efforts to influence health outcomes. Policies affect large numbers of people as well as social 
norms and have tremendous potential for preventing needless suffering, injuries and deaths. 
In order to assess policies in relation to HPV vaccination, study participants were asked what 
factors should be considered when recommending policies for HPV vaccine introduction. 
Table 4.6 lists these factors for consideration. 
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Table 4.6: Factors to consider for HPV vaccine policy recommendations 
 
FACTOR INFORMANT RESPONSES 
ISSUE 
 HPV vaccination is not a substitute for cervical cancer screening 
 Address burden of disease & disparities in cervical cancer/ STI rates among 
population 
 Understand SES factors impacting poor health outcomes (i.e. education, 
income, policies and practices) 
EDUCATION 
 Policymakers need to understand this as an issue on three fronts (public health, 
women’s health, minority health) 
 Support strategic plan for comprehensive education and outreach to 
communities aimed at increasing understanding, acceptability, and improving 
communication 
 Proactive in addressing safety concerns  
ACCESS 
 Allocate funding for vaccine (ensure low cost ways to get vaccine, availability 
and equal access) 
 Fund entities and build infrastructure to design effective mechanisms to provide 
vaccine within existing systems, without posing an additional burden 
 Mandates associated with HPV vaccination should be used judiciously  
PARTNERS/STAKEHOLDERS 
 Engagement of a variety of stakeholders  
o Intended Audience 
o Decision-makers (Legislative & Policymakers) 
o Medical Community 
o Industry (Pharmaceutical, Insurance, Business)  
o Colleges & Universities 
o Advocacy & Policy Groups/Organizations 
o Media 
 
Consideration of disparities in HPV related disease and addressing them through policy 
intervention was prominent among respondents. One respondent stated: 
Understanding African-American health issues and those that impact disparities in 
health outcomes is essential when recommending polices for HPV vaccine 
introduction. That the disparities are always related to education, income, those kinds 
of things, but it may be the policies themselves or practices in the healthcare 
environment. (Public Interest Group- Health Education nonprofit)   
 
Respondents commonly identified the establishment of policies that would have an impact on 
the fiscal aspects of enhancing access to HPV vaccination. A government official suggested 
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delivery methods of vaccine could be greatly enhanced through the political process, “That 
would mean that you fund entities to build infrastructure to provide the vaccines in systems 
that would not put great financial burden on the healthcare system as it exists. An effective 
mechanism where you know that you’re going to need x number of doses at a specific time 
would be more efficient.” Certainly, reducing the cost of the vaccine is vital to expanding its 
use to communities at highest risk.   
Policies should ensure that there are low cost ways in which to get the vaccine; so 
that we can ensure equal access to the vaccine. (Public Interest Group- AA Health 
nonprofit) 
 
 
The importance of education was a prevailing issue. Quite often respondents pointed out the 
necessity of understanding the complexities of HPV and vaccination and communicating 
information about the subject to a multiplicity of audiences as an emerging health concern  
From a policy standpoint, working with state health departments or local health 
departments and implementing policies that support education of young women about 
vaccines such as the HPV vaccine and the role that it can play in staying healthy. 
(Public Interest Group- Legislative policy nonprofit ) 
 
Certainly by passing laws that encourage the development of community competent 
educational methods that are well understood and accepted, and again dispelling the 
mistrust that can often be associated with having something come to minority groups 
from a political entity that they often fear or are suspicious of, I think is extremely 
important. (Government Official) 
 
Additionally, collaboration amongst a diverse group of stakeholders facilitates a dialogue in 
hopes of bringing forth the needs and concerns of the community while being a catalyst for 
broad-scale change.   
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Implementation Strategies 
Sustainable health behavior change can be facilitated through a variety of means. 
Achieving or maintaining high levels of vaccination coverage can be accomplished by 
implementing effective population-based strategies. The methods for reaching individuals, 
communities, or the public can vary. According to the Task Force for Community Preventive 
Services, demonstrated strategies for increasing immunization rates include: 1) increasing 
community demand, 2) enhancing access to vaccination services, and  3) provider based 
interventions.88 In order to more fully understand factors that might hinder or enhance use of 
the HPV vaccine among young adult African-American women, a population regarded to be 
at higher-risk for HPV-related disease, participants were asked to identify effective strategies 
and program attributes for successful vaccine implementation. Table 4.7 lists the strategies 
that participants considered most useful. 
Many of the proposed strategies are aligned with those presented in the Guide to  
Community Preventive Services (The Community Guide) recommendations to improve 
targeted vaccination coverage among high-risk adults. Additional proposed strategies are 
based on the respondents experience supporting HPV vaccination efforts. As stated 
previously, the implementation recommendations generally fell into the three intervention 
strategy categories with a fourth category ‘Other’ included for additional approaches for 
successful execution of HPV vaccination programs.    
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Table 4.7: Strategies for Effective HPV Vaccine Implementation, 18-26 Year Olds 
COMMUNITY GUIDE  
INTERVENTION STRATEGIES 
KEY INFORMANT HPV VACCINE   
IMPLEMENTATION RECOMMENDATIONS 
Improve health literacy (patients, providers, public) 
Social Marketing Education Campaign-(What’s Available, Why Important, 
Where, Costs) 
Ensure messages are framed appropriately 
° Combine w/ women’s and  sexual health education 
° Culturally/literacy appropriate 
Engage Community (Intended audience)  
° Community empowerment (demand vaccine) 
° Drive education efforts 
° Gain buy-in 
Increasing Community Demand for 
Vaccinations 
° Client reminder/recall 
° Multicomponent interventions including 
education 
° Vaccination requirements for childcare, 
school and college attendance 
° Community-wide education-only 
interventions 
° Clinic-based education-only interventions 
° Client or family incentives 
° Client-held medical records Intergenerational Approach ° Education and screening  
° Involve grandmothers, mothers, daughters 
° Gain buy-in 
 
Enhance Access to Vaccine 
° Ensure affordability (i.e, cost-sharing or free) 
° Vaccine readily available in non-traditional community settings 
° Pharmacies 
° Beauty salons 
° Churches 
Enhancing Access to Vaccination Services 
° Reducing out-of-pocket costs 
° Expanding access in health care settings 
° Vaccination programs in women, infants 
and children settings 
° Home visits 
° Vaccination programs in schools 
° Vaccination program in childcare centers 
Integrate into Existing Programs  
Cervical Cancer Screening Programs 
° Pap test  and  vaccination same visit 
° Education 
° Infrastructure  
° Support to community  
NBCCEDP screening sites  
° University/college student health services 
° Family Planning/Planned Parenthood  
° Utilize existing models i.e. HIV Model/ REACH 
 
Standing Orders 
Decrease Missed Opportunities 
Provider-Based Interventions 
° Provider reminder/recall 
° Standing orders 
° Provider education only 
° Assessment and feedback for vaccination 
providers 
Provider reminder systems 
° Tickler systems 
° Scheduling appt in advance 
  
Other Interventions (** not  Community 
Guide) 
 
Patient Compliance (3 Doses) 
° Message of compliance thru multiple channels 
° Use of technology (text message/email reminders) 
° MERCKs ‘3 is Key’ reminder (thru doctors office) 
° Financial incentives 
° Expedited vaccine schedule 
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° Vaccine registry w/ call back system 
° Reveal consequences of disease 
Partnerships & Collaborations 
° Foster coalitions and networks (community, government, industry, 
academia, health sector) 
Monitoring  & Evaluation 
° Vaccine uptake 
° Collect data  
° Document programmatic effectiveness 
° Modify efforts based on data 
Involvement of Males 
° Education and messengers 
° Partners of women 
 
Source: Adapted from Task Force for Community Preventive Services 
 
 The analysis of effective strategies and program attributes revealed several main 
ideas: 1) characteristics of the program must improve access and entail a comprehensive 
education plan, 2) role of the community is critical, 3) integration of vaccination into existing 
health services, with an emphasis on cervical cancer screening programs, and 4) the 
importance of patient compliance. A successful HPV vaccination program would require 
considerable investment in educating a range of audiences. Additionally, a reduction in the 
vaccine’s cost to females and providers would be necessary to expand access and availability. 
Incorporating HPV immunization into existing cervical cancer screening programs, across a 
variety of health settings, surfaced as the least complicated option for young adult females to 
gain access to the vaccine.         
 
Areas for Further Exploration 
 There were a number of other issues that surfaced during the interviews. Several 
respondents introduced the issue of males and their role or involvement in the great HPV 
debate. Respondents were committed to the idea that males should be educated about HPV, 
the risks and benefits of vaccination, and share in decision-making with their partners, while 
taking an active role as a messenger of HPV information. Currently, there are a number of 
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studies underway exploring vaccination of males. The verdict is still out; however, the need 
to expand coverage of the vaccine to include young males was perceived by some as ‘the 
missing link’ in reducing the cycle of HPV transmission.  
Community mobilization and empowerment was addressed repeatedly. Respondents 
agreed that getting African-American communities to understand that HPV isn’t about good 
or bad, but rather about an issue that can be dealt with; and HPV vaccination is a prevention 
tool to  keep ‘us’ healthy came across from several respondents. More than that, it involves 
the community taking ownership of an issue and thinking through how best to handle; it’s 
having the resources within the community, not only to provide the medical service, or 
information and education, but to be a conduit between the two. One respondent noted the 
role of African-American women as decision-makers in their families, communities, 
churches, etc., recognizing that this was something to be embraced. They went on to say, by 
respectfully reaching out to grandmothers, mothers, aunts, we are empowering women to 
want better healthcare for themselves, their daughters, their loved ones. While this study 
addresses the needs of young adult African-American women, there are several issues that 
pertain to girls and women of other racial/ethnic groups.  
 
Variation in Key Informant Responses    
 The possibility of preventing HPV-related cervical cancer and other conditions 
through vaccination has kindled broad interest from a diverse group of audiences; key 
informants contributing to this study are representative of some of these factions. As 
illustrated in these findings, the responses were mixed and as diverse as the participants 
themselves; differences between and within interest groups were noted across several topics. 
For example, sharing information about health disparities in the African-American 
  83
community was perceived as both a barrier and facilitator to uptake of the vaccine. 
Participants representing public interest groups were more likely to indicate that statistics 
highlighting negative outcomes were a hindrance, deepening opinions of information bias 
and mistrust. In addition, there was no consensus reached regarding cervical cancer as a 
priority among African-American women. However, it should be noted, across informants, 
African-American respondents were least likely to consider prevention of cervical cancer a 
primary concern in comparison to other health conditions afflicting this community. While 
the benefits of vaccination to those aged 18-26 were consistently acknowledged across 
respondents, there were differences in opinion about classifying African-Americans in this 
age range as priority for HPV vaccination. Government officials, with one exception, 
explicitly stated that 11 and 12 year olds were the target group; while stakeholders from 
public interest groups and healthcare professionals favored immunizing the ‘catch-up’ 
population. The range of views reported in these findings raise a number of questions that are 
certain to have implications for HPV vaccine introduction and public policy.  
  
CHAPTER V: POLICY ANALYSIS 
 
 
This chapter describes the results and analysis of policy considerations to increase 
acceptance and use of the HPV for use in the development of an advocacy plan. The findings 
are presented and answer the study’s research Aim 4. 
Aim 4:  Use the data collected to recommend policy considerations for 
enhancing acceptance of the HPV vaccine among young adult African-
American women. 
 A review and interpretation of relevant literature was conducted associated with 
vaccine policy, diffusion of medical innovations, and the adoption of policies. Policy 
interventions will focus on both clinical practice-based and public health initiatives. Relevant 
findings from analysis of the immunization literature are discussed below.   
Immunization 
Historically, vaccination laws were enacted to control epidemic diseases; currently 
these laws are used to protect the public’s health by increasing vaccination coverage, even in 
the absence of epidemics. Public health officials confirm that wide use of vaccinations 
encourages what is known as “herd immunity.” Herd immunity is achieved when a high 
proportion of the population is immunized to stop the spread of disease. 
Vaccines are delivered to hundreds of thousands of children and adults in the United 
States annually. The delivery of immunizations occurs through a network of public- and 
private partnership activities, with a large fraction occurring in the private sector. At one 
time, the provision of those services for less advantaged groups occurred primarily through 
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the public health departments and clinics. As a result of changes in Medicaid policies, and 
creation of programs such as Vaccine for Children (VFC), and the State Children’s Health 
Insurance Program (SCHIP), a shifting of resources has emerged, removing coverage from 
many low-income, uninsured and underinsured individuals and families who were once 
served by the traditional public health system. 89, 90 
One of the great successes of public health are vaccines, as evidenced by their ability 
to prevent disease and reduce healthcare costs. The effectiveness of preventing disease 
through universally recommended vaccination is well-documented. While childhood 
vaccination programs have achieved great success with coverage levels exceeding 95% for 
some vaccines, the same does not hold true for adults, as universally recommended vaccines 
among this group are underused.88, 91 Consequently, disparities in access to vaccines, due to 
socioeconomic factors (i.e. differences in geography and economics), have led to reduced 
levels of immunization coverage among certain populations.88, 90, 91 
Whereas access to immunization is known to be a contributing factor to increasing 
vaccine coverage rates, the evidence reports a mixture of methods that can be utilized. The 
Task Force on Community Preventive Services conducted a  
systematic review of population-based interventions to improve vaccination coverage. A 
summary of recommendations on the use of interventions to improve vaccination levels 
across the lifespan (children, adolescents, and adults) is presented in Table 5.1 below.88    
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Table 5.1: Recommendations Regarding Interventions to Improve Vaccination Coverage   
INCREASING COMMUNITY DEMAND 
FOR VACCINATIONS 
ENHANCING ACCESS TO 
VACCINATION SERVICES PROVIDER-BASED INTERVENTIONS 
Client reminder/recall Reducing out-of-pocket costs Provider reminder/recall 
Multi-component interventions 
that include education 
Expanding access in 
health care settings Standing orders 
Vaccination requirements for 
childcare, school and college 
attendance 
Vaccination programs in women, 
infants and children settings Provider education only 
Community-wide education-only 
interventions Home visits 
Assessment and feedback for 
vaccination providers 
Clinic-based education-only 
interventions Vaccinations programs in schools  
Client or family incentives Vaccination programs in childcare centers  
Client-held medical records   
Source: Task Force on Community Preventive Services  
 
Many groups have a stake in vaccine-related issues. Federal, state, and local health 
agencies jointly support the roles of the national immunization system (See Figure 5.1 
below), while collaborating with other public and private partners. The six fundamental 
functions of the national immunization system, as described below, are to 89: 
 Assure the purchase of recommended vaccines for the total population of U.S. 
children and adults, with particular emphasis on the protection of vulnerable groups 
 Assure access to such vaccines within the public sector when private health care 
services are not adequate to meet local needs 
 Control and prevent infectious disease 
 Conduct population wide surveillance of immunization coverage levels, including 
the identification of significant disparities, gaps, and vaccine safety concerns 
 Sustain and improve immunization coverage levels within child and adult 
populations, especially in vulnerable communities 
 Use primary care and public health resources efficiently in achieving national 
immunization goals 
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Figure 5.1: Functions of National Immunization System 89 
 
The federal government and its respective agencies share responsibilities related to 
research and development, licensing, protecting health and the safety of populations, 
surveillance and monitoring of adverse reactions, provision of health services, trade and 
homeland security. State and local governments primarily conduct vaccine activities as part 
of their pubic health role; through administering vaccines and maintaining immunization 
registries and establishing and enforcing requirements for school attendance. Organizations 
and interested parties outside of government also play a key role. They include consumers, 
employers who provide health benefits and insurers, professional healthcare associations, the 
pharmaceutical industry, and an array of public interest groups.89, 92    
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Vaccine Policy Issues 
Public policy is a strong tool for primary prevention because policy shapes the 
environment in which we live, work and play. While there are a number of players involved 
in vaccine-related issues, there is no one central authority for vaccine policy within the 
federal government. A multi-disciplinary, multi-level approach is required to address the 
complex nature of policy adoption across states and among varying populations, all of whom 
have their own unique needs and challenges. For the most part, legislative issues pertaining 
to vaccines that political bodies/state legislatures consider usually fall into 3 categories: a) 
availability, b) safety, and effectiveness and c) access89, 92 as detailed in Table 5.2 below.  
      Table 5.2: Vaccine Policy Issues 
ISSUE PROBLEM SOLUTION 
Production Costs Financial incentives 
Production Failures Liability 
Liability Partnerships 
Market Improved Coordination 
Availability 
Planning Alternatives to Safety Documentation 
Side Effects Improving Post Licensure Adverse Event Surveillance 
Insufficient knowledge and 
inadequate risk communication 
Education and Risk 
Communication 
Assessment of competing products Studies in Pharmacoepidemiology and Pharmacoeconomics 
Safety and Effectiveness 
Production of Generic Biologics Compensation 
Completion of Vaccination Schedule Global Health 
Regional and Economic Disparities Coordination of Government Financing Programs Access 
Varying Health Benefit Coverage Payment for Vaccination and Follow-up Care 
      Source: Adapted from Congressional Research Service-Library of Congress 
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Vaccine Financing Mechanisms 
 Vaccine programs are funded through a mix of federal and state resources. Federal 
funding for immunizations programs subsidizes state costs for vaccine purchases and 
infrastructure support. Two vaccine-financing mechanisms were established by the federal 
government to aid in increasing immunization coverage rates in the U.S. The Vaccines for 
Children (VFC), is a federal entitlement program, the Section 317 Immunization Program, is 
a federal grants program that receives an annual appropriation from Congress which is 
subject to change from year to year. In addition, states invest funds in immunization 
programs through direct or in-kind support. 89   
 The federal VFC provides free immunization to uninsured children and children on 
Medicaid at their regular healthcare provider. VFC provides vaccines for qualified children 
to private providers, and free vaccines to children at Federally Qualified Health Centers 
(FQC) and Rural Health Clinics (RHC). Children 18 years of age or younger who are either 
uninsured, Medicaid eligible, or of Alaska Native/American Indian descent are eligible to 
receive VFC vaccine. Additionally, underinsured children 18 years of age or younger who 
receive care through a Federally Qualified Health Center (FQHC) or Rural Health Clinic 
(RHC) are VFC eligible. The CDC negotiates federal contracts with vaccine manufacturers 
for VFC vaccines, as recommended by the ACIP, and states distribute and administer the 
vaccines through public health clinics and private providers. 17, 89, 90, 92 
 The Section 317 program was authorized through the Public Health Service Act to 
support vaccination infrastructure and direct service delivery. CDC provides grants to state 
and local (jurisdictional) health departments (immunization programs) to vaccinate children, 
adolescents and adults who have no means to pay for vaccines and are not eligible for other 
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government programs which provide vaccines. With reductions in funding and the increased 
need for services, Section 317 program funds have focused on conducting routine 
vaccination of children. As the costs of vaccinating uninsured and underinsured children 
grow and expensive vaccines are added to the immunization schedule, states face the 
challenge of contributing more toward financing immunization programs.89 Because the 
Section 317 grants program does not require a state match, fiscal incentives for states to share 
the costs do not exist. Despite the need, vaccines to adolescents and adults who are largely 
underserved, and racial and ethnic disparities persist.88, 91    
 Private vaccine financing is another method through which immunization services are 
purchased. Private funding generally occurs as an out-of-pocket expense by the individual, 
through some type of insurance benefit coverage or a combination of both. Approximately 
three-fourths of those with private health insurance obtain it through employer-sponsored 
health plans. Among employer-sponsored health benefit plans coverage of childhood 
immunizations is common. Many states have passed legislation to require insurance 
companies to cover immunization services.89 
HPV Vaccine: Costs v. Benefits 
 As new vaccines are introduced and recommendations are made for their use; federal, 
state and private entities have had to respond accordingly. Based upon the CDC Vaccine 
2009 Price List, the cost of the HPV vaccine is considerably higher than other adult 
recommended vaccines.17, 90  Table 5.3 illustrates the cost differential between the HPV 
vaccine and other recommended vaccines. As shown, private sector and CDC cost of the 
HPV vaccine per dose ranges from $70 to $76 more than other vaccines. While it is true that 
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the price of the vaccine is costly, the actual expense of delivering the vaccine includes 
education, counseling and delivery mechanisms; the costs of which are yet to be determined. 
 
Table 5.3: Vaccine Cost per Single Dose, 2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Adapted from Centers for Disease Control and Prevention 
 
The burden of HPV-associated disease and cancers is considerable and has substantial 
direct and indirect costs; both to the individual and society. Costs attributable to cervical 
screening, diagnosis, management, and treatment of cervical abnormalities are in the billions 
of dollars.93  Premature death, disability, medical costs, and loss productivity pose a societal 
burden and adversely affect the health of our nation.94 Ekwueme et al, estimated mortality 
costs (years of potential life lost-YPLL and productivity costs) from HPV-associated cancer 
deaths in 2003, accounted for approximately 3% of the mortality costs of all malignant 
cancers. These costs ranged from $2.9 billion to $5.3 billion; with cervical cancer having the 
highest estimated cost of $1.8 billion among women.  
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When evaluating policy considerations for introduction of HPV vaccination 
programs, both the health and economic implications must be considered. Several published 
studies have conducted analyses assessing the cost-effectiveness of vaccinating young girls-
11 and 12 year olds, those in the catch-up age range- 13 to 26, and most recently boys. 
Studies have used numerous mathematical models, based on a variety of assumptions, to 
estimate the cost-effectiveness of prophylactic vaccination of HPV types 6-11-16 and 18. In 
general, HPV vaccination is most cost-effective among young adolescent girls, with the cost 
of extending vaccination to girls and women to age 26 years becoming less cost effective as 
the cut-off age of vaccination increases. However, as the potential benefits of preventing 
non-cervical HPV associated cancers increases, the cost-benefit of extending vaccination up 
to 21 years of age becomes more favorable.95, 96 According to Kim & Goldie, the cost-
effectiveness of vaccination will be optimized by attaining high rates of coverage among 
preadolescent girls, targeting initial catch-up efforts to girls and women younger than 21 
years of age and revising screening policies.95-98  
 Through effectively integrating primary and secondary cervical cancer prevention 
strategies, reductions in morbidity, premature death, and the economic burden associated 
with HPV-related cancers can be achieved. If one weighs the costs of a $500 vaccine versus 
the tens of thousands of dollars it takes to treat a case of cervical cancer, the millions of 
dollars spent on the follow-up of abnormal Pap test results’, and the mortality costs of HPV-
associated cancers, the economic benefits to individuals and society are apparent. 
 Equally important in determining public health policy are aspects beyond the cost-
effectiveness of a new technology or medical intervention. Concerning HPV vaccination, 
inclusion of issues such as socioeconomic status, acceptance of the vaccine among certain 
racial/ethnic groups, and the current disparities in HPV-related disease, enhance decision-
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making regarding prevention efforts. For example, among African-Americans, acceptance of 
the vaccine increases with age of child; parents are less accepting of the vaccine for their 
daughters under age seventeen. Differential uptake and utilization of HPV vaccination will 
have both positive and negative consequences for cervical cancer prevention.   Therefore, 
careful deliberation must be undertaken. 
Policy Goal 
 Disparities in health among some income, racial, and ethnic groups in the U.S. are 
significant and, by many measures, expanding. Communities of color and those of low socio-
economic status disproportionately experience worse health and safety outcomes across a 
broad spectrum of illnesses and treatments. Cervical cancer is no exception, as minority 
women bear an unequal share of the disease burden.  
For the purposes of this analysis, the public health goal is to reduce the burden of 
cervical cancer and HPV-related disease among all women, through use of the HPV vaccine; 
with an emphasis on the disparities that exist among African-Americans who are markedly 
impacted by its negative health consequences. The ACIP recommends routine vaccination for 
11-12 year old girls prior to sexual debut, with a “catch-up” vaccination for females ages13-
26 years.8, 28 While the evidence suggests that those not previously exposed to HPV can more 
fully benefit from vaccination, there are advantages to vaccinating young adult women that 
are sexually experienced who too will derive some benefit from vaccination.17, 28  
The key to successful implementation of the HPV vaccine will be in how key 
stakeholders, from policymakers and healthcare providers, to parents, women and girls, 
respond to ensure that all those who can benefit have access to it. There are a variety of 
comprehensive and incremental approaches that could be taken together or separately to 
move towards achievement of this goal.   
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A. Diffusion of Innovations 
 An innovation may be a product, service, a process, system, a structure that is 
new to an organization.99 The process by which individuals and social groups adopt 
innovations to improve health care delivery is a composite process.  Everett Rogers describes 
the diffusion of innovation as “a process by which (1) an innovation (2) is communicated 
through certain channels (3) over time (4) among the members of a social system.”100, 101 For 
the purpose of this study, the general Diffusion of Innovations theory will be discussed to 
facilitate decision-making as it relates to the adoption of the HPV vaccine. 
 The process of innovation of diffusion describes the existence of five distinct 
population sub-groups; the innovators, early adopters, early majority, late majority, and the 
laggards. The innovators are the first to adopt an innovation. The second sub-group to adopt 
innovation are the early adopters, comprised of a large concentration of opinion leaders. 
Members of the early majority utilize their interpersonal connections as a catalyst for change. 
The late adopters are very cautious and skeptical, and are generally obliged to adopt an 
innovation due to peer pressure.100, 101 According to Rogers, the last to adopt an innovation 
are the laggards who are typically suspicious and retain the least power and influence as a 
result of their socio-economic standing.  
 The speed at which an innovation is adopted is determined by the members of the 
social system, as described above. Several attributes act as independent variables to rate of 
adoption including: relative advantage, compatibility, trialability, and observability.100, 101 
Relative advantage refers to the cost-benefit of the innovation over the current method, for 
example HPV vaccination versus other methods of cervical cancer prevention- screening. 
Decision-makers often seek an innovation that will yield tangible benefits in the form of cost 
savings; this does not negate the intangible benefits that are similarly valuable. The 
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opportunity costs of adopting the innovation the potential return on investment are also 
measured. The relative advantage of preventive innovations is difficult to demonstrate and 
can be uncertain, as the advantages of the innovation occur at some future point in time.101 
Innovations associated with a perceived high degree of risk or uncertainty have a lower 
likelihood of adoption.99  
 In adopting an innovation, decision-makers want to be clear about what will be 
gained and its capacity to further the goals. Compatibility relates to the innovation’s 
alignment with the group’s socio-cultural values, beliefs, and previously held ideas. A high 
degree of compatibility between an innovation and the adopters increases the rate and 
success of adoption.99  
 The ability to try an innovation on a limited basis is important to innovators and early 
adopters. Trialability provides decision-makers an opportunity to see if the innovation 
addresses a particular need in a beneficial manner on a non-committal basis. Oftentimes, an 
organization will conduct a pilot study of an innovation to determine its acceptability and 
assess whether the innovation needs to be adapted. An incremental, phased approach can also 
be used to build support and promote success of the innovation. Trialability is associated 
with higher rates of adoption and assimilation.99, 101 Policymakers and states follow this 
pattern of diffusion by watching the actions and results of policy adoption of others to similar 
issues and then either adopt or reject the policy.100 As a final point, Rogers describes 
observability as the degree to which the results of an innovation are visible to others. 
Innovations that have observability are more likely to have a high rate of adoption.100, 101 
 Two essential elements absent from Rogers theory are the importance of readiness for 
change and feasibility. Successful adoption of an innovation is greatly enhanced when there 
is a perceived need for change, at all levels. Ensuring that all stakeholders- patients and 
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families, community organizations and others- have a positive attitude toward the innovation 
can be critical to its success.99 As with all innovations, some degree of change is required; 
policy-makers must also assess whether adoption of a particular innovation is feasible. A 
state’s passage of a school mandate, requiring HPV vaccination and its associated costs 
(economic, parental rights), illustrate the significance of these aspects of adopting innovation.  
Diffusion of HPV Vaccination 
HPV vaccine is a preventive innovation, in that it was created to address the looming 
risk of cervical cancer, genital warts, and their associated costs; these include economic, 
social, and personal costs.100 The introduction of emerging technologies, such as vaccines to 
reduce the spread of preventable diseases, have far exceeded federal, state and private-sector 
investments in these innovations. Significant policy implications come along with the 
introduction of an innovation, as decision-makers consider laws and policy to further 
implementation and uptake of the vaccine.  
Employing the Diffusion of Innovation theory, the rate of adoption of Gardasil®, the 
HPV vaccine, has faced challenges as a result of its low relative advantage, incompatibility 
with some beliefs, lack of trialability, and lack of observability. For these reasons, the 
vaccine has experienced difficulty integrating easily into the population and states as an 
adoptable innovation.101 Prevention innovations are generally slow to implement. 
Additionally, the HPV vaccine has only been on the market for about three years. Its novelty 
alone has contributed to slow policy adoption, as the information available early on to help 
policymakers reduce uncertainty in decision making was somewhat limited and obscure. As 
more information beyond the vaccine’s efficacy becomes available, such as its cost-
effectiveness, policymakers will be in a better position to assess the economic feasibility of 
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adopting policies.100, 101 Over time, acceptance of HPV policy options will likely increase as 
policy options diffuse through states.   
 
Kingdon’s- Three Streams Framework 
The policy formulation process is wrought with ambiguity. Many attempts have been 
made to explain why some policy agenda items are prominent while others are abandoned. 
Kingdon suggests that policy alternatives occur across three independent streams- problems, 
policies and politics- in which different stakeholders each play a role.85 The likelihood that 
an issue will receive serious policy-maker attention is enhanced at the point in which the 
three policy streams converge, creating a window of opportunity. This coupling is known as 
the “policy window,” a fleeting moment in time, by which heightened attention to and action 
on a specified agenda are most likely to occur. A favorable environment for any form of 
health policy is dependent upon a number of actors and requires a number of elements that 
are aligned accordingly.85 A clear understanding of the policy environment, stakeholder 
perceptions of that environment, as well as perceived roles and relations among the various 
actors, is increasingly relevant in achieving health policy outcomes as evidenced in 
formulation of HPV vaccine policy options.   
The streams flowing through the policy system are independent. Kingdon’s problem 
stream includes concerns that individual citizens and policymakers have. Some indicators 
provide evidence to focus attention on the magnitude of a particular issue; the indicator alone 
is not sufficient to define the issue as a problem until a disaster event occurs.85, 102  The 
burden of cervical cancer caused by persistent infection with high-risk ‘oncogenic’ types of 
HPV in the United States and globally, has been well-documented. Even more alarming are 
the proliferation of disparities among certain groups based on income, race/ethnicity, 
  98
geography, and other factors. The escalation in healthcare expenditures and continuous 
decline in health outcomes has been described as a “crisis” by many who are advocating for 
reforms in the U.S. healthcare system. The reallocation of resources toward preventive care 
rather than the treatment of illness has been identified as a potential solution. 
 The policy stream, according to Kingdon, is represented by a collective of ideas, of 
which only a few are given serious consideration. This consideration is demonstrated in 
various forms such as resource investments, hearings and white papers, among other 
products.85, 102 Of those given consideration, certain characteristics enhance their odds of 
moving forward; technical feasibility, value acceptability among policy-makers, cost, public 
acquiescence, and receptivity among elected officials and decision-makers. Within this 
stream, political actors representing the wishes and demands of their constituencies, share a 
common concern for a single issue and select the means by which it should be attended to.102 
Relative to the HPV vaccine, multiple monographs and numerous studies, and financial 
investments in the form of funding through VFC, and routine ACIP meetings indicate its 
significance within certain policy networks. 
Kingdon’s third stream is politics, representative of the various political forces: 
national mood, organized interests, the political ideology of elected officials and legislative 
turnover.85, 102 In the 2008 Presidential election, a sweeping shift in the national mood was 
conveyed by the election of President Barack Obama, a Democrat whose political orientation 
is in stark contrast to that of his predecessor; furthermore, majority and minority makeup of 
Congress shifted, altering the ownership of power. The political stream plays a critical role in 
promoting or inhibiting the rise or fall of an issue on the policy agenda.  
The point at which the three streams converge is known as the policy window; the 
“fleeting moment in time” in which a policy option is likely to receive traction and be 
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adopted by policy makers. Immediate action is taken on the part of policy entrepreneurs to 
seize the moment.85, 102 Policy entrepreneurs are those advocates that are willing to invest 
resources- time, energy, reputation, and money- in hopes of a future return on their 
investment. The success of a policy entrepreneur lies in their ability to manipulate the 
coupling of the policy streams, access policy makers and devote substantial resources. 
MERCK actively participated as a policy entrepreneur in promoting the acceptability and use 
of Gardasil®. The pharmaceutical company invested resources to increase awareness of HPV 
and the vaccine that protects against the virus; and were successful in gaining access to state 
legislators and policy-makers through the organization Women in Government (WIG),  a 
national bi-partisan organization of women state legislators, initiating a momentous degree of 
highly charged political engagement in the prevention of cervical cancer, across the nation, 
within state and local governments.  
The current favor toward a domestic policy agenda in which an overhaul of our 
systems of healthcare, education, and energy are being aggressively championed, as 
demonstrated by the participation of various political actors, exemplifies a potential ‘window 
of opportunity.’ By extension, the HPV vaccine debate is likely to gain policy traction 
because of its role in supporting prevention and wellness that may have been previously 
limited.       
Status of Existing HPV Related Policy Options 
While adoption of HPV related policy has been deliberate, it has not slowed the flurry 
of debate that has occurred since the FDA’s approval and ACIP’s recommendation of the 
vaccine to protect against human papillomavirus. Discourse taking place around HPV and the 
vaccine has centered around three major issues: 1) mandated school vaccine requirements, 2) 
education and awareness about HPV and cervical cancer, and 3) improving access.103, 104 
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Table 5.4 from the State Cancer Legislative Database (SCLD) shows cervical and HPV-
related state legislation, dating back from 1977 thru 2008. 
Table 5.4: State HPV-Related Legislation (1977-2008) 
 
Policymakers across the country have taken varied approaches to addressing cervical 
cancer prevention. Several states have introduced and enacted legislation aimed at increasing 
awareness and education about cervical cancer, and the virus that causes it, HPV. Other 
states have sought to improve access to new screening and preventive technologies by 
requiring insurers and public programs to offer advanced services, such as the HPV test. 
Some of these approaches, examined here, are summarized below in Table 5.5. 103, 104    
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Table 5.5: Proposed/Enacted HPV-Related Legislation by Type 
TYPE OF STATE LEGISLATION DESCRIPTION OF HPV RELATED  LEGISLATIVE ACTIVITY 
# OF STATES PROPOSED/ 
ENACTED 
LEGISLATION 
1. Cervical Cancer Task Force 
State law or resolution designating creation of task 
force or commission to study and make policy 
recommendations around cervical cancer prevention 
24 
2. Education and Awareness State laws aimed at educating the public, parents, and students about HPV and cervical cancer 15 
3. Mandated School 
Requirements 
State laws requiring HPV vaccination requirements 
for school attendance 2 
4. Funding for Vaccination State laws aimed at allocating funds to pay for the HPV vaccine for females 9-26 years of age 1 
5. Mandated Insurance 
Coverage 
State laws aimed at requiring third party insurers to 
provide coverage for cervical cancer screening, HPV 
screening and the HPV vaccine 
29 
Total  71 
Sources: National Conference of State Legislatures/NCI: State Cancer Legislative Database 
 
Policy Evaluation Criteria 
In an effort to gauge ease of implementation of the policies, a review of the policy 
options was conducted, examining the following three criteria—political feasibility, degree 
of health protection, and cost.85, 102 Each of these different options for improving 
acceptability and use of the HPV vaccine to reduce the burden of HPV related disease varies 
in terms of the degree of political feasibility, offers different degrees of health protection, and 
is associated with different types and amounts of economic costs.  Political feasibility is a 
combination of factors such as public acceptance of the idea, acceptance by policymakers 
and key stakeholders, and timing relative to other legislative considerations. Feasibility is an 
important measurement tool because it predicts the likelihood of enactment of the policy 
option by state governments.    
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The degree of health protection offered by each policy option is important because 
the ultimate goal is to more adequately protect the health of the greatest number of women, 
who are likely to benefit most from HPV vaccination. A policy option that does not protect 
the most people would not be considered a viable policy option unless it offered some 
external tradeoff that ultimately would produce greater health benefits or accomplish some 
other related policy goal. Economic costs are a third and final important consideration for 
deciding among the policy options described in this paper because costs to the State are 
generally undesirable. However, some social or economic costs could be considered 
acceptable either by policy makers or the public if there are substantial social and health 
benefits.   
 
 
Policy Option #1: Establish Cervical Cancer Task Forces 
Approximately twenty-four states have established Cervical Cancer Elimination Task 
Forces or some accountable entity, providing the infrastructure needed to support and 
monitor progress of cervical cancer prevention efforts. Their ultimate goal is the elimination 
of cervical cancer through policy initiatives. In addition, they provide leadership in the 
development of cervical cancer-related laws and regulations and identify gaps in policy, 
programs, and services that can be dealt with through legislative means.105 For example, 
some have devised recommendations on steps to improve how low-income and uninsured 
women are screened for policymakers and health agency officials. An overarching priority of 
the task forces is improving education about cervical disease and its cause, HPV, while 
addressing health disparities in vaccination, screening and treatment. 
A central aim of the task force is to complement and build upon existing activities 
that may be performing similar tasks; therefore, a number of these groups work in 
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collaboration with state Breast and Cervical Cancer Early Detection and Comprehensive 
Cancer Control Programs.105 They have been successful in bringing together lawmakers, 
public health and medical professionals, insurance industry officials, communications experts 
and women's health groups in the development of statewide cervical cancer prevention 
initiatives. The following is an example of how the state of Maryland’s Cervical Cancer Task 
Force (the task force) worked collaboratively to integrate efforts: 
House Bill1049, introduced by the task force, established the HPV Vaccine 
Subcommitee, through the Maryland Comprehensive Cancer Control Plan- Cervical 
Cancer Committee. The HPV Vaccine Subcommittee is charged with increasing 
awareness and education about HPV; evaluating the availability and affordability of 
the HPV vaccine and identifying barriers to its administration; identifying resources 
to cover the costs of the vaccine and evaluating mechanisms to increase access.103  
This illustrates the utility of the cervical cancer task forces and the critical role that they can 
play in introducing and adopting state policy for increasing acceptance of and access to the 
HPV vaccine. Task forces are an opportunity to both inform policymakers and gather 
credible evidence.  
Cervical Cancer Task Force membership is composed primarily of Women in 
Government (WIG) members. Women in Government (WIG), a non-profit, national bi-
partisan organization of women state legislators has been very instrumental in the creation of 
these task forces across the country, through their Challenge to Eliminate Cervical Cancer 
Campaign, launched in 2004.105 Collectively, they have been particularly influential in 
identifying opportunities to expand or improve current mechanisms to ensure that women 
have access to routine and appropriate cervical cancer screening. Furthermore, as part of their 
campaign platform, WIG and the task forces are actively engaged in efforts to implement the 
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HPV vaccine to all age-appropriate girls and women- regardless of their socioeconomic 
status.105, 106 Uniting of the cervical cancer task forces and WIG, a visible and vocal group of 
female policymakers, is extremely valuable as they are in a position to educate their fellow 
legislators about the HPV vaccine and advocate for a more comprehensive cervical cancer 
prevention agenda.  
 
Policy Option #2: Educate Public, Parents, and Students about HPV and Cervical 
Cancer    
Numerous states have proposed or enacted some form of legislation aimed at 
expanding cervical cancer and/or HPV awareness and identifying innovative ways to better 
disseminate the information. 103 Types of legislation addressing one or more of these issues 
are displayed in Table 5.6 below. Strategies for increasing awareness are generally aimed at a 
one or more audiences including: the general public, students in grades 6-12, and in some 
instances public versus private schools are stipulated, as well as parents of students and those 
considering vaccination. Examples of those entities responsible for carrying out and 
enforcing the legislation represent health departments and schools, among others.  
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Table 5.6: Education & Awareness Legislation by Type 
 
*Data are not Mutually Exclusive 
 
The approaches to increasing knowledge about HPV/HPV vaccination and cervical 
cancer are broad and diverse, ranging from requiring schools in Louisiana to provide HPV 
information and vaccines under certain circumstances, to the mailing of age-appropriate 
written materials to parents of female students via direct mail in Missouri. During the current 
legislative period (2009-2010), New York introduced A3202/S1983  which would require: 
Parents and guardians of a child in New York State be encouraged, through 
written educational materials and consultation, to be vaccinated against human 
papillomavirus; The measure also encourages voluntary, informed vaccination 
against human papillomavirus (HPV) for adults. The bill is currently in 
committee.103  
In reviewing this particular legislation and others, it is apparent that policies centered 
on heightening awareness do not necessarily expand the breadth of ones knowledge. 
Information sharing and distributing educational materials about HPV is a necessary step 
toward reaching that goal. Nevertheless, providing information about an issue as complex as 
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HPV must be coupled with a mechanism to ensure that the information is being interpreted 
appropriately and that any uncertainties are responded to in an appropriate manner.  
Health policies designed to increase awareness do not necessarily ensure the public’s 
understanding of or their ability to adhere to recommended preventive services. This finding 
suggests the need for policies that encourage comprehensive and integrated approaches to 
education, such that truly informed decisions can be made about ones health at the 
appropriate time. Existing statewide entities focused on cancer prevention and/or health 
should take the lead with like-minded organizations and execute programs to educate and 
involve stakeholders (e.g., policymakers, providers, parents, men, women, school 
administrators, advocacy groups, etc.) about cervical cancer, HPV, and the role of available 
preventive technologies.  
 
Policy Option # 3: Mandate HPV Vaccination Requirement in Schools 
The addition of the HPV vaccine to the school-based immunization requirement is a 
highly effective way of ensuring its rapid and widespread use, as has been the case for 
vaccines for meningococcal disease, pertussis (whooping cough) and Hepatitis B.89 A 
number of laws have been proposed mandating HPV vaccination as a prerequisite for school 
attendance. Currently one state and the District of Columbia have an HPV requirement. In 
general, legislation would establish requirements for immunization against HPV for 11 and 
12 year old girls entering into the sixth grade or in accordance with the ACIP immunization 
schedule.103, 104 Even after recommendations by the ACIP, school vaccination requirements 
are decided mostly by state legislatures.  
Many who support availability of the vaccine do not support a school mandate. 
Proposed mandates requiring vaccination of school-aged girls for HPV have met with great 
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opposition. Critics have cited concerns about the drug’s cost, safety, and parents’ rights to 
refuse. One of the strongest arguments against having a law requiring the HPV vaccine 
relates to how HPV is transmitted, through sexual contact. The influence of religion and 
moral values has played a significant role in this issue. Parents oppose a mandatory 
requirement and instead prefer a policy that provides for voluntary use of the vaccine; they 
also believe that the decision to be vaccinated should be in consultation with their doctor.  
There is strong sentiment that the legislature should be used to inform the public and 
especially parents so that they can make their own decisions. Those in favor of individual 
rights and the right to choose also oppose mandatory requirements. In addition, anti-vaccine 
groups who are concerned about the safety and efficacy of such a new vaccine have already 
voiced their disapproval.  
 It is likely that the measure would add millions of dollars in health insurance costs to 
state and local government childhood immunization programs. Girls with access to the 
vaccine through private insurance will incur a co-payment or insurance deductible, 
administrative costs each time a dose of the vaccine is administered. Likewise, the costs 
incurred by private insurers will likely be passed on to employers and employees in the form 
of higher premiums. Augmenting the current schedule of vaccines for school attendance to 
include Gardasil® would be rather easy to do.  
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Policy Option # 4: Expand Coverage/Access to Uninsured Adult Women, 19-26 for 
vaccination of HPV   
Very few states allocate funds to pay for the HPV vaccine for females 18 years and 
younger. Some states have proposed and/or enacted legislation to require vaccination of girls 
entering the sixth grade. One state has put forth/enacted legislation recommending that the 
state pay for the vaccine for adult women 19 to 26 years of age.  
Disparities in cancer burden (incidence, mortality and survival) are highly correlated 
to race/ethnicity and socioeconomic status. Uninsured and/or underinsured women between 
the ages of 19-26 will not have access to the HPV vaccine, as there are no public programs to 
cover adult immunizations with the exception of Medicare and Medicaid (for adults who 
qualify).  
Existing public health programs, screening and vaccination, should be adequately 
funded and utilized to ensure that uninsured or underinsured females have access to HPV 
vaccination and cervical cancer screening. Potential resources in the form of direct or in-kind 
support might include: Medicaid/SCHIP, Section 317 Grants Program or MERCK’s Vaccine 
Patient Assistance Program. By extending Medicaid or SCHIP eligibility to age 24, more 
low-income young adults would qualify for public coverage through their college years or 
first years in the job market. The inclusion of $300 million for the Section 317 Grants 
Program was authorized and signed into law by President Obama, as part of the American 
Recovery and Reinvestment Act of 2009. A greater proportion of a state’s/jurisdiction’s 
Section 317 funds should be dedicated for vaccine purchases of recommended adult 
immunizations.   
Additionally, MERCK the manufacturer of Gardasil® established the Vaccine Patient 
Assistance Program (VPAP) to provide MERCK vaccines free of charge to eligible 
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individuals, primarily the uninsured whom would not have access to them otherwise. All of 
Merck's vaccines for adults are available through the program; however, the program is 
targeted toward women aged 19-26 who have no other source of payment for Gardasil®.107 
VPAP is operated through private provider offices as a vaccine dose replacement program; 
most recently the MERCK VPAP Public Sector program was implemented to extend 
participation to health departments and public health clinics.  
Federal, state, and private-sector investments in vaccine purchases and immunization 
programs are critical, given the complexity of our fragmented vaccine delivery system. 
Policy makers should seek opportunities to collaborate with industry, as demonstrated above, 
to maximize resources. Extending access to uninsured women thru existing public health 
programs (immunization or STD clinics, family planning clinics, and breast and cervical 
screening programs) would be advantageous to women and the state. A large percentage of 
the uninsured utilize hospital emergency rooms more frequently, presenting at acute stages of 
illness, which poses an additional burden to an already strained health system. Expenditures 
related to indigent care have sky-rocketed; the monetary costs associated with needless 
follow-up and treatment due to HPV related disease can be reduced considerably when one 
gains access to primary prevention services.   
 
Policy Option # 5: Mandate Coverage of the HPV Vaccine by Insurers 
The more costly immunizations become, the less incentive exists for insurers to offer 
them as a benefit.  Many believe vaccines, once they have been recommended for widespread 
use, should not be an optional benefit of health plans, as is the current practice. Vaccines 
should be integrated as part of a plans basic healthcare package. Several states, 
approximately twenty-nine, have passed laws requiring third-party reimbursement for 
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cervical cancer screening, HPV screening and/or the HPV vaccine. In general, those laws 
addressing immunization against HPV specify that health benefit plans cover the costs of the 
HPV vaccine for female beneficiaries.   
  Despite lawmakers best efforts, insurance mandates would not apply to self-insured 
employer-sponsored health plans as they are governed by the Employee Retirement Income 
Security Act of 1974 (ERISA) and are not subject to individual state laws. In 2003 the IOM 
Committee on the Evaluation of Vaccine Purchase Financing in the United States made a 
recommendation that included a combined mandate, subsidy, and voucher plan to improve 
access and availability of vaccines. The recommendation has not been implemented; 
however, if executed it would require coverage of vaccines endorsed by the ACIP in all 
private and public insurance plans.89  Federal intervention mandating insurance coverage 
may be necessary to reduce the inconsistencies between public and private health plan 
benefits. Insurance mandates remove a barrier to accessing preventive health and primary 
care services and are relatively easy to implement in comparison to some other policy 
options.  
B. Analysis of Options 
Several states have proposed or enacted legislation/policies in support of eliminating 
cervical cancer. There are arguments in support of and against each of the policy options 
described. Using the three criteria- political feasibility, degree of health protection, and cost- 
for analysis, four of the five policy options examined are expected to have the most influence 
achieving higher levels of acceptability and uptake of the HPV vaccine. In terms of health, 
extending insurance coverage/access to uninsured individuals, including young adult women 
ages 19-26, offers the most protection to the greatest number of people. Mandating 
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reimbursement of the vaccine by third-party insurers would be an effective means for 
protecting health by improving access to a select group of insured individual’s, however it 
would likely have minimal impact on young adults who are most likely to be uninsured. 
Establishing cervical cancer task forces or coalitions who can yield some political clout 
offers a moderate degree of protection; as does implementing an educational campaign to 
increase knowledge and awareness about HPV and cervical cancer. However, the potential 
for these two options to extend the health protection benefits to a larger number of people 
increases over the long-term.  
Launching a cervical cancer task force or coalition of some sort is likely to be among 
the more politically feasible options. The National Comprehensive Cancer Control Program 
(NCCCP) provides funding to all 50 states, several tribes, and territories in support of 
comprehensive cancer control (CCC) coalitions to address cancer prevention and control 
initiatives. By identifying cervical cancer as an issue of significance, it is likely to become a 
priority to be addressed by the coalition within the context of the cancer plan. The CCC plan 
provides a blueprint for coordinating the actions of coalition partners and stakeholders; 
ensuring the efficient use of resources and that objectives are met. This approach to 
addressing HPV, vaccination and cervical cancer through established networks is likely to be 
more acceptable, as it lessens the burden for those involved. Likewise, any and all efforts to 
increase knowledge and understanding about HPV related disease and acceptability of HPV 
vaccine across stakeholder groups, the public and policymakers is also likely to be among the 
most politically feasible options. Developing an educational campaign and providing 
resources can be done in collaboration with the work of the cervical cancer task force or 
coalitions.  
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 Mandating coverage by insurers has a moderate level of political feasibility. The 
majority of health insurance plans include coverage of most or all of the ACIP recommended 
immunizations in their benefits for children, adolescents and adults; however, given the high 
cost of the HPV vaccine and its requirement of three doses, there may be some resistance to 
covering this particular vaccine. The degree of political engagement by insurance interest 
groups in particular regions, may be an inhibiting factor. While the policy option expanding 
public health insurance benefit programs to an additional category of uninsured seems to 
have a low level of political feasibility. It is more likely that some sort of incremental change 
will need to occur first in order for legislators and the public to accept comprehensive 
change. The alternative strategy of increasing access include participation in MERCK’s 
VPAP, which will minimize costs to state governments, is politically more favorable than 
expanding public health benefits.  
Cost of two of the four options- cervical cancer coalitions and education programs is 
relatively low. Covering the expense for uninsured women is likely to be a high cost option 
for policy makers, unless some form of cost-sharing mechanism is enacted; for example, 
public-private partnerships such as MERCKs VPAP or perhaps requirement of a fee to 
individuals on a sliding scale. Similarly, the costs of requiring coverage of the HPV vaccine 
by insurers is also a relatively low cost option to policy makers; however there may be 
political costs and the costs to insurers are assumed to be relatively high.  
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Table 5.7:  Evaluation of Policy Options for Improving Cervical Cancer Prevention  
 ESTABLISH CERVICAL 
CANCER TASK 
FORCES 
EDUCATION & 
AWARENESS 
MANDATE 
SCHOOL 
REQUIREMENTS 
EXPAND 
COVERAGE/ACCESS TO 
UNINSURED WOMEN 
MANDATE 
COVERAGE BY 
INSURERS 
HEALTH  
PROTECTION 
 
Moderate 
 
Moderate 
Moderate 
Immediate; High 
Potential 
 
Moderate Immediate;  
High Potential 
 
High: Insured 
Low: Uninsured 
      
POLITICAL 
FEASIBILITY High High 
 
Low 
 
 
Low;  Moderate 
Potential 
 
Moderate 
      
ECONOMIC 
COST Low Low 
Individual: 
Moderate 
Insurers: Moderate 
State: High 
 
Moderate  to High 
Individual:  Low 
Insurers: High 
State: Low 
 
 When all of the policy options are examined using the criteria, some options are less 
desirable than others, but each would achieve some component of the goal to reduce the 
burden of cervical cancer and HPV-related disease among young adult African-American 
women, aged 18-26. Four of the five options summarized in Table 5.7 above— establishment 
of a cervical cancer task forces, executing an educational campaign, expanding 
coverage/access to uninsured, and mandating third-party insurance coverage-  could be 
pursued simultaneously or independently of one another. Based on the experiences of some 
states it might be most effective to first invest advocacy efforts into the establishment of 
cervical cancer task forces or coalitions in conjunction with a broad-based education and 
awareness social marketing campaign. Next steps would include pursuit of mandates 
requiring coverage of the vaccine by third-party insurers, followed by expansion of insurance 
coverage to comprehensive preventive health services for low-income uninsured individuals. 
However, enhancing access to the vaccine through alternative funding mechanisms should be 
pursued. The policy mandating school requirements will have the least impact on this 
population and therefore is not considered a viable option.  
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 The following policy options will be pursued and an advocacy strategy and 
implementation plan will be described in Chapter 6. 
Strategy #1- Educate Public, Parents, and Students about HPV and Cervical Cancer 
In collaboration with Academy for Educational Development (AED), the Women 
ROCC! (Women Reaching Out Against Cervical Cancer) social marketing educational 
campaign, will be expanded to two historically black colleges and universities (HBCUs) 
in states with high cervical cancer rates (Southeast region of the United States). The 
curriculum utilizes a peer education model to conduct trainings, presentations and 
disseminate information.   
Strategy #2- Expand coverage/access to Uninsured Adult Women, 19-26 for vaccination 
of HPV 
Through the National Cancer Prevention and Control Programs, an assessment will be 
conducted to determine the potential for integrating HPV vaccination into existing 
programs of the National Breast and Cervical Cancer Early Detection Program 
(NBCCEDP). 
 These combined efforts seek to expand access to vaccination among, 19-26 year olds.  
Additional information regarding plans for implementation will be further described in 
Chapter 6: Implementation Plan.  
 
  
CHAPTER VI: IMPLEMENTATION PLAN 
 
As the findings of this study- the literature review, key informant interviews and 
policy analysis- suggest implementing HPV vaccination among African-American women 
requires that a comprehensive, multi-phased approach be employed. There are arguments in 
support of and against each of the policy options described in Table 5.7 (See page 127). For 
the purposes of this paper, the choice of policy options to further support implementation of 
HPV vaccination among the upper age limit of the ‘catch-up’  group will address the gaps in 
knowledge of HPV and cervical cancer and access to vaccination, that currently exist. 
As outlined earlier, education and information about HPV and cervical cancer is 
necessary for making informed decisions; conveying information and communicating 
messages about HPV are critical to increasing acceptance and uptake of the vaccine. 
Furthermore, cost  and availability collectively pose barriers to entry into vaccination among 
this population- low-income and uninsured young adults. Access to immunization against 
HPV types can be facilitated by identifying alternative sources of funding and expanding the 
number of venues that offer vaccination.   
 The purpose of this plan for change, then, is to take an incremental and targeted 
approach to addressing the burden of HPV-related disease among young adult African-
American women. This twofold strategy is intended to serve as a guide to expanding vaccine 
coverage and participation in HPV vaccination catch up programs, specifically designed for 
African-American women, aged 18-26. Discussion of the elements of the implementation 
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plan follow; however the actual plan would be developed by the target audience and multiple 
stakeholders. 
• Adapt and implement Women ROCC! and the Women Reaching Out Against 
Cervical Cancer (ROCC): A Guide for successful HPV and cervical cancer 
prevention toolkit at two Historically Black Colleges and Universities (HBCUs). 
• Conduct an assessment to determine the potential for integrating HPV vaccination 
into existing programs of the National Breast and Cervical Cancer Early Detection 
Program (NBCCEDP).  
Implementation Strategy #1 
Adaptation of Cervical Cancer Prevention Social Marketing Campaign 
The Academy for Educational Development (AED) through its partnership with the 
National Education Association-Health Information Network (NEA-HIN) designed a cervical 
cancer prevention campaign focusing on colleges and universities. Colleges and universities 
historically have utilized peer educators to conduct intervention activities on campus and 
within the community; this model is known to be effective in a campus setting. The Women 
ROCC program is designed to:108 
1) Engage young adults 18-25 in cervical cancer prevention activities in the campus 
environment 
2) Increase knowledge about cervical cancer, HPV and screening 
3) Assist students in identifying cervical screening resources on campus or in the 
community 
4) Develop student peer educators to speak about cervical cancer prevention, while 
encouraging broader student participation, and 
5) Build sustainability of the program on campus/community 
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The curriculum development was guided by the Task for Community Preventive 
Services guidelines for cervical cancer prevention strategies;108 HPV and cervical cancer 
prevention were addressed in an interactive format through the integration of one-on-one 
education, small media and multi-component interventions. The content and materials were 
developed through coordination with HBCUs and Hispanic-Serving Institutions (HSIs). In 
addition, the program will be adapted to also address vaccination against HPV and related 
issues (i.e. risk/benefits of vaccination, safety and efficacy concerns and potential resources 
for vaccination). Below Table 6.1 describes the Women ROCC! core elements adapted to 
include the HPV vaccine. 
 
Table 6.1: Women ROCC! Core Elements adapted to include HPV Vaccination 
DISSEMINATION OF 4 KEY MESSAGES DELIVERY OF EDUCATION PRESENTATION 
• HPV is an STI that is linked to cervical cancer and 
genital warts 
• Cervical cancer is preventable 
• HPV vaccination and regular Pap tests  are tools 
available to you to protect your health 
• Schedule an appointment to discuss your options 
with a healthcare provider 
• HPV and it’s link to cervical cancer 
• What is a Pap test? 
• What is the HPV vaccine? 
• Importance of prevention 
• Inclusion of at least one Guide activity (e.g. game) 
RESOURCES FOR HPV VACCINATION AND CERVICAL CANCER 
SCREENING HPV AND CERVICAL CANCER FACT SHEET 
• Provide list of locations that provide quality and 
accessible services 
• Business card format for something portable 
 
• Organization mission & role in Women ROCC! 
• 4 key messages 
• Burden of HPV-related disease statistics 
• Healthcare provider resource list 
• Organization contact information 
Source: Academy for Educational Development 
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Women ROCC!  
 The AED has made a guide and CD-ROM available which includes a variety of tools, 
templates, and materials that are easily customizable to those interested in adapting the 
program to their campus. The materials fall into three categories: 1) planning and promotion 
materials, 2) education materials, and 3) assessment and evaluation materials. The materials 
are posted on the Women ROCC! website, www.GetThePap.org.108  
 
Step 1: Identification of HBCUs 
 Selection of universities to implement Women ROCC will be primarily based on their 
location in states with higher than average cervical cancer mortality rates among African-
American women. Furthermore, HBCUs should be given particular consideration based on 
their capacity to execute the campaign and ability to complete program requirements. 
 
Step 2: Establish a core Women ROCC! team on campus 
 The core team should be composed of key stakeholders who have a role or interest in 
addressing the preventive health needs of college students, with an emphasis on cervical 
cancer prevention, HPV education and improving safe-sex behaviors. Members of the team 
should be specific to the community/environment; however, recruitment should include 
faculty, staff and students; examples include student health, colleges/schools representing 
public health, allied health sciences (nursing) and social work, Greek fraternal organizations, 
etc. One essential member of the core team should be a healthcare professional who is 
knowledgeable about the HPV vaccine, and is able to communicate to students in a 
meaningful way, addressing any concerns. A staff/faculty member(s) champion and student 
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representative will co-manage the program and a campus ‘home’ for the campaign should be 
designated for organizational purposes, to provide structure and the necessary administrative 
support.    
 The goals of the team should be to: educate and engage the university (students, staff, 
faculty) and surrounding community in dialogue and frank discussions about health and 
healthy lifestyles, for positive health outcomes; support campus program efforts to increase 
peer educator knowledge and awareness of HPV and cervical cancer and primary and 
secondary prevention strategies (vaccination and screening); increase behavioral intention of 
young adult women to participate in HPV vaccination and cervical cancer screening, as 
appropriate; identify benchmarks against which to measure program outcomes; monitor and 
report on the progress of meeting established targets through use of process and outcome 
evaluations; and engage additional partners within and outside of the university community 
to leverage resources, sustain and enhance program goals. 
Step 3: Identify target audience 
While Women ROCC! is designed to be implemented campus-wide, the target 
audience for this campaign should be incoming freshmen. Incoming freshmen will be 
required to participate in specific program events. Additionally, they will be asked to 
complete routine online evaluations to assess current prevention (i.e. screening and 
vaccination) and lifestyle practices. The freshmen activities should be coordinated through 
the universities’ Student Health Services and Residence Life in collaboration with the core 
Women ROCC! team. 
Step 4: Obtain and allocate appropriate resources necessary to plan, implement and 
maintain program 
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 Based on the scope of the program an array of resources will be required for its 
successful development and execution. An overall budget should be established with set 
parameters for program needs (space, equipment, refreshments, photography/ videography, 
materials, etc). It is assumed that minimal financial resources will be necessary. To begin 
determine the number of people available to help plan, promote and staff particular events. A 
fair amount of human capital and effort will likely be required.  
Given the nature of university culture, the scope of program activities, time constraints,  and 
competing priorities should be taken into consideration when allocating resources.   
Step 5: Recruit and train a cadre of peer educators  
 Peer education implies a role model-method of education in which trained, self-
identified members provide education sessions to their peers;108 in this case HPV and 
cervical cancer education. Peers generally share an identity with the intended audience and 
speak a common ‘language.’ Due to their familiarity with the group’s cultural nuances (based 
on race, age, gender, student status, etc), they are able to convey certain norms and values; 
while serving as a liaison between the university and student/community group(s) in an 
advocacy role.108 
 The core Women ROCC! team should recruit at least 15-20 volunteers to serve as 
peer educators; they should represent a variety of class years and academic disciplines. An 
initial kick-off training should be held at each school, in which the program and toolkit will 
be rolled-out and students will be trained to be peer spokespersons using the AED 
curriculum. Volunteers will participate in a training to increase their basic knowledge about 
cervical cancer and HPV, the importance of prevention and increase attendees’ capacity to 
conduct formal presentations and engage in informal discussions about HPV-related disease 
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and prevention.  A pre/post survey will be administered at each training to assess the peer 
educator’s knowledge around the topic and prevention program.  
 Peer educators should commit to the following responsibilities: 1) attend program 
trainings, 2) conduct education presentations to peers about cervical health in an interactive 
and engaging forum, 3) plan and conduct outreach to community through program events and 
activities, and 4) collaborate with partners.  
 
Step 6: Adapt Women ROCC! program 
 The AED has made a guide available at www.GetThePap.org to be used in the 
adaptation and design of a Women ROCC! program for college/university settings. However, 
tailoring the guide to meet the organizations need is encouraged. Internal and external 
partners should be integrally involved in this stage of program development. Additionally, 
the core elements of Women ROCC! (See Table 6.1- page 126) should be maintained to 
ensure success of the program.  
 
Step 7: Implement Women ROCC! on campus 
 Peer spokespersons should implement a variety of programmatic activities on campus 
and surrounding community (where appropriate) over a given time frame (i.e. semester/ 
school-year). Ideally, the program would begin in the fall and be implemented over the 
course of two semesters. Student outreach, communications, and health education activities 
should be coordinated and closely monitored. Using the materials provided in the toolkit, it is 
suggested that each peer educator at minimum be required to: 
• Deliver Women ROCC! education presentation in a formal setting to at least 25 
students(each), 
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• Engage in informal dialogues reaching a minimum of 40 students, 
• Partake in campus or community outreach activities individually and in small 
groups (i.e. media outreach, partner activities and high-profile campus events)  
 
Step 8: Evaluation and Monitoring of Program Activities 
 Both process and outcome evaluations could be carried out to assess the effectiveness 
of implementing the Women ROCC! campaign and identify lessons learned. The overarching 
goal of increasing the number of college women (age 18-25) attending HBCUs who are 
knowledgeable about HPV, cervical cancer, primary and secondary prevention strategies 
should be measured. The evaluations should be conducted by the faculty/staff advisor and 
student co-managers in collaboration with AED.  
 
Process Evaluation 
The process evaluation is designed to assess the process of recruiting and training 
peer educators and tracking of volunteer spokespersons activities. Peer educators should 
track activities using a variety of mechanisms and tools to attain feedback from students 
they’ve interacted with on behalf of the Women ROCC! program. The following can be  used 
to gather feedback: peer educator training pre/post survey, sign-in sheets, student feedback 
forms, monthly logs of outreach activities and other tracking methods.108  
 
Outcome Evaluation 
 Utilizing the results from the behavioral assessment of prevention and lifestyle 
practices conducted with freshmen students, several quantitative measures might be used to 
assess the effects of the cervical health program; for example numbers of students seeking 
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HPV vaccination and/or cervical cancer screening, health behaviors, increased sharing of 
information.   
Local Implementation of Women ROCC! 
 For the purposes of this study, consideration should be given to implementing the 
Women ROCC! program or some adapted version at two HBCU’s- Clark Atlanta University 
and Spelman College- in Atlanta, GA.  
 
Implementation Strategy #2: 
Assessing Potential Implications for Integration of HPV Vaccination within NBCCEDP 
 
In developed nations, the U.S. being no exception, cytology screening has been a 
public health success in cancer control. Many of these countries mobilize substantial 
resources toward screening whether it is through organized screening programs or 
opportunistic screening. Even with the introduction of the HPV vaccine as a primary 
prevention tool, cervical cancer screening will have to continue.93, 109-111 The adoption of 
HPV vaccination represents an opportunity to consider what to do with existing screening 
programs, and how synergy can be achieved between vaccination and screening. 
 In 1990 Public Law 101-354 established the National Breast and Cervical Cancer 
Early Detection Program (NBCCEDP). Through the NBCCEDP, the Centers for Disease 
Control and Prevention (CDC) provides low-income, uninsured, and underserved women 
access to timely, high-quality screening and diagnostic services, to detect breast and cervical 
cancer. The NBCCEDP provides screening support in all 50 states, the District of Columbia, 
5 U.S. territories, and 12 American Indian/Alaska Native tribes or tribal organizations. A 
network of providers in the program work collaboratively to provide breast and cervical 
cancer screening, diagnostic evaluation, and treatment referrals (where appropriate). An 
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estimated 8–11% of U.S. women of screening age are eligible to receive services through the 
NBCCEDP. Federal guidelines establish an eligibility baseline to uninsured and underinsured 
women at or below 250% of federal poverty level; ages 18–64 for cervical screening; ages 
40–64 for breast screening.  
The NBCCEDP proactively recruits high risk women for screening. CDC's goal is to 
facilitate access to screening for women and in support of this goal  makes use of a strong 
public health infrastructure. The NBCCEDP is a one-of-a-kind program which employs a 
public health approach for the delivery of breast and cervical cancer screening services 
across the nation to low income, under and uninsured women; the program’s success can be 
attributed in part to its comprehensive model. This model not only includes the 
reimbursement of clinical screening services,  but also outreach to rarely and never screened 
women, case management, public awareness and education, professional education and 
quality assurance, tracking and surveillance, and, program assessment/evaluation. 
While the majority of women screened through the NBCCEDP are aged 40 to 64 
years, there is a small proportion of women under the age of 30 who receive cervical 
screening services. Of the sixty-eight funded NBCCEDP grantees, approximately one-third 
provide cervical screening and/or diagnostics services to young women <30 years of age. 
Among this group of women, a considerable number of abnormal Pap tests occur within the 
NBCCEDP.112 Recognizing the vast resources and expenditures associated with the 
management of abnormal cytology, facilitating vaccination of young women who are also 
NBCCEDP-eligible could potentially yield great benefits. Figure 6.1 below illustrates the 
potential opportunity for conducting both cervical screening and HPV vaccination among a 
group of age-eligible women. As was evident in the key informant interviews and policy 
analysis, an integrated approach to HPV immunization and cervical screening delivery would 
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likely enhance vaccine uptake while supporting continued Pap testing among young adult 
AA women, who have less access and limited resources.   
 
Figure 6.1: Age-eligibility requirements for NBCCEDP, VFC and the 2006 ACIP HPV Vaccine 
Recommendations 112 
 
 
Proposed Evaluation Plan  
 
Given that there is so much influx with respect to implementing HPV vaccination, the 
current cervical cancer prevention policy environment suggests it is an ideal time to examine 
the capacity of the NBCCEDP to engage in immunization of a select group of clients/women 
and examine models of integrated vaccination/screening to better understand the benefits and 
drawbacks of each on the NBCCEDP.  The researcher will conduct an assessment, resulting 
in the development of a White Paper that explores NBCCEDP in the context of HPV 
vaccination and identify any pressing programmatic and policy issues. This assessment will 
help the NBCCEDP take stock of the emerging issues that will be of interest. 
The primary objective would be to understand the implications for the NBCCEDP in the 
realm of HPV vaccine delivery and/or reimbursement and identify potential opportunities 
and barriers to advancing policies to promote cervical cancer prevention (primary and 
secondary) for uninsured, low-income women.  
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Specific Objectives: 
 
• The primary objective of this assessment is to determine the capacity for integration 
of HPV vaccination within the NBCCEDP.    
• To assist the NBCCEDP in establishing its role in primary prevention efforts as it 
relates to cervical cancer. 
A preliminary list of evaluation questions regarding the integration of HPV vaccination into 
the NBCCEDP are presented in Table 6.2 below.  
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Table 6.2: Integration Evaluation Questions 
1. Is there an interest in providing HPV vaccination through the NBCCEDP to eligible clients? (Interest 
assessed at the national and grantee levels) 
 
2. Are NBCCEDP programs currently involved in HPV vaccination endeavors? If so, in what ways and to what 
extent? 
 
3. What are some ways in which the NBCCEDP can become actively engaged in HPV immunization practice or 
policy issues? 
 
4. What would encourage or discourage the participation/ integration of vaccination and cervical cancer 
screening via the NBCCEDP? 
 
5. What lessons can be learned from integrated cervical cancer prevention programs already implemented (e.g. 
New York)? 
 
6. Should incorporating immunization into an existing cervical screening program be encouraged, how will 
issues such as vaccine supply, reimbursement and administration of vaccine be addressed? 
 
7. What other considerations (e.g., provider adequacy, vaccine availability, compliance with 3 dose 
immunization schedule) might need to be addressed? 
 
8. How would low-income, uninsured women served by the NBCCEDP fare? (Consideration should also be 
given to provider network)? 
 
9. What ways can other CDC cancer programs; specifically the National Comprehensive Cancer Control 
Program (NCCCP) and the National Program of Cancer Registries (NPCR) support/ encourage integration of 
HPV vaccination into existing cervical screening programs? 
 
10. How can public-private partnerships be used to support this effort (e.g. MERCK’s Vaccine Patient Assistance 
Program (VPAP) designed to provide access to low-income, uninsured women, aged 19-26)? 
 
11. What would be the implications for the NBCCEDP in general and CDC? 
 
12. What policy questions should the Division of Cancer Prevention and Control seek to try to address as a way 
to inform decision- makers? 
   
Since the program’s inception, research and scientific advances in new technologies 
have required CDC to make determinations about the implementation and reimbursement of 
emerging technologies in the NBCCEDP. CDC considers a wide range of factors and 
strategically and systematically develops programmatic and reimbursement policies for new 
technologies. Given the stipulations placed on the program by PL 101-354, this is not meant 
to be a document advocating for changes to the law; but rather an assessment of the role of 
the NBCCEDP in furthering cervical cancer prevention efforts.  
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 CDC’s DCPC should conduct an assessment and develop a white paper to be 
delivered to address the above mentioned evaluation questions as it relates to screening and 
vaccination in the NBCCEDP. Although the paper might be empirically based, it would be 
more of a thought piece designed to identify emerging issues of potential interest. The goal 
would be to shape recommendations that are useful in determining how immunization 
delivery and screening service delivery might be strengthened through the NBCCEDP. 
Additionally, an assessment of this nature may also help inform the larger issue of combining 
HPV vaccination and cervical cancer screening for all women.  
The evaluation will position CDC/NBCCEDP to proactively determine and lead 
action steps based on sound evidence and research findings. The results will serve to guide 
the development of recommendations that can be used to inform policies and decision-
making. Findings from this project will be shared with a variety of stakeholders who have an 
interest in achieving reductions in cervical cancer incidence, morbidity and mortality. The 
findings could also be disseminated via reports, publications in peer-reviewed journals, and 
via presentations at professional meetings and conferences.  
  
CHAPTER VII: DISCUSSION 
 
 
 In an effort to more fully understand the issue of HPV vaccination acceptance and 
use among African-American women, this study examined two key questions: 
1. What are the attitudes, practices and beliefs about human papillomavirus among 
young adult African-American women? 
2. What factors would be likely to hinder or enhance the effectiveness of policies aimed 
at increasing use of the HPV vaccine for cervical cancer risk reduction among young 
adult African-American women, aged 18-26? 
Through all phases of the study- review of the literature, key informant interviews 
and the policy analysis- insights were gleaned to address the research questions. The  
literature  review sought to describe knowledge and attitudes of young adult women as it 
relates to HPV vaccination; illuminate factors that may influence and/or deter young  adult 
women from receiving the HPV vaccine; and evaluate the multiple frameworks utilized to 
analyze and develop policy for bringing about change. Through the process of interviewing 
key informants, the goal was to further explore the determinants of HPV vaccine use among  
a specific population, African-American women aged 18-26; and to identify factors that may 
hinder or facilitate acceptance of the HPV vaccine to inform policy considerations for 
increasing use and widespread implementation of the vaccine. The key informant interviews 
explored the perceptions and beliefs of respondents; building upon the findings of the 
literature review regarding- cervical cancer prevention, health practices and beliefs, and HPV 
vaccine acceptance and use. During the final phase of the study, an analysis and 
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interpretation of the relevant policy and vaccine literature was conducted; policy options for 
improving vaccine use were examined; and policy considerations and implementation 
strategies informed by the literature and key informants were evaluated. The findings of all 
three study phases- the literature review, key informant interviews and policy analysis and 
interpretation- are synthesized along those lines. The results can be summarized as follows: 
1. Social inequities persist along the cervical cancer continuum across several social 
domains, particularly among communities of color. These factors, commonly known 
as social determinants of health, are beyond the realm of the healthcare system and 
speak to broader issues of equity and social justice. 
2. Facilitators of HPV vaccination acceptance and uptake, among young adult African-
American women, are represented within the social, cultural, and political context of 
health. Broadly, these factors are associated with education, personal beliefs, access, 
social support and trust in the medical establishment.  
3. Public policy can play a role in the effective implementation of strategies to reduce 
the burden of HPV-related disease, including cervical cancer. Addressing this 
challenge will require response from a “diversity of actors, interests, norms, 
processes, initiatives, and funding streams.”113  
In the United States, and particularly across communities of color, there is a crisis in 
health. Despite the trillions of dollars spent annually on diagnosis and treatment of illness, 
disparities across disease conditions remain. Much of the pain and suffering and countless 
deaths that occur can be attributed to preventable causes; unfortunately, low-income and 
minority populations bear a disproportionate share of the burden. Among African-American 
women, disparities in cervical cancer morbidity and mortality persist. In addition, the rates of 
sexually transmitted infection, including HPV are higher among this population. 
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A range of explanations associated with disparities in HPV infection and cervical 
cancer diagnosis and deaths can be offered. Race and ethnicity, racism, socioeconomic 
position (income), insurance status, and access to care; their relation to screening, diagnosis, 
treatment, and survival are frequently acknowledged as contributors to the persistent 
inequalities that exist. Just as significant among these are the disparities that encompass 
gender, age, language, literacy, immigrant status and geography.114, 115  Furthermore, an 
under-representation of African-Americans participating in clinical studies contribute to 
ongoing disparities. Clinical studies are crucial to the development of effective prevention 
and treatment methods for cancer and other diseases. The relevance and application of 
clinical trial results into practice is directly related to the type and number of participants 
enrolled. Fostering greater diversity in clinical research is necessary for lessening differences 
in negative health outcomes.   
Overall, African-American women have high rates of participation in cervical cancer 
screening, which illustrates prevention of cervical cancer as a concern among this group. 
Additionally, screening rates among women of reproductive age have shown to be higher, 
when compared to older women.115 Conversely, while African-American women are reported 
to have higher rates of screening for cervical cancer as compared to White women, the 
incidence and mortality rates of cervical cancer are two-fold higher among African-American 
women. This reinforces the idea that there are inherent differences in how and when African-
American women are diagnosed and treated.114, 115   
The association between preventive health practices of African-American women and 
cervical cancer reduction were examined. Results of this dissertation acknowledge that 
cervical cancer prevention is an issue of importance, in addition to other priorities, among 
African-American women. Current health practices of young adult AA women- cervical 
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screening, an abnormal Pap test, previous history of STI, condom use and routine check-ups 
correlate to her intent to be immunized. As a group, 18-26 year olds are generally healthy, 
utilize the healthcare system less frequently, and are also more likely to be low-income and 
uninsured. One can infer having health insurance or coverage of preventive services among 
this population is likely to positively influence use of cervical cancer prevention approaches, 
such as vaccination and screening. 
 Attitudes and beliefs about health as well as individual health practices and behaviors 
are influenced at multiple levels- individual, relationship, community, and societal. For the 
purposes of this dissertation, a socio-ecologic framework was employed to guide exploration 
into those factors that might hamper or facilitate acceptance and/or use of immunization 
against HPV, among young adult African-American women. The results of this dissertation 
offer an array of explanations into the dynamics and complexities associated with the 
determinants of health behavior and decision-making, within the context of HPV vaccination. 
The research revealed the following- education, personal beliefs, access, social support, and 
trust- to be variables in this process. 
The value and importance of education and information are essential for prevention 
efforts to be effective and equally important to personal decision-making. Currently, there is 
a deficit in literacy as it pertains to health.  Several studies have linked literacy as an 
important predictor of health behavior. Consistent with others, the findings of this research 
revealed variations in access to health information about HPV and cervical cancer prevention 
among African-American women. Newmann and Garner, explored the relationship between 
health behavior and health literacy and found that patients most at risk for non-screening 
behavior have limited access to cervical cancer education materials; and those information 
resources that are available are written at inadequate literacy levels.115 Access to information 
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is an essential element in reducing barriers and decreasing disparities in HPV infection and 
HPV-related disease.116, 117 
More recently there has been considerable attention given to HPV and cervical 
cancer, with the introduction of the vaccine to prevent against four HPV-types. Given the 
surge in media coverage and advertising for the HPV vaccine, one might assume that 
knowledge and understanding of the virus and related diseases have improved as a 
consequence. However, awareness does not necessarily correlate to accurate knowledge, 
particularly among certain racial/ethnic minorities and low socioeconomic groups.116, 117  
Studies assessing awareness and knowledge of infection with human papillomavirus and its 
link to cervical cancer show that African-American women appear to be less informed.116  
Conclusions from this study regarding African-American women and their understanding of 
HPV are comparable to the results of similar analyses. Although much confusion remains 
around HPV and its link to cervical cancer, it was generally reported that African-American 
women show a high level of interest in being educated about HPV. Similarly, the results of 
this research reinforced the association between enhanced knowledge and awareness of HPV 
and increased vaccination uptake. 
Opportunities to increase knowledge of HPV and cervical cancer prevention should 
engage young women and communities. Educational efforts must be comprehensive, 
personalized to the intended audience- the public, patients, and healthcare providers and 
enlist a tailored approach. Specifically, study findings identified physicians of color as 
priority for targeted educational efforts aimed at influencing their knowledge and beliefs 
about HPV and the vaccine; likewise this approach was described as an opportunity to 
encourage providers to become champions of HPV vaccination within the African-American 
community. 
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Communications and messaging to further advance HPV education and encourage 
uptake of the vaccine cannot be undervalued. The importance of education for increasing 
acceptance and uptake of the HPV vaccine, the types of messages, how they are 
disseminated, and to whom, is a piece of the puzzle with which many practitioners struggle. 
When attempting to reach minority communities regarding health matters, a multi-faceted 
approach should be utilized. Educational materials and information must be transparent, 
culturally and literacy appropriate; furthermore the information must be perceived as 
nonbiased. Where possible, young women, the intended audience, and community members, 
should be engaged in all aspects of dialogue and the exchange of ideas.  
Exploring effective ways that are comprehensive in scope to improve knowledge 
about the disease and risk factors will be advantageous to the utilization of cervical cancer 
prevention methods. For African-American women, an understanding of personal risk should 
be included as a part of communications related to HPV and cervical cancer prevention. 
Given the sensitive nature of HPV as a sexually transmitted infection, the way in which 
education and information about the disease and vaccination are framed is central to 
understanding the issue. Acceptance of the HPV vaccine and intent to be vaccinated are also 
shown to be influenced by message framing. In a study conducted by Leader et al, intentions 
to vaccinate were significantly higher when information about the vaccine was presented as 
protecting against cervical cancer and there were little or no costs to the individual or family 
members.118  
Depicting HPV as an STI has a negative connotation and carries with it a social 
stigma associated with feelings of shame and promiscuity. Results of this study further 
support previous research findings, which suggest that the stigma associated with an STI 
such as HPV may pose barriers to participation in vaccination programs among young adult 
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African-American women.118 Therefore, the principal message to the public and patients 
regarding HPV and vaccination should highlight the virus’ link to cervical cancer and the 
benefits of immunization against HPV as a tool to prevent cervical cancer. In addition to its 
protection benefits, thoughtful consideration should be given to highlighting the safety and 
effectiveness of the HPV vaccine and potential side effects. Thus, the way in which 
information is framed, has the potential to either hinder or facilitate health behaviors and 
decision making.  
Equally important to the information being shared is the source of information and 
mode of delivery. Multiple information channels and communication types are used within 
communities of color. For younger women, technology and electronic media are customarily 
used for the exchange of information and an effective means of reaching this audience on an 
array of matters including health messages. Due to the internet’s influence and broad reach 
among this age group, accurate and accessible information on the world-wide- web from 
credible sources is needed. Regarding African-American women, perhaps the most 
significant attributes of those supplying information about HPV, are trust, credibility, and 
same race. Healthcare providers are commonly perceived as highly credible sources of 
information; however, among some communities of color this is not the case. With respect to 
healthcare professionals, similar race of the provider was highly correlated with increased 
acceptance of HPV information and the vaccine. Results of this dissertation recognized peer 
groups and social networks as being vitally important communicators of messages and 
information in minority communities; the use of peer educators, commonly used at HBCU’s 
for health education purposes, was advocated as an effective vehicle for increasing 
knowledge about the disease and support of the vaccine.   
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 Among young adult African-American women, attitudes about HPV and the vaccine 
were influenced by factors that were similar to AA women of all ages; perceived risk of 
infection, stigma associated with an STI, and concerns about the vaccine were foremost. 
Perceived risk or susceptibility can be defined as one’s belief about the likelihood of harm.71, 
75, 119 Consistent with other findings, knowledge of personal risk of acquiring HPV and 
developing cancer are generally low; as is knowledge of the link between HPV and cervical 
cancer among this group.  One can assume that an insufficient understanding of HPV and 
HPV-related disease has some bearing on African-American women’s perception of risk of 
exposure to HPV and susceptibility to cervical cancer. Although statistics confirm disparities 
in cervical cancer and STI rates, the findings reported lower levels of perceived risk of 
acquiring HPV among African-American women.  As evidenced in this study’s results and 
the literature, an African-American woman’s opinion of her risk positively correlates to 
decision making to participate in primary and secondary cervical cancer prevention efforts.  
One’s ability to accurately assess disease risk relies heavily on knowing about HPV, 
in particular how it is acquired, and the disease process; furthermore, it requires 
consideration of participation in cervical cancer risk behaviors. Both sexual activity and 
screening practices are behaviors/practices that contribute to a woman’s perceived risk. 
Sexual activity is significantly associated with age; young women, aged 16-24 years, are 
likely to have had more partners or concurrent sexual relationships compared to older 
women;71, 119, 120 therefore, risk of acquiring HPV is higher among this group. Due to HPVs 
sexually transmitted nature, steps must be taken to limit any unnecessary anxiety or negative 
feelings. Women must be encouraged to engage in positive health practices and be reassured 
that there are options for controlling some risk behaviors. Further exploration into those 
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factors that contribute to the beliefs and health behaviors of African-American women as it 
relates to cervical cancer reduction is needed. 
 Routine funding for adult immunization is limited at best and in some cases non-
existent. Improving affordability and access to the vaccine is influenced by factors such as 
cost, insurance and availability of the vaccine. The results from this study are consistent with 
other studies which confirm differences in cervical cancer morbidity and mortality 
experienced by certain groups- specifically minority women and those of low socioeconomic 
status; African-American women are no exception. For this reason, young adult AA women 
who are more frequently low-income and uninsured, will likely have restricted access to both 
primary and secondary cervical cancer prevention methods. Successfully advocating in 
support of a reduction in the cost of the vaccine is expected to improve access and 
availability, on many fronts.  
While the HPV vaccine appears to be regarded as beneficial by the provider 
community at large, variations in its use are wide across medical disciplines, engendering the 
potential for inequalities in access to and availability of immunization services. The ACIP 
recommendation allows for vaccination of girls beginning at nine years old as well as 
vaccination of girls and women 13-26 years old, with the routine vaccination of 11-12 year 
olds prior to the onset of sexual activity.  One significant study finding revealed a perceived 
or real bias against vaccinating those in the ‘catch-up’ population, particularly those who are 
sexually active, by many in the medical community. Physicians considered the least 
knowledgeable about HPV disease and vaccination, appear to be more stringent in only 
recommending and administering the vaccine to those fitting the criteria for routine 
vaccination; girls prior to the onset of sexual debut. Such a strict interpretation of the 
guidelines raises concerns, as it may impose a systematic barrier to accessing the vaccine 
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intended for women up to age 26, including those who are sexually active, for which 
protection benefit and efficacy have been shown. These findings illustrate the value 
judgments shared by many about a woman’s worthiness to receive the HPV vaccine after she 
has become sexually active. It further demonstrates that policies and knowledge about HPV 
vaccine delivery may not be universally known or widely accepted. 
 Moreover some providers face challenges in dispensing the HPV vaccine due to its 
high cost and lower reimbursement rates, inadequate vaccine supply, burdensome 
administrative requirements and patient compliance with the immunization schedule. This 
particular study finding may have implications on access to the vaccine by low-income 
individuals and among communities of color wherein providers have chosen not to make the 
vaccine available. Given the burden of disease in this population, hesitancy on the part of 
providers to recommend the vaccine is certainly an obstacle that must be overcome. 
Inequities in access to and the availability of HPV vaccination will further expand the health 
gap between those that have and those that have not.   
Another finding from this study confirms the importance of support from one’s 
partner, family, and community in influencing health beliefs and behaviors. Results of this 
research revealed that the benefits of vaccination were perceived as favorable in relation to 
the protection of oneself and one’s partner. It was further reported that the belief that 
influential people in one’s life would approve of vaccination, was deemed to encourage 
immunization. Young adult women can be very persuasive within their peer group; they are 
trusting of one another and enthusiastically accepting of information and recommendations 
from each other. In the same way that peer groups and social networks disseminate 
information, they also shape beliefs and influence acceptance and understanding of health 
practices among African-Americans. Because of the significant influence these networks 
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have, communities themselves need to become better informed and educated; grandmothers, 
mothers, daughters, opinion leaders and in fact the male partners of these women.   
As with previous studies, provider knowledge and attitudes of HPV, cervical cancer, 
the vaccine and recommendation to be vaccinated by a healthcare professional can be 
powerful motivators for or against receiving immunization against HPV.  Providers have a 
particularly influential role, which is shaped by a composite of dynamics; personal beliefs, 
education and professional opinions, experience with HPV and vaccination, as well as 
policies and their interpretation. Additionally, provider buy-in of HPV vaccination is 
strengthened when there is support amongst one’s colleagues 
 Yet another finding of this study revealed the significance of mistrust and the role that 
it plays in the decision to participate in HPV vaccination within the African-American 
community.  Dating back to slavery, African-Americans have been discriminated against 
in several areas: education, employment, and unfortunately health services research. Feelings 
of mistrust and skepticism have positioned themselves staunchly in the midst of the multitude 
of problems that plague the African-American community, including health. Negative views 
of these institutions- government, the medical establishment, and industry- have been 
fashioned for generations of people of color, in response to a history of racism and 
discrimination. Trust in this country’s systems of health care (public and private), healthcare 
practices, providers, and health information has been broken for many minority communities.  
 The results of this research confirm a veil of suspicion of public health and 
government agencies that is significant even today, which leads one to conclude that vaccine 
acceptance and use may be negatively impacted. This study’s findings also suggest that 
efforts to overcome trust as a barrier must start from within communities of color. Health, 
government, and industry officials must successfully engage minority communities as 
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collaborators, supplying them with the necessary tools to comprehend HPV-related 
information and apply that knowledge, assess the risks and benefits of vaccination, and 
translate that information into decision-making. Only then can individuals and communities 
of color be empowered to want better health for themselves and take action to improve health 
status.    
Sustainable health behavior change can be facilitated through a variety of means. 
Both legislative and policy domains represent opportunities for broadly addressing 
improvements in health. Policies affect large numbers of people as well as social norms and 
have tremendous potential for preventing needless suffering, injuries, and deaths.121 
Arguments driving public health policy should take action toward- improving population 
health, reducing health inequalities and sustainable public health solutions. Harnessing the 
energy of stakeholders and coordinating their activities is essential for a healthy society. 
Beyond that of government, stakeholders possessing the power to influence health include 
business, employers, academia, foundations, the media, civil society, and most importantly 
communities themselves. An effective response to disparities in HPV-related disease requires 
that stakeholders share responsibility for key dimensions of the problem within appropriate 
‘policy channels’ or policy streams.113, 122  
Results of this dissertation suggest that the capacity of different stakeholders to 
respond and address the challenges of implementing effective HPV vaccination programs 
will require considerable collaboration and coordination, employing a variety of strategies- 
programmatic, legal, political and economic.113, 122 Furthermore, achieving and maintaining 
high levels of HPV vaccination coverage are associated with successfully implementing 
population-based approaches and effective strategies. This study’s analysis of effective 
strategies and program attributes for HPV vaccine implementation revealed several main 
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ideas: 1) characteristics of a program must improve access and entail a comprehensive 
education plan,  2) role of the community is central and engagement of community members 
should be at the core of all activities, 3) integration of vaccination into existing health 
services is likely to be the most effective strategy for reaching this population, young adults, 
aged 18-26, with an emphasis on cervical cancer screening programs, and 4) the importance 
of patient compliance in vaccination and continued cervical screening. A successful HPV 
vaccination program would require considerable investment in educating a range of 
audiences. Additionally, a reduction in the vaccine’s cost to females and providers would be 
necessary to expand access and availability; while incorporating HPV immunization into 
existing cervical cancer screening programs.  Findings from this study reinforce the strategies 
for increasing immunization rates as described by the Task Force for Community Preventive 
Services.        
A. Conclusion 
 
Cervical cytology and advances in cancer screening tools and methods have 
contributed significantly to the decline in rates of cervical cancer over the past several 
decades. Despite these advances, social inequities persist along the cervical cancer 
continuum across several social domains. Commonly referred to as social determinants of 
health, these factors are beyond the realm of the healthcare system and speak to broader 
issues of equity and social justice.  In the United States, disparities in cervical cancer and 
STIs are public health problems that reflect cracks in society that follow place, class and 
race. An effective approach to prevention acknowledges the underlying factors- risk and 
protective- that influence the burden of disease.121  
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 Measures to protect against cancer and sexually transmitted diseases, both threats to 
the health of communities of color, are necessary and should be widely supported. 
Vaccination against four HPV types 6-11-16-18 that cause the majority of genital warts and 
70% of cervical cancers has shown to be 100% effective. However in some ways, the ACIP 
recommendation inadvertently differentiates the upper age limit as a second class group 
despite the fact that it is highly unlikely that young adult females have been infected with all 
HPV types. Given the evidence supporting effectiveness of the HPV vaccine, it is important 
for young adult African-American women, aged 18-26 to be vaccinated. From a public health 
perspective, a population-based approach to HPV vaccination is evidenced by higher rates of 
immunization coverage of women, which has direct benefits to men in terms of decreased 
transmission of the virus. Furthermore, a population approach to vaccination is considered to 
be less resource intensive on physicians and the healthcare system in general. The advantages 
to the individual and society are many, and will have a significant impact on the 
disproportionate rates of HPV and cervical cancer disease among African-American women 
as well as other racial and ethnic minority groups. Conversely, there are some drawbacks to 
vaccinating a group with a high prevalence of HPV, as the maximum protection benefit is 
derived before the initiation of sexual intercourse. Furthermore, studies have confirmed that 
the vaccines  
efficacy diminishes among females infected or previously infected with certain HPV types. 
Table 7.1 presents additional benefits and drawbacks to vaccination of African-American 
women, aged 18-26.  
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Table 7.1. Advantages/Drawbacks to HPV Vaccination of African-American females, age 18-26  
 BENEFITS DRAWBACKS 
Scientific/  
Public Health 
Aspects 
 
• Protection benefit derived from vaccination (full 
or partial prevention of HPV 16/18 ) 
• Reduced transmission of disease 
• Cross protection against infection with non-
vaccine HPV types 
• Effects of  reduced HPV disease may be 
realized sooner among ‘catch-up’ population 
• Duration of protection extended during sexually 
active years without booster 
• Disparities in burden of disease among AA may 
improve with vaccination 
• Protection against genital warts 
• Vaccination may benefit those who have less 
access to routine healthcare (Pap tests) 
• Reduction in costs- personal, emotional, social 
and financial 
• Easily integrated into cervical cancer screening  
 
• High prevalence of HPV among this age 
group (18-26 years) 
• Vaccine efficacy diminishes among females 
currently infected or previously infected with 
HPV types 
• Lower immune response for older women 
compared to younger 
• Provision of low cost vaccine limited for 
‘catch-up’ population (eg. Section 317 
programs) 
Behavioral 
Aspects 
• Acceptance of vaccination  increases when 
administered to aged 17 or older 
• Lower perceived risk of infection 
 
 
• Stigma associated with receipt of vaccine 
against STI 
• Mistrust of government, healthcare system, 
new technologies among communities of 
color 
• Concern about reproductive health and 
pregnancy 
• Decreased belief in importance of  cervical 
cancer screening 
 
A noteworthy study finding indicated that African-American women are likely to 
have a more holistic view of health and wellness. In recent years heightened awareness and 
attention have been given to other chronic disease conditions, such as obesity, cardiovascular 
disease, hypertension, and their root causes- for example poor nutrition and physical activity 
patterns and tobacco use- all of which significantly impact the health status of African-
American women. These co-factors are also shown to contribute significantly to cancer. 
Whereas, vaccination, improving diet and increasing exercise are considered primary 
prevention strategies to combating disease before poor health occurs none of them can be 
done in isolation. Efforts utilizing a disease-specific approach to prevention may 
inadvertently contribute to disparities, as the causes that contribute to one disease are 
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multiple and manifest themselves across medical conditions. Primary prevention must occur 
at the individual and community level through a combination of education, advocacy and 
policy to effect change. 121 Strengthening individual knowledge and skills as well as 
promoting community education by providing information and resources to promote health 
and safety are critical; and in communities of color, social networks are a valuable source for 
education and programmatic efforts meant to enhance participation in vaccination. The utility 
of public policy in promoting primary prevention efforts to influence health outcomes is 
evidenced in practice today.  
Moving forward, action must be taken at multiple levels to address the societal and 
structural determinants of STIs and cervical cancer; a matter of importance that has too long 
been neglected. It is the view of this researcher that the foundations of public health are built 
upon the values of equity, unity, justice and accountability. Let us be reminded that public 
health and health inequities are –and must remain- societal matters for which we are all 
responsible.  
B. Limitations of the Research Study 
 
 The three phases of this study allowed for a better understanding of those factors that 
might hinder or facilitate acceptance and use of the HPV vaccine. The data collected 
provided a basis to answer all the research aims, however there were limitations to this study. 
First, the study did not assess the perceptions and opinions of African-American 
women, aged 18-26, the target population for this research. While the literature review and 
participation by key informants representing the views of young adult African-American 
women provided an understanding of women’s barriers and facilitators to HPV vaccination 
and strategies for implementing effective immunization policies, the lack of consumer input 
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is a study gap. Young adult African-American women should participate in future efforts to 
effect widespread use and implementation of the HPV vaccine.  
A second limitation of this study is related to the key informant interviews. Since all 
of the interviews were conducted by one researcher, bias may have been introduced into the 
results of the key informant interviews. The relatively small sample size, the sampling 
methodology and participation may have introduced selection bias. This limitation was 
partially addressed through purposeful inclusion of representatives in each of the sampling 
categories through maximum variation as described in the study’s Methods section (Chapter 
3).   
General limitations of the key informant interviews include heavy reliance on the 
knowledge and expertise of the key informants interviewed. Key informants undoubtedly 
injected bias into their responses and there was variability in the respondents’ abilities to 
perceive the full extent and intention of the question(s), and to effectively communicate all of 
the information requested by the researcher. Study limitations were primarily addressed 
through validation techniques, such as triangulation of data sources.   
 
Implications for Further Study 
 
 In order to gain a better understanding of the issues surrounding HPV vaccine 
decision making among African-American women findings from this dissertation suggest at 
least four avenues for next steps or further study: 
1) Recruitment of racially diverse participants in studies. Racial and ethnic minorities as 
well as those of low-socioeconomic status should be included in research. Enhanced 
collaboration with African-American investigators, HBCU’s, community members 
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and physicians is likely to improve representation of this population in medical 
research. 
2) Integration of vaccination and screening for cervical cancer reduction. An 
assessment of opportunities to combine HPV vaccination into existing cervical cancer 
screening programs should be conducted and implemented where appropriate.  
3) Employ novel health communication strategies. Development and dissemination of 
tailored HPV health messages through a variety of approaches such as risk-based 
education. 
4) Consideration of viable policy options. Legislative and policy options that have the 
capacity to expand access to the HPV vaccine to all segments of the population 
should be explored. These might include consideration of extending Medicaid or 
State Children’s Health Insurance Program coverage, the Vaccine for Children’s 
Program, or the Section 317 Program to include primary and secondary cervical 
cancer prevention services for low-income women who have no other resources for 
accessing preventive health services. More could be done to expand the services that 
are reimbursed by insurers as it relates to education and counseling of patients. While 
providers have an interest in providing learning opportunities to patients, the 
investment of time required addressing the complexities of HPV and vaccination is 
sizeable. Preventive measures are more likely to be offered and fully utilized by 
healthcare providers as reimbursement for these types of services are augmented.  
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C. Final Word 
 
“Democracy is only possible if equality, participation, and mutual respect are part of 
society’s major institutions.”123 
 
 
 Health is produced by the conditions under which people live, and the roots of 
inequalities in health lie in social and economic disparities; they result from preventable, 
avoidable conditions and policies.123 Addressing disparities in cervical cancer and other 
disease conditions will require that pubic health take risks and assume a greater leadership 
role in decision-making and public policy. Public health leaders must ignite concern about 
the link between social and economic equality and the health of this nation. Our democracy is 
dependent upon the willingness of ordinary people to participate in “social movements aimed 
at the collective empowerment of all people.”123  
  
APPENDIX A 
 
Literature Review Keywords/Search Terms 
Search Terms-The databases were searched using a combination of terms and keywords as 
outlined in the table below:  
Human 
Papillomavirus 
AND Cervical Cancer AND Knowledge AND Young Adult 
Women 
HPV  AND Cervical Cancer AND Knowledge AND Women 
HPV AND Cervical Cancer AND Knowledge AND Adolescents 
and Young 
Adult Women 
Human 
Papillomavirus 
AND  Vaccine AND Attitude(s) AND Young 
Women 
HPV AND Vaccination AND Attitude(s) AND Adolescent 
and Young 
Adult Women 
Human 
Papillomavirus 
AND Immunization AND Acceptability AND Women 
 
 
Literature Review Criteria for Inclusion/Exclusion: 
 The inclusion criteria used for this review were limited to those that focused on 
knowledge and/or attitudes of young adult women and the relationship to the human 
papillomavirus, cervical cancer, and the human papillomavirus vaccination.  Articles were 
included if they were produced from credible sources such as peer reviewed journals, health 
organizations, news journals, etc. and contained supporting arguments for the relationship 
mentioned above. In addition, availability of articles in English and availability of full text of 
the article were also criteria for inclusion.  Full text was preferred due to time limitations of 
the reviewer. While, no date limits were placed on the search, it should be noted that most of 
the literature on the HPV vaccine is very recent, within the last 2-4 years.  
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 Exclusion criteria included those articles focusing on knowledge and/or attitudes of 
adolescents only, parents, or providers and the relationship to the human papillomavirus, 
cervical cancer and the human papillomavirus vaccination. In addition, articles in languages 
other than English were also excluded. 
  
APPENDIX B 
Level of Influence Factors 
 Associated with Acceptance of 
 An HPV Vaccine  
 
 
Intrapersonal (Individual) Factors:  
Acceptance of the HPV vaccine involves the attitudes, behaviors, knowledge and beliefs of 
individuals. Understanding and dispelling personal fears and anxieties one may have is key. 
Perceived risk of HPV and cervical cancer, including beliefs about sexual activity and 
contraceptive use; an individual’s commitment to personal health; and understanding the 
benefits of vaccine and its efficacy are constructs of the Health Belief Model which facilitate 
health behaviors.  
 
Intrapersonal (Relationship) Factors:  
Involves social support and social networks, including family, friends, peers, and sexual 
partners influencing a woman’s decision-making. Both formal and informal support systems: 
Does she rely on their guidance and opinions?(i.e. family values and rules) Does the 
individual have a relationship with a healthcare provider that might serve as a barrier or 
facilitator?  
 
Community/Organizational Factors: 
 Includes rules, cultural and social norms and organizational attributes. Is the university 
promoting safe and healthy sexual practices through education/ awareness campaigns? What 
is the role of the university’s student health services center as it pertains to provision of 
vaccine, screening (Pap tests), physician referral and education? Issues related to 
accessibility to transportation, locale of nearest healthcare facilities are identified within a 
community/ neighborhood.  
 
Societal Factors:   
Includes local state and federal laws, policies and regulations that support the distribution, 
control and management of the HPV vaccine to appropriate groups. Media and 
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communication channels play a major role in an individual’s health behaviors and lifestyle 
choices, politics, and societal acceptance of the HPV vaccine.  
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APPENDIX C 
 
Recruitment Script 
IRB Study # 08-1601 
Dear XXX,  
 
Hello. My name is Chastity Walker and I am a doctoral student from the University of North Carolina 
at Chapel Hill in the School of Public Health, Department of Health Policy and Management. I am 
conducting research on factors that may help inform the development of effective policies for use of 
the HPV vaccine among young African-American women. I’d like to give you a bit of background on 
my project and invite your participation.   
  
The purpose of the study is to identify factors that are likely to hinder or enhance the effectiveness of 
policies aimed at increasing use of the HPV vaccine for cervical cancer risk reduction. My hope is 
that the information gained will be useful in contributing to the development of policies concerning 
the use and acceptance of the HPV vaccine among young adult African-American women.  
 
Given your knowledge of cervical cancer prevention and control, your insights would be particularly 
helpful to me. With your permission, I would like to conduct an interview with you. The interview 
will last approximately 60 minutes and will be scheduled at your convenience; interviews can be 
conducted in person or by phone. If you live in Atlanta, I can come to your office or preferred 
location. Alternatively, we can conduct the interview by phone. Interviews will be audio-recorded and 
transcribed for analysis. All the information I receive from you, including your name and any other 
identifying information, will be strictly confidential and will be destroyed upon completion of my 
dissertation. Written work resulting from my project will contain no information that could identify 
individual participants. Upon completion of the project, participants will receive a $25 gift card to use 
as they see fit.   
 
As I noted above, I am conducting this study as part of my doctoral program in public health. My 
research is being supervised by Dr. Suzanne Havala Hobbs, and she can be reached at 919-843-4621 
for additional questions about the study.  All research on human volunteers is reviewed by a 
committee that works to protect your rights and welfare.  Human subjects review approvals have been 
received from the UNC institutional review board for this study.  
 
I'll follow up with you shortly by email to confirm your interest. Thank you very much for 
considering this request.  
 
Sincerely,  
Chastity L. Walker, MPH  
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APPENDIX D 
University of North Carolina-Chapel Hill 
Consent to Participate in a Research Study  
Adult Participants  
Social Behavioral Form 
________________________________________________________________________ 
 
IRB Study #__08-1601__________ 
Consent Form Version Date: 10/17/08________  
 
Title of Study: Attitudes, Practices and Beliefs about HPV Vaccine Among Young Adult 
African-American Women: Implications for Effective Implementation  
 
 
Principal Investigator: Chastity L. Walker, MPH 
UNC-Chapel Hill Department: Department of Health Policy and Management 
UNC-Chapel Hill Phone number:            
Email Address: wchastit@email.unc.edu 
 
Faculty Advisor:  Suzanne Havala-Hobbs DrPH, MS, RD, Clinical Assistant Professor, 
Department of Health Policy and Administration, University of North Carolina at Chapel 
Hill, Chapel Hill, North Carolina  
Funding Source and/or Sponsor: Not funded 
Study Contact telephone number:  404-317-7908 
Study Contact email:  cwalker@cdc.gov 
_________________________________________________________________ 
 
What are some general things you should know about research studies? 
You are being asked to take part in a research study.  Participation in this study is entirely 
voluntary. You may refuse to join, or you may withdraw your consent to be in the study, for 
any reason, at any time, without penalty.  
 
Research studies are designed to obtain new knowledge. This new information may help 
people in the future.   You may not receive any direct benefit from being in the research 
study. There also may be risks to being in research studies. 
 
Details about this study are discussed below.  It is important that you understand this 
information so that you can make an informed choice about being in this research study.  
You will be given a copy of this consent form.  You should ask the researchers named above, 
or staff members who may assist them, any questions you have about this study at any time. 
 
What is the purpose of this study?  
The purpose of this research study is to generate knowledge and identify factors that are 
likely to hinder or enhance the effectiveness of policies aimed at increasing use of the HPV 
vaccine for cervical cancer risk reduction among young adult African-American women. The 
  154
information will be used to explore policy options for widespread implementation and/or 
uptake of the vaccine and determine the best strategy to increase use and acceptance of the 
HPV vaccine among young adult African-American women.  
 
How many people will take part in this study? 
If you decide to be in this study, you will be one of approximately 25 participants. The 
research involves approximately 25 individual interviews with key stakeholders who have 
knowledge and expertise in cervical cancer prevention and control. 
 
How long will your part in this study last?  
Interviews are an extremely important data source, in part because they provide such rich 
data. All interviews will be conducted at your convenience and should not last more than 60 
minutes. In addition to the actual interview, you should plan for approximately 15 minutes to 
review the informed consent form and allow for any follow-up questions and answers related 
to the study immediately after the interview.  
 
What will happen if you take part in the study? 
• The research involves approximately 25 individual interviews with key stakeholders who 
can provide insight into the development of effective policies for use of the HPV vaccine 
among young adult African-American women. 
• You have been selected to participate in a 60 minute interview. The interview is a one-
time event, although the researcher may contact you again for clarification of comments 
made during the interview. 
• The interview will be conducted in person or by phone at your convenience. 
• The interview will be audio-recorded. You may refuse to answer any question and ask to 
turn off the tape recorder at any time. 
• Upon completion of the interview, you will receive a $25 gift card to use as you see fit. 
• All information received from you, including your name and any other identifying 
information, will be strictly confidential and will be destroyed upon completion of the 
research study. 
 
What are the possible benefits from being in this study? 
 
Research is designed to benefit society by gaining new knowledge.  While you may not 
benefit personally by participating in this research study, your participation will contribute to 
the public’s health to the extent that the knowledge gained will provide specific 
recommendations for widespread vaccination. In addition, the knowledge gained will inform 
researchers and practitioners of the facilitators to successful administration of the HPV 
vaccine to priority populations.   
 
What are the possible risks or discomforts involved from being in this study? 
There may be uncommon or previously unknown risks.  You should report any problems to 
the researcher. The proposed research study poses no more than minimal risk to you as a 
participant. The primary risk to subjects participating in this study is a breach of 
confidentiality.  The risk of such a breach is minimized by the principal investigator’s 
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training in human-subjects protection.  Assurances of confidentiality will be maintained 
throughout the research study.   
 
How will your privacy be protected? 
 
Participants will not be identified in any report or publication about this study. The PI will 
not divulge, publish, or otherwise make known to unauthorized persons or to the public any 
information obtained in the course of the study that could identify the persons who 
participated in the study.  The interviews will be conducted privately. None of the questions 
asked are very personal or of a sensitive nature, however there is a chance you may feel 
uncomfortable answering them. You may refuse to answer any question that you don't want 
to for any reason.  You may also request that audio recordings be turned off and stop the 
interview at anytime. 
 
Audio-recordings will be erased upon completion of the study.  Electronic and hard copies of 
interview notes and other data will be stored without personal identifiers on a password-
protected laptop kept in a secure location.  While each study participant will be assigned a 
unique identification number, the master list linking names and identification numbers will 
be stored separately from project data.  Only the PI will possess the master list.  Access to 
electronic and hard copies of notes will be restricted to the PI and dissertation committee 
only.  Any oral presentations and written reports on the data will contain no identifying 
information linking individuals with specific comments. 
 
Although every effort will be made to keep research records private, there may be times 
when federal or state law requires the disclosure of such records, including personal 
information.  This is very unlikely, but if disclosure is ever required, UNC-Chapel Hill will 
take steps allowable by law to protect the privacy of personal information.  In some cases, 
your information in this research study could be reviewed by representatives of the 
University, research sponsors, or government agencies for purposes such as quality control or 
safety. 
 
Check the line that best matches your choice: 
_____ OK to record me during the study 
_____ Not OK to record me during the study 
 
Will you receive anything for being in this study? 
 
You will be offered an incentive, not to exceed $25, for taking part in this study. The 
incentive will be in the form of a VISA gift card. If you withdraw from the study prior to 
completion of the interview, you will not receive any incentive.  
 
Will it cost you anything to be in this study? 
There will be no monetary costs for being in the study. The only cost of  participation is your 
time. 
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What if you have questions about this study? 
You have the right to ask, and have answered, any questions you may have about this 
research. If you have questions, or concerns, you should contact the researchers listed on the 
first page of this form. 
 
What if you have questions about your rights as a research participant? 
All research on human volunteers is reviewed by a committee that works to protect your 
rights and welfare.  If you have questions or concerns about your rights as a research subject 
you may contact, anonymously if you wish, the Institutional Review Board at 919-966-3113 
or by email to IRB_subjects@unc.edu. 
 
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
Title of Study: Attitudes, Practices and Beliefs about HPV Vaccine Among Young Adult 
African-American Women: Implications for Effective Implementation  
 
 
Principal Investigator: Chastity L. Walker, MPH 
 
Participant’s Agreement:  
 
I have read the information provided above.  I have asked all the questions I have at this time.  
I voluntarily agree to participate in this research study. 
 
_________________________________________ _________________ 
Signature of Research Participant Date 
 
_________________________________________ 
Printed Name of Research Participant 
 
 
_________________________________________ _________________ 
Signature of Person Obtaining Consent Date 
 
_________________________________________ 
Printed Name of Person Obtaining Consent 
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APPENDIX E 
Interview Guide- Government Officials 
 
Introduction 
 
 The purpose of the interview is to learn more about the determinants of HPV vaccine use 
among African-American women aged 18-26, and to identify factors that may hinder or 
facilitate acceptance of the HPV vaccine. Twenty to twenty-five stakeholders who have an 
interest in cervical cancer prevention will participate in the interviews. It is anticipated that 
the interview should take about 60 minutes.  The interviews will be strictly confidential. The 
themes that emerge from the interviews will be used to inform policy considerations for 
increasing use and widespread implementation of the vaccine. The comments and answers 
you provide will not be linked to your identity. This interview session will be recorded with 
your consent.  Tape recordings and transcribed notes will be stored in a secure location and 
destroyed upon completion of this study.   
 At this time, do you have questions about the study or the interview session? 
 Do I have your permission to record the interview? 
 
 
Education/Communications 
1. What measures should be taken to improve health literacy about HPV and cervical 
cancer prevention?  
2. What is the best way to ensure that women have enough information to make 
informed decisions about HPV vaccination and cervical cancer prevention? 
 
Fiscal 
3. What are the key influences associated with the costs and benefits of HPV 
vaccination? 
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4. Given the high cost of the HPV vaccine, what fiscal considerations should be allowed 
to ensure affordability and cost-effectiveness of the vaccine to young adult African-
American women? 
[Probe] How might use of state 317 Program funds be used  to support vaccination of 
underserved women? 
5. What are the potential public health benefits of  investing public funds for HPV 
vaccination of young adult African-American women? 
6. How might the economic investment case for HPV vaccines best be made for 
national-level decision makers? (i.e. governments, insurers, professional 
organizations) 
 
 
Implementation Strategies 
7. What are the benefits to vaccinating the catch-up population, those aged 18-26? 
8. What is the benefit of HPV vaccination programs from a population-based public 
health perspective?  
[Probe] Are there any potential negative effects of HPV vaccination programs? 
9. What factors should be considered when recommending policies for HPV vaccine 
introduction among African-American women? 
[Probe] Which vaccination guidelines should be considered (i.e. ACIP versus ACS) 
10. How can an integrated service delivery approach to prevention be utilized to reduce 
the burden of cervical cancer? 
[Probe] What form might it take? 
11. What specific program attributes can contribute to the successful implementation of 
vaccine policies and program performance? 
12. How will cervical cancer screening policies change among vaccinated populations? 
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Barriers and Facilitators 
13. What do you perceive to be barriers to HPV vaccination among African-American 
women? 
14. What actions can be taken to support African-American women in overcoming 
barriers associated with HPV and HPV vaccination? 
[Probe] What can be done to address a woman’s fears and anxieties? 
[Probe] What can be done to address a woman’s concerns regarding efficacy and 
safety issues? 
15. Given the mistrust issues in the African-American community, how important do you 
think it is to focus on African-American women, aged 18-26? 
 
Advocacy 
16. What role can government play to support acceptance and use of the HPV vaccine 
among at risk groups? 
17. How can political support for HPV vaccines be created? 
18. What steps can be taken to ensure that the inequities that currently exist in cervical 
screening will not worsen with the introduction of the HPV vaccine?  
19. How can we ensure that women will still get the message to continue screening 
 
Closing 
Thank you for your time. What additional comments about the determinants of HPV 
vaccine use and acceptance among African-American women do you have? 
Have we covered everything that you think is important? 
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APPENDIX F 
Interview Guide- Healthcare Professionals 
 
 
Introduction 
 
 The purpose of the interview is to learn more about the determinants of HPV vaccine use 
among African-American women aged 18-26, and to identify factors that may hinder or 
facilitate acceptance of the HPV vaccine. Twenty to twenty-five stakeholders who have an 
interest in cervical cancer prevention will participate in the interviews. It is anticipated that 
the interview should take about 60 minutes.  The interviews will be strictly confidential. The 
themes that emerge from the interviews will be used to inform policy considerations for 
increasing use and widespread implementation of the vaccine. The comments and answers 
you provide will not be linked to your identity. This interview session will be recorded with 
your consent.  Tape recordings and transcribed notes will be stored in a secure location and 
destroyed upon completion of this study.   
 At this time, do you have questions about the study or the interview session? 
 Do I have your permission to record the interview? 
 
Knowledge of Human Papillomavirus (HPV) 
 
1. How common is human papillomavirus (HPV)?  
[Probe] How easy is it to clear? 
2. How familiar are you with the vaccine to prevent infection of HPV? 
[Probe] Who are the priority populations for vaccination? 
[Probe] What does the vaccine protect against? 
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[Probe] How familiar are you with the various vaccination guidelines (ACIP vs. 
ACS)?  
 
Provider Experience with the HPV Vaccine 
3. What types of patients do you see in your clinic/office? 
4. What has been your experience with the HPV vaccine? 
5. Do you recommend the HPV vaccine to your patients? 
[Probe] If yes, for what age group(s)? 
6. Do you administer the HPV vaccine? 
[Probe] If yes, for what age group(s)? 
7. What has been your experience with those who get the vaccine in your practice? 
8. Which groups are requesting the HPV vaccine in your practice? 
[Probe] What age and racial/ethnic groups? 
[Probe] Are women with abnormal Pap results requesting the vaccine? 
9. What are some of the issues associated with getting the vaccine for girls or women 
who want it?  
[Probe] What group(s) of women are having issues? 
 
Preventive Health 
10. How much of a priority is cervical cancer risk reduction for preventive health among 
African-American women? 
[Probe]  How does this fit within the/their cultural values and understandings of 
health and wellness? 
11. What measures should be taken to address cervical cancer risk behavior among  at-
risk populations, such as African-American women? 
 
Education/Communications 
12. Where do African-American women generally get information about HPV? 
13. What measures should be taken to improve health literacy about HPV and cervical 
cancer prevention?  
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14. What is the best way to ensure that women have enough information to make 
informed decisions about HPV vaccination and cervical cancer prevention? 
15. What types of educational materials are needed to inform patients about HPV and 
cervical cancer prevention? 
[Probe]  What groups/organizations should be involved in the development of these 
educational materials? 
 
Implementation Strategies 
16. What are the benefits to vaccinating the catch-up population, those aged 18-26? 
17. What is the benefit of HPV vaccination programs from a population-based public 
health perspective?  
 [Probe] Are there any potential negative effects of HPV vaccination programs? 
18. How can cervical cancer screening programs support vaccination? 
19. What kind of systematic interventions would be helpful for encouraging full 
compliance of the three doses of vaccine among 18-26 year olds? 
20. How will cervical cancer screening policies change among vaccinated populations? 
[Probe] Should there be differences between those vaccinated pre-sexual debut 
versus those vaccinated post-sexual debut? 
 
Barriers and Facilitators 
21. What do you perceive to be barriers to HPV vaccination among African-American 
women? 
22. What actions can be taken to support African-American women in overcoming 
barriers associated with HPV and HPV vaccination? 
[Probe] What can be done to address a woman’s fears and anxieties? 
[Probe] What can be done to address a woman’s concerns regarding efficacy and 
safety issues? 
23. Given the mistrust issues in the African-American community, how important do you 
think it is to focus on African-American women, aged 18-26? 
24. What challenges do health care providers (public/private) face with regard to 
incorporating HPV vaccination into existing preventive health services?  
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Advocacy 
25. What role can the healthcare sector play to support acceptance and use of the HPV 
vaccine among African-American women? 
26. How can we ensure that women will still get the message to continue cervical cancer 
screening? 
 
Closing 
Thank you for your time. What additional comments about the determinants of HPV 
vaccine use and acceptance among African-American women do you have? 
Have we covered everything that you think is important?
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APPENDIX G 
 
Interview Guide- Public Interest Groups 
 
Introduction 
 
 The purpose of the interview is to learn more about the determinants of HPV vaccine use 
among African-American women aged 18-26, and to identify factors that may hinder or 
facilitate acceptance of the HPV vaccine. Twenty to twenty-five stakeholders who have an 
interest in cervical cancer prevention will participate in the interviews. It is anticipated that 
the interview should take about 60 minutes.  The interviews will be strictly confidential. The 
themes that emerge from the interviews will be used to inform policy considerations for 
increasing use and widespread implementation of the vaccine. The comments and answers 
you provide will not be linked to your identity. This interview session will be recorded with 
your consent.  Tape recordings and transcribed notes will be stored in a secure location and 
destroyed upon completion of this study.   
 At this time, do you have questions about the study or the interview session? 
 Do I have your permission to record the interview? 
 
Knowledge of Human Papillomavirus (HPV) 
 
1. How common is human papillomavirus (HPV)?  
[Probe] How easy is it to clear?  
2. How familiar are you with the vaccine to prevent infection of HPV? 
[Probe] Who are the priority populations for vaccination? 
[Probe] What does the vaccine protect against? 
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[Probe] How familiar are you with the various vaccination guidelines (ACIP vs. 
ACS)?  
 
Preventive Health 
 
3. How much of a priority is cervical cancer reduction for preventive health among 
African-American women? 
[Probe]  How does this fit within the/their cultural values and understandings of 
health and wellness? 
4. What measures should be taken to address cervical cancer risk behavior among  
African-American women, aged 18-26? 
Education/Communications 
5. Where do African American women generally get information about HPV? 
6. What measures should be taken to improve health literacy about HPV and cervical 
cancer prevention?  
7. What is the best way to ensure that women have enough information to make 
informed decisions about HPV vaccination and cervical cancer prevention? 
8. How can cervical cancer prevention educational campaigns be tailored to meet 
individual/cultural needs of African-American women? 
[Probe] What specific messages should be communicated about HPV for African-
American women?  
9. Who is best to communicate these messages? 
 
Fiscal 
10. What are the key influences associated with the costs and benefits of HPV 
vaccination? 
11. Given the high cost of the HPV vaccine, what fiscal issues should be considered to 
ensure affordability and cost-effectiveness of the vaccine to young adult African-
American women? 
[Probe] How might use of state 317 Program funds be used  to support vaccination of 
underserved women? 
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12. What are the potential public health benefits of  investing public funds for HPV 
vaccination of young adult African-American women? 
 
13. How might the economic investment case for HPV vaccines best be made for 
national-level decision makers? (i.e. governments, insurers, professional 
organizations) 
 
Implementation Strategies 
14. What are the benefits to vaccinating the catch-up population, those aged 18-26? 
15. What factors should be considered when recommending policies for HPV vaccine 
introduction among at- risk population groups? 
16. How can an integrated service delivery approach to prevention be utilized to reduce 
the burden of cervical cancer? 
[Probe] What form might it take? 
17. How can cervical cancer screening programs support vaccination? 
18. What specific program attributes can contribute to the successful implementation of 
vaccine policies and program performance? 
[Probe] What kind of systematic interventions would be helpful for encouraging full 
compliance of the three doses of vaccine among 18-26 year olds? 
19. How will cervical cancer screening policies change among vaccinated populations? 
 
Barriers and Facilitators 
20. What do you perceive to be barriers to HPV vaccination among African-American 
women? 
21. What actions can be taken to support African-American women in overcoming 
barriers associated with HPV and HPV vaccination? 
[Probe] What can be done to address a woman’s fears and anxieties? 
[Probe] What can be done to address a woman’s concerns regarding efficacy and 
safety issues? 
22. Given the mistrust issues in the African-American community, do you think it is more 
important to focus on African-American women, aged 18-26? 
    167
23. What challenges do health care providers (public/private) face with regard to 
incorporating HPV vaccination into existing preventive health services?  
 
 
Advocacy 
24. In what ways can communities be mobilized to increase awareness about HPV and 
acceptance of the HPV vaccine?   
25. What role can advocacy groups play to support acceptance and use of the HPV 
vaccine among at risk groups? 
26. How can political support for HPV vaccines be created? 
27. What steps can be taken to ensure that the inequities that currently exist in cervical 
screening will not worsen with the introduction of the HPV vaccine?  
28. How can we ensure that women will still get the message to continue screening 
 
Closing 
Thank you for your time. What additional comments about the determinants of HPV 
vaccine use and acceptance among African-American women do you have? 
Have we covered everything that you think is important? 
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APPENDIX H 
 
HPV VACCINE STAKEHOLDER INTERVIEWS 
CODING MANUAL/ DEFINITIONS 
 
 
HPV Vaccine Issues  
 
Operational definition:   This code refers to the human papillomavirus (HPV) vaccine, Gardasil® 
(developed by MERCK), the first vaccine developed to prevent cervical cancer, precancerous genital 
lesions, and genital warts due to HPV. Another HPV vaccine (being developed by GlaxoSmithKline) is 
in the final stages of clinical testing, but it is not yet licensed. Issues  surrounding the vaccine include 
it’s novelty (new technology), safety, efficacy, duration of protection, and understanding of what the 
vaccine protects against. 
 
Priority Populations   
 
Operational definition: This code refers to the group(s) recommended to receive priority for HPV 
vaccination.  
 
Vaccination Guidelines/Recommendations  
 
Operational definition: This code refers to the written recommendations for the routine 
administration of vaccines, specifically the HPV vaccine, to children and adults in the civilian 
population; recommendations include age for vaccine administration, number of doses and dosing 
interval, and precautions and contraindications. 
 
Cervical Cancer and HPV 
 
Operational definition: This code refers to genital human papillomavirus (HPV) infection and  
cervical cancer, an HPV related disease. Genital HPV infection is a sexually transmitted disease 
(STD) that is caused by human papillomavirus (HPV). There are approximately 40 types of genital 
HPV. Some types can cause cervical cancer in women and can also cause other kinds of cancer in 
both men and women. Other types of HPV can cause genital warts in both males and females. 
Cervical cancer is a gynecologic cancer that affects a woman’s reproductive organs. Cervical cancer 
begins in the cervix, which is the lower, narrow end of the uterus. (The uterus is also called the 
womb.) The human papillomavirus is the main cause of cervical cancer.      
 
Providers/Provider Experience 
 
Operational definition: This code refers to health care providers and their experience as a health 
care provider with HPV and the HPV vaccine.  A provider is a health professional in an organization 
or person who delivers health care to an individual(s) in need of health care services. Provider 
experience encompasses: knowledge and beliefs about HPV, the HPV vaccine, recommendation of 
the HPV vaccine to patients, and the purchase and administration of the vaccine to patients. 
 
Patient(s) 
 
Operational definition: This code refers to an individual(s) who receives medical attention, care or 
treatment from a physician or other health professional.   
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Preventive Health 
 
Operational definition: This code refers to an action(s) which can reduce the burden of mortality or 
morbidity from negative health affects and disease. Preventive health measures occur at primary 
(vaccination), secondary (screenings) and tertiary (treatment) prevention levels.  
 
 
HEALTH BELIEFS 
 
Perceived Risk/Susceptibility  
 
Operational definition: This code refers to ones perception of his/her own risk of contracting a 
sexually transmitted infection (HPV), transmitting HPV and/or developing cervical cancer. 
 
Vaccination Beliefs 
 
Operational definition: This code refers to any personal or higher level belief (African-American 
community) regarding vaccinations. 
 
Social Norm/Peer Influence 
 
Operational definition: This code refers to the shared expectation by and/or influence of peers to 
engage/not engage in preventive health measures such as vaccination (HPV vaccination) and routine 
screenings (Pap tests), or to change/improve health practices when he/she may not normally engage 
in these behaviors. 
 
Perceived Social Support/Lack of Social Support 
 
Operational definition: This code refers to emotional support or comfort, or a favorable attitude 
given by ones family, spouse/partner, friends, and others toward health related behaviors (HPV 
vaccination, cervical cancer screening, condom use).  
 
Cultural/Religious Beliefs 
 
Operational definition: This code refers to the cultural and/or religious beliefs of an individual(s), 
community, society as it relates to HPV (a STI), HPV vaccination and cervical cancer. 
 
HPV Knowledge & Awareness 
 
Operational definition: This code refers to one’s awareness and understanding of HPV, the HPV 
vaccine, cervical cancer and the relationship between the two.  
 
 
Education/Information 
 
Operational definition:  This code refers to the ways in which an individual(s) can learn specific 
knowledge, information and skills through instruction, teaching, training and experiences. More 
specifically, this code refers to knowledge pertaining to HPV, HPV vaccination and cervical cancer.   
 
 
Messages 
 
Operational definition: This code refers to a thought, idea or concept expressed to communicate 
knowledge or information. Messages can be verbal (exchange of information using words) or 
nonverbal (exchange of information through actions or behaviors rather than words).   
 
    170
 
Benefits 18-26/Public Health 
 
Operational definition: This code refers to the actual or perceived benefits of HPV vaccination. At 
the individual level HPV vaccination directly benefits the woman, ages 18-26 years. From a 
population-based public health perspective, public health activities aim to improve health status and 
reduce the burden of disease in communities or populations.   
 
 
Three (3) Dose Compliance 
 
Operational definition: This code refers to patient compliance regarding completion of the three 
dose series required for administration of the HPV vaccination. The HPV vaccine is given in a series 
of three injections over a six-month period. The second and third doses should be given two and six 
months (respectively) after the first dose. 
 
Cervical Cancer Screening (Pap Test) Programs 
 
Operational definition: This code refers to the Pap test (or Pap smear) which looks for precancers, 
cell changes on the cervix that might become cervical cancer if they are not treated appropriately. 
Pap tests are a secondary prevention (screening) strategy for the prevention and early detection of 
cervical cancer. Health professionals in a variety of clinical settings provide cervical cancer screening 
services. Routine cervical cancer screening is recommended for all women.  
 
Continue Cervical Screening (Pap Test) 
 
Operational definition:  This code refers to girls/women participating in cervical cancer screening 
(Pap tests) after being vaccinated against HPV, the virus that causes cervical cancer.   The Pap test 
can prevent cervical cancer by finding precancers, cell changes on the cervix that might become 
cervical cancer if they are not treated appropriately. 
 
Facilitator 
Operational definition: This code refers to anything, either real or perceived, that facilitates ones 
acceptance and/or use of the HPV vaccine. 
 
Barriers 
 
Operational definition: This code refers to anything, either real or perceived, that serves as a barrier 
to ones acceptance and/or use of the HPV vaccine.  
 
Overcome Barriers 
 
Operational definition: This code refers to anything/actions, either real or perceived,  that may aide 
in reducing or eliminating a barrier(s) (as described above) to ones acceptance and/or use of the HPV 
vaccine.  
 
 
Mistrust 
 
Operational definition: This code refers to a lack of trust by some minority populations of 
governmental agencies and the healthcare system/medical establishment in the United States. More 
specifically, mistrust in this context refers to the African-American community which has suffered 
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needlessly as a result of discrimination and various injustices inflicted upon them by the U.S. 
government in education, employment and health services research, dating back to slavery. 
 
 
Implementation Strategies/Program Attributes 
 
Operational definition: This code refers to factors that might be considered for developing and 
introducing HPV vaccination programs into various settings. In addition, specific attributes that may 
contribute to successful implementation of HPV vaccine program performance are included.  
Fiscal Considerations 
 
Operational definition:  This code refers to factors that should be considered to ensure affordability 
and cost-effectiveness of HPV vaccination.  
 
 
Policies 
 
Operational definition: This code refers to factors that might/should be considered when 
recommending policies for HPV vaccine introduction to multiple audiences across various settings. 
 
 
Cost/Benefit (Economic Investment) 
 
Operational definition: This code refers to important factors associated with the costs and benefits 
of HPV vaccination, specifically at the individual level and more broadly at the population level. 
 
 
Community Mobilization 
 
Operational definition: This code refers to opportunities for communities to come together, 
specifically the African-American community, in support of efforts to reduce the burden of HPV 
infection and HPV related disease. Community members lead efforts to create sustainable change 
while ensuring that prevention efforts are culturally appropriate and effective.  
 
Advocacy Efforts 
 
Operational definition: This code refers to opportunities for organizations and/or groups (i.e. 
healthcare providers, governmental agencies and interest groups) to support actions that work toward 
reducing the burden of HPV infection and HPV related disease (i.e. cervical cancer and genital 
warts).  
 
 
Health Disparities 
 
Operational definition: This code refers to factors associated with disparities in HPV infection and 
cervical cancer rates among certain populations (in this case African-Americans) and steps that can 
be taken to ensure that similar inequities do not arise with the introduction of the HPV vaccine. 
Cancer health disparities can be defined as "differences in the incidence, prevalence, mortality, and 
burden of cancer and related adverse health conditions that exist among specific populations groups 
in the United States (National Cancer Institute, 2008). 
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Additional Codes 
 
Males   
 
Operational definition: This code refers to the role of males in the transmission of HPV, HPV 
vaccination of males, and efforts to support increased acceptance and/or use of the HPV vaccine 
among men and women.  
 
Empowerment/ Self-efficacy 
 
Operational definition: This code refers to an attitudinal, structural, and cultural process whereby 
individual’s/community’s gain the ability, authority, and agency to make decisions and implement 
change in support of improving their own lives, which includes health status, and the lives of other 
people. Empowerment is associated with self-efficacy, ones perception of his/her own skills and the 
ability to use those skills effectively to change or improve ones health status.  
 
 
Motivation 
 
Operational definition: This code refers to ones motivation as a factor in improving or attempting to 
improve ones health status by taking preventive health measures. It is also associated with an 
individuals acceptability of the HPV vaccine and willingness to be immunized.  
 
Health Equity & Social Justice 
 
Operational definition: This code refers to the fair distribution of society’s resources, benefits, 
responsibilities and their consequences. The relative position of one social group in relationship to 
others in society, and the root causes of disparities influence health status. Social justice assumes 
that in order to ensure health equity and advance human well-being, improving health must address 
meeting the needs of the most disadvantaged. (Center for Health Equity, 2008) 
 
Other 
Operational definition: Miscellaneous 
 
Slam Dunk 
 
Operational definition: This code refers to “words from the field” or quotations that support the 
themes identified.  
 
References: 
Bandura A. Self-efficacy: Toward a Theory of Behavioral Change. Psychological Review, 1977 
84:191-215 
 
Center for Health Equity- Louisville Metro Department of Public Health and Wellness, 
http:/www.louisvilleky.gov/Health/equity/Accessed February 2009  
   
Definition of Cancer Health Disparities www.cancer.gov/cancertopics/types/disparities, National 
Cancer Institute, Accessed February 2009     
 
Definition of Empowerment. www.wikipedia.org Accessed February 2009 
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APPENDIX I 
 
Immunization Policy Analysis 
Description of Sources 
 
CDC-National Center for Infectious and Respiratory Diseases 
The Centers for Disease Control and Prevention (CDC), National Center for Infectious and 
Respiratory Diseases (NCIRD) is the federal governments leading public health entity whose 
primary mission is the prevention of disease, disability, and death through immunization and 
by control of respiratory and related diseases. Through the work of its Immunization Services 
Division (ISD), individuals and communities are protected from vaccine-preventable 
diseases.  ISD activities involve: measuring vaccination coverage, provider and public 
education, research and evaluation to identify methods to improve immunization service 
delivery, development of immunization information and surveillance systems, and 
administration of the Vaccines For Children (VFC) and Section 317 grant program. The 
vaccines and immunizations website provides a wide array of resources for the public and 
health professionals alike related to immunization schedules, vaccination guidelines, vaccine 
safety, state immunization laws and requirements, publications and training resources.  
 
Immunization Action Coalition 
The Immunization Action Coalition (IAC), which began as a nonprofit grassroots coalition, 
has established itself as one of the leading clearinghouses of childhood, adolescent, and adult 
immunization information for healthcare professionals. The central aim of IAC is to increase 
immunization rates, enhance the delivery of safe and effective immunization services, and 
facilitate dialogue across the immunization spectrum of stakeholders. IAC works in 
partnership with the CDC to create and distribute educational materials for providers and the 
public, educate health professionals about U.S. vaccine recommendations, improve 
immunization practices, and provide disease/vaccine specific information. The Vaccine 
Policy and Licensing (VPL) site was created by IAC as an official one-stop shop vaccine 
policy resource.  The VPL website hosts a variety documents concerning  science and 
financing policy including:  recommendations for vaccine use,  product approvals, journal 
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publications, video podcasts,  policy statements and position papers indexed by date, vaccine, 
and topics of interest.  
 
NCI State Cancer Legislative Database  
The National Cancer Institute's (NCI) State Cancer Legislative Database (SCLD) serves as 
resource for federal and state agencies, Congress, health departments, academia, professional 
organizations, and the public for research and analysis of cancer-related health policy. The 
SCLD monitors cancer-related state legislation around select topics such as cervical cancer 
and health disparities; while supporting evaluation of the impact of state legislative activities 
on pubic health and cancer control, and monitoring legislative trends that may reflect shifts in 
attitudes and practices toward cancer prevention and control. The SCLD Program website 
houses publications and conference presentations, quarterly newsletters containing reviews of   
is a resource state cancer-related legislation enacted each quarter and an inquiry response 
system for customized searches of the database for specific inquiries about the status of state 
laws and cancer-related legislation.  
 
Other Documents & Sources 
Several other documents and sources were included from the following websites and 
organizations:  Congressional Research Service, Guide to Community Preventive Services, 
Henry J. Kaiser Family Foundation, Institute of Medicine (IOM) Committee on 
 Immunization Finance Policies and Practices,  National Conference of State Legislatures, 
Women in Government, and the Global Alliance for Vaccines and Immunization. 
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